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Abstract 
The traditional paradigm relying on drug discovery to treat and heal the 
body is changing. Medicine for the 21st century is moving towards using 
the body’s internal language of DNA and RNA to cure disease and repair 
injuries to the body.  
We now appreciate the complexity of signalling through the genome 
and its transcribed RNA. The role of micro RNAs and short interfering 
RNAs are gaining much interest as potential therapeutics. This interest 
has been sparked by the discovery that the dysregulation of micro RNAs 
is the origin for a spectrum of diseases from cancer through to 
osteoporosis.  
Small regulatory RNAs have been shown to influence stem cell 
maintenance, proliferation and differentiation, offering the potential to 
produce new tissue by manipulating RNA levels. 
However delivery of these molecules is fraught with difficulties. Without 
protection these molecules are quickly degraded in vivo and in vitro 
before reaching their intended target.  With this in mind, this thesis 
aims to investigate the potential role for gold nanoparticles to deliver 
small regulatory RNAs and in turn produce a non-toxic and 
physiologically significant effect upon the cells.  
Initial investigations revealed the importance of PEG density and AuNP 
concentration; with lower PEG densities, allowing attached therapeutic 
siRNA against C-Myc to reduce C-Myc protein levels and cell 
proliferation. Subsequently we determined that modulating the 
expression of osteo-suppressive miRNA, with a nucleic antagonist 
sequence was able to influence osteogenesis in two cell models (MG63s 
and hMSCs). This thesis has shown that AuNPs can be used to 
effectively deliver therapeutically active small molecules to cells in vitro. 
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1 Chapter 1: Introduction 
1.1 Nanoparticle Overview 
Nanoparticles have been hailed as revolutionary vehicles for biomedical 
research in the 21st century. Nanoparticles (NPs) can be defined as a 
material that has at least one dimension less than 100nm (Bosselmann 
S Fau - Williams and Williams, 2004). At the nanoscale, materials 
develop novel properties that are distinctive to the bulk material. 
Indeed, NPs develop unique and often advantageous properties 
including optical, magnetic, catalytic, thermodynamic and 
electrochemical properties (Levy and Shaheen et al., 2010).  
At present there are a multitude of NP types, with an inherent range of 
functions and capabilities.  These particles are generally sub-divided 
into either organic NPs, such as organic polymers, liposomes (Torchilin, 
2005) and dendrimers (Lee and MacKay et al., 2005); or inorganic NPs 
including quantum dots (Medintz and Uyeda et al., 2005) magnetic iron 
oxides (Lu and Salabas et al., 2007), gold NPs (Huang and Jain et al., 
2007.,Sanvicens and Marco, 2008) and mixed alloy NPs (Liong and Lu 
et al., 2008.,Sun and Kandalam et al., 2006).  Each type of NP has 
different properties that infer advantages depending on the biomedical 
application being considered (Ferrari, 2005). These unique properties 
allow better imaging, delivery and remote activation of the NP, allowing 
for a more intelligent delivery system (Bosselmann S Fau - Williams and 
Williams, 2004.,Jokerst Jv Fau - Gambhir and Gambhir, 2011).  
When considering inorganic particles, a main advantage of their use as 
a delivery platform are their inherent optical and imaging properties, 
whether in vitro or in vivo; which is hugely beneficial in a clinical setting 
as it allows remote NP tracking.  For example, quantum dots (QDs), 
which are fluorescent inorganic nanocrystals with a broad absorption 
spectra, can be tailored to release a narrow band of emission 
frequencies; producing better signal brightness and a greater resistance 
to photo bleaching of samples when compared with traditional organic 
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dyes (Liu and Yang et al., 2012). Gold NPs are more established, having 
been used for decades in biological imaging, including via immunogold 
labelling in transmission electron microscopy. A further example is the 
use of magnetic NPs, such as iron oxide, which are employed as 
contrast agents in magnetic resonance imaging to aid image generation 
(Ghosh and Han et al., 2008). These imaging technologies play a crucial 
role in disease diagnoses and their subsequent treatment (Na and Song 
et al., 2009.,Leduc and Jung et al., 2011).  
Aside from the benefits of allowing remote imaging, inorganic NPs  
provide researchers and clinicians with a multifunctional tool that can be 
used as a cellular or tissue delivery system. The control of NP design 
and assembly, through recent advantages in nanotechnology, can help 
tailor the properties of a NP towards a particular application (Aili and 
Gryko et al., 2011). The success of NPs in this regard is due to 
multivalency; a property that allows a NP to have a range of 
attachments or ligands that can facilitate a multitude of tasks (see 
section 1.1.2). 
Nanoparticles have gained more interest for medical application than 
larger particles for a number of reasons. Larger particles such as micro 
particles have poor circulation in vivo, have difficulty crossing 
membranes and can aggregate producing complications like embolisms 
or ischemic events (Kohane, 2007). 
1.1.1 Cellular Uptake of NPs 
Before the successful application of biomedical NPs, the issue of delivery 
must be addressed, whereby cells must first uptake the NPs. Uptake 
can naturally happen through the process of phagocytosis (occurs only 
in specialised cells), passive diffusion and endocytosis (Kuhn and 
Vanhecke et al., 2014). Here we focus on endocytosis, which can be 
loosely divided into three main mechanisms: i) clathrin mediated 
endocytosis, ii) caveolin mediated endocytosis, iii) macropinocytosis. 
Endocytosis can be receptor mediated, as shown in Figure 1-1, and 
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when considering the uptake of NPs, generally relies on either clathrin-
mediate uptake or caveolin-mediated uptake (Benfer and Kissel, 
2012.,Chithrani and Chan, 2007.,McMillan and Batrakova et al., 2011). 
Clathrin mediated endocytosis involves small 100 nm vesicles that are a 
complex of proteins associated with the cytosolic protein Clathrin 
(Mukherjee and Ghosh et al., 1997.,Mellman, 1996). Found in virtually 
all cells, clathrin-coated vesicles are formed from initial invaginations in 
the cell membrane, to which clathrin is recruited. Clathrin coated pits 
are then generated, which are pinched off from the membrane to form 
vesicles via dynamin. Large extracellular molecules have 
different receptors responsible for clathrin-receptor-mediated 
endocytosis such as antibodies, transferrin and growth factors. 
Caveolin mediated endocytosis is also a common feature of many cell 
types and includes Vip21 a cholesterol-binding protein (Doherty and 
McMahon, 2009.,Conner and Schmid, 2003). Caveolin-mediated uptake 
is characterised by ~50 nm diameter pits in the membrane with up to a 
third of the plasma membrane covered in these pits in some cells such 
as smooth muscle and fibroblasts. It is thought that extracellular uptake 
of molecules/nanoparticles is mediated via receptors in the caveolae.  
As indicated in Figure 1-1, macropinocytosis also occurs. This is 
essentially cell drinking, with general uptake of the surrounding fluid 
(Swanson and Watts, 1995). It occurs within highly ruffled areas in the 
plasma membrane; these invaginations in the cell membrane form a 
pocket, which closes over to form a vesicle (0.5–5 µm in diameter) filled 
extracellular fluid, unintentionally containing any added NPs. This allows 
around 100 times more extracellular fluid to enter the cells compared to 
clathrin-mediated endocytosis and is a non-specific uptake mechanism. 
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Figure 1-1. Mechanisms of endocytosis. The three main mechanisms of 
endocytosis are (i) clathrin-mediated, (ii) caveolae and (iii) 
macropinocyctosis. Endocytosis is a naturally occurring process whereby 
a cell uptakes external material. It is readily capitalised upon to 
enhance the uptake of therapeutic nanoparticles. (© 2012 Maude 
Boisvert, Peter Tijssen. Adapted from (Boisvert and Tijssen, 2012); 
originally published under CC BY 3.0 license. Available from: 
http://dx.doi.org/10.5772/45821 
1.1.2 Multivalency 
Multivalency describes our ability to use a NP surface as a platform to 
attach ligands, in particular the capability of attaching multiple 
individual ligands. This allows us to functionalise a NP with specific 
cargo or to provide certain beneficial properties, such as genetic 
material (e.g. DNA or RNA sequences), peptides and drugs, or cell-
targeting ligands respectively. This creates a multifunctional NP, 
allowing us to combine the inherent NP properties (e.g., in terms of 
imaging etc.) with further benefits in terms of molecule delivery to cells 
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and tissues.  This ability to produce a particle with a number of different 
ligands or tags allows for a wide range of both diagnostic and 
therapeutic capabilities (Figure 1-2) (Cheng and Meyers et al., 2011).  
Gold NPs (AuNPs) are particularly well situated in this regard. They are 
well established in cell biology, and are known to be relatively inert and 
therefore very applicable in biomedicine, with a history of use that 
spans decades both in vivo and in vitro. AuNPs are easily produced in a 
range of diameters and easily functionalised with a number of different 
components using thiol linkage (Levy and Shaheen et al., 2010).  A 
variety of ligands are typically considered when designing a NP for 
biomedical applications.  
 
Figure 1-2. Schematic of the multiple types of ligand that can be 
attached to create a multivalent NP. 
1.1.2.1 Passivating Ligand 
Passivating ligands are attached to NPs with the aim of both conferring 
NP stability in solution and also shielding the NP from the immune 
system in vivo, allowing for a longer half-life. Various arrays of sugars 
and polymers have been used to date, however the most widely used is 
polyethylene glycol, PEG, (a polymer of ethylene oxide) (Wang and Wei 
et al., 2013 .,Simpson and Agrawal et al., 2011.,Sant and Poulin et al., 
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2008.,Rahme and Chen et al., 2013.,Pittella and Zhang et al., 
2011.,Oishi and Nakaogami et al., 2001b.,Kah and Wong et al., 
2009.,Jokerst and Lobovkina et al., 2011.,Free and Shaw et al., 2009). 
Adding PEG to the NP surface a process known as PEGylation, is known 
to increase the circulation time of NPs by resisting opsonisation, leading 
to PEG being described as having ‘stealth’ properties. Opsonisation is a 
process involving the absorption of proteins on to the surface of the 
material, leading to the NPs being recognised, phagocytised and cleared 
(Juliano and Alam et al., 2008). PEG is amphipathic, has a range of 
molecular weights depending on polymer length and can be further 
functionalised with other reactive groups. Indeed, organic polymers 
such as PEG, are invaluable for increasing the stability of the NP and in 
turn increasing the therapeutic potential (Liu and Shipton et al., 2007). 
Additionally PEG has a low toxicity, is FDA approved and has been used 
in biomedical applications for decades (Jokerst and Lobovkina et al., 
2011).  Varying the chain length of PEG, the density of PEG on the NP 
particle and the conformation of the PEG can alter the level of steric 
hindrance exhibited by a NP. Steric hindrance is the reduction or 
blocking of intra- and intermolecular interactions due to the spatial 
arrangement of passivating molecules. By using steric hindrance, NPs 
can be produced with a low aggregation potential. 
1.1.2.2 Targeting Ligand 
Targeting ligands are selected with a view towards localising NPs to the 
cell surface and encouraging cellular uptake, thereby increasing the 
potency of the drug/gene cargo. The integrin-binding motif RGD 
(Arginine-Glycine-Aspartic acid), which ubiquitously binds to specific 
integrins on the plasma membrane of many cell types, has been used 
as a potential targeting molecule to aid cell-nanoparticle binding and 
allow for greater uptake (Kumar and Ma et al., 2012a). Cell penetrating 
peptides such as TAT peptide (derived from the transactivator of 
transcription sequence) isolated from the HIV virus, have been used 
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extensively to increase NP uptake (Meade and Dowdy, 2008.,Berry, 
2008)  
In addition, targeting ligands are also selected to associate with specific 
cell surface receptors, allowing cell-type targeting (Gao and Dagnaes-
Hansen et al., 2009.,Leamon and Low, 1991.,Davis and Zuckerman et 
al., 2010).  For example CRGDK (a peptide sequence that binds to 
neuropilin-1, a receptor over expressed in certain cancers) was used to 
target AuNPs and a therapeutic payload to cancer cells, and folate has 
also been adopted for cancer cell targeting (Kumar and Ma et al., 
2012b).   
 
1.1.2.3 Imaging Ligand 
Depending on the type of NP, some have innate imaging properties, 
such as magnetic NPs (viewed by NMR) and QDs (viewed by NIR 
imaging) (Medintz and Uyeda et al., 2005.,Jokerst and Gambhir, 
2011.,Weng and Song et al., 2006.,Liong and Lu et al., 2008.,Derfus 
and Chen et al., 2007), however others, such as gold NPs, may require 
additional ligands to allow NP imaging in vitro and in vivo. These have 
ranged from attaching biotin onto the NP and using streptavidin-linked 
fluorophores, to directly conjugating fluorescent tags to the NP, such as 
fluorescein, cy- dyes and dylight to name a few (Conde and Ambrosone 
et al., 2012).  
 
1.1.2.4 Therapeutic Ligand  
Whilst passivating, targeting and imaging ligands are important, the 
attachment of a therapeutic ligand is perhaps the more interesting, as 
this opens up the potential for NPs to be used in nanomedicine.  There 
have been many types of therapeutic ligands used to date, ranging from 
small molecules, such as siRNA and miRNA, through to larger drug 
entities. Some NPs however have innate therapeutic potential, e.g. 
using an NIR laser on AuNPs can induce heating, with the resulting 
22 
 
thermal ablation killing tumour cells (Huang and El-Sayed, 2010).   The 
mechanism of attachment to the NP is critical, and can determine the 
success or failure of the NP as a delivery platform.  For example ionic 
attachment has been shown to be weaker than covalent attachment, 
with the resulting payload dissociating too quickly, often in the 
extracellular space before gaining cellular entry (Conde and Ambrosone 
et al., 2012).Covalent attachment is generally much stronger and when 
considering AuNPs, using a thiol linkage is an excellent method, 
allowing for very high association with the NP, whilst also permitting 
intracellular dissociation via glutathione in the cell cytoplasm (Lushchak, 
2012.,Meister and Anderson, 1983.,Wu and Fang et al., 2004.,Lei, 
2002.,Fang and Yang et al., 2002.,Meister, 1988). Glutathione is a 
common antioxidant found within cells.  The reduced form of 
glutathione (GSH) prevents damage to intracellular components from 
free radicals. GSH has been shown to reduce thiol bonds and is the 
main mechanism for release of components attached by thiol bonds to 
the AuNP surface (Kumar and Meenan et al., 2012). 
The point of attachment is also of importance, if attached directly to the 
NP and shielded by the passivating ligand, the payload remains stable 
and functional for longer, whereas direct attachment onto the 
passivating ligand surface can result in degradation, and poor functional 
effects for the targeting ligand (Conde and Ambrosone et al., 2012). 
1.1.2.5 Benefits of Multivalency 
When designing multifunctional NPs it is important to consider the 
optimal concentration of each ligand on the NP surface, and how these 
functional groups could interact with each other. A study by Derfus et al 
investigated the optimal number of siRNA per QD NP to induce efficient 
protein down regulation coupled with anti-cancer peptides. They found 
that a single siRNA molecule in conjunction with 15 or more anti-cancer 
peptides attached to a PEGylated QD gave optimal silencing.  Doubling 
the siRNA molecules attached to the NP achieved the same level of 
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silencing, but required less than 10 targeting peptides (Derfus and Chen 
et al., 2007).  
As described above, multivalency offers benefits, not only in terms of 
delivery into cells (using targeting ligands), but also as a protection 
against degradation of the payload. For example, the delivery of siRNA, 
with a view to silencing specific target genes, has much potential. 
However siRNA molecules with no delivery vector are rapidly removed 
from the blood system by the kidneys. By attaching the siRNA directly 
to a NP, the half-life of these siRNA molecules can be significantly 
extended (Derfus and Chen et al., 2007.,Juliano and Alam et al., 
2008.,Soutschek and Akinc et al., 2004). In 2010 a multifunctional NP 
was employed in human phase I clinical trials (Davis and Zuckerman et 
al., 2010). The NP was a cyclodextran-based polymer (CDP) NP, 
stabilized with polyethylene glycol (PEG), with siRNA cargo and a cell 
targeting peptide (transferrin). The NP was administered to patients 
with solid tumors, resulting in an intracellular accumulation of NPs 
predominantly within the tumors. The siRNA conjugated NPs were 
shown to be functional, via reduced levels of the target mRNA and its 
protein by quantitative real-time PCR and western blotting. Immuno-
staining of tumour biopsy pre- and post-treatment, show an acute 
reduction in the spread of the melanised tumour. This groundbreaking 
study showed that by using RNAi technology via a multifunctional NP as 
delivery agent, oncogene expression in humans could be altered. 
Multivalency also presents us with the opportunity to create a NP to 
broadly target and knockdown multiple genes at once (Juliano and Alam 
et al., 2008). The potential to create multi-therapeutic vectors is 
believed by Paciotti et al (2004) to be vitally important for treating 
many disease states, being particularly effective with potential cancer 
treatments (Paciotti and Myer et al., 2004). Tumours do not exist in a 
homogenous environment; they are composed of multiple cancerous 
cell types, requiring an effective NP to target a broad spectrum of cells 
present within the tumour (Spremulli and Dexter, 1983.,Dexter and 
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Kowalski et al., 1978). This could be achieved, for example, by 
attaching multiple siRNA sequences against a variety of oncogenic 
proteins, or by a combination of siRNA and anti-cancer drugs such as 
paclitaxel (a chemotherapy drug, from the taxane family) working in 
partnership to increase the potency of the NP (Iwase and Shimada et 
al., 2006). 
Song et al studied the functional properties of a multivalent protamine-
antibody fused protein with multiple siRNAs targeting three oncogenes 
in vivo (Song and Zhu et al., 2005). In their study they used siRNA 
targeting C-Myc, MDM2 and VEGF; three well established oncogenes. C-
Myc induces cell proliferation (de Nigris and Balestrieri et al., 2006), 
MDM2 silences p53 (a cell cycle check point protein)(Halaby and Yang, 
2007) and VEGF is a growth factor predominantly found up regulated in 
tumour cells to promote angiogenesis and metastasis (Grothey, 2006).  
The multiple siRNA strategy significantly reduced proliferation of the 
melanoma cells in mice. Proving this approach can work in complex 
biological systems. Changing Song et al’s delivery vector of a 
protamine-antibody fusion protein to a liposome based NP, Li et al 
where able to increase the potency of the siRNAs. Metastasis in the 
murine lung cancer model was reduced by 70-80% in comparison to 
free siRNA (without a delivery vector) (Li and Chono et al., 2008). 
Therefore, combining multiple siRNAs with a NP delivery vector allowed 
Li et al to improve on Song et al’s previous work, by increasing the 
RNAi’s potency whilst protecting the siRNA sequences through the 
properties of the nanocarrier. 
1.1.3 Multivalency Leading Towards a Theranostic Nanoparticle 
As described above, NPs can be functionalised with imaging molecules, 
such as fluorescent tags, targeting molecules and a therapeutic 
payload. This potential allows for NPs to be used with a view to 
simultaneously diagnose disease, and apply treatment therapeutically, 
coining the term  “theranostic” NPs (Lee and Lee et al., 2009.,Derfus 
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and Chen et al., 2007). A theranostic NP would aim to target a specific 
disease site, report back via imaging the diseased cells and in turn 
deliver some form of treatment (eg. siRNA, peptides, molecules). Such 
a theranostic NP was reported in 2007 by Medarova et al, where a 
magnetic NP was designed to specifically associate with tumours, using 
a modified membrane translocation peptide (myristoylated polyarginine 
peptides) as detected by imaging using both an attached Cy5.5 dye and 
via MRI. The NPs successfully delivered siRNA sequences against green 
fluorescent protein (GFP) into GFP-expressing cells (Medarova and 
Pham et al., 2007).  The authors reported an accumulation of NPs 
within the tumours, due to the enhanced permeability effect (Kobayashi 
and Watanabe et al., 2014). Tumours tend to have high retention 
effects as a result of the highly leaky and vascularised tissue, known as 
the enhanced permeability and retention effect. The addition of tumour-
targeting moieties should increase this targeting effect (Chauhan and 
Stylianopoulos et al., 2011).  
In 2009 Cheon et al created a theranostic magnetic NP, which featured 
a fluorescent dye, a cell-specific targeting motif and siRNA with a view 
to targeting, imaging and treating diseased cells in vitro (Lee and Lee et 
al., 2009). Also in that year, Lee et al furthered the concept of a 
theranostic NP. They created a multifunctional NP that utilised (i) the 
integrin-binding motif Arg-Gly-Asp (RGD) as a means to increase 
cellular uptake; (ii) PEG to increase the stability of the NP; (iii) Cy5 to 
facilitate imaging; and (iv) siRNA against GFP as the therapeutic model. 
The NP was found to be less toxic than the popular delivery method of 
polyethyleneimine (PEI), with the authors concluding that creating 
synergy between diagnosis and treatment is the direction future 
medicine must take to increase potency and reduce off-target effects 
(Lee and Lee et al., 2009). 
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1.2 Gold Nanoparticles 
Gold NPs (AuNPs) have been used for centuries, such as colloidal gold in 
stained glass, but only in the last few decades has the extent of their 
abilities been realised for potential biomedical applications (Alkilany and 
Murphy, 2010.,Chithrani and Chan, 2007.,Cho and Cho et al., 
2010.,Conde and Ambrosone et al., 2012.,Ghosh and Singh et al., 
2012.,Oh and Delehanty et al., 2011.,Paciotti and Myer et al., 2004). As 
alluded to in section 1.1.2, gold nanoparticles can be easily synthesised, 
in a wide range of sizes, quite simply by changing the length of time a 
solution of gold salts are left to be reduced by sodium citrate. Gold is 
typically an inert metal that is biocompatible, eliciting no immune 
response. As described briefly when considering multivalency, gold can 
be easily functionalised by thiol-linkage and click chemistry (generation 
of substances quickly and reliably by joining small units together), 
allowing for the relatively simple design and construction of a diverse 
range of multifunctional AuNPs (Salem and Searson et al., 
2003.,Sanvicens and Marco, 2008.,Chen and Li et al., 2012.,Cheng and 
Al Zaki et al., 2012.,Conde and Ambrosone et al., 2012). To protect the 
therapeutic payload and ensure NP stability, amphiphilic polymers such 
as PEG can be attached using thiol linkage directly onto the gold NP 
surface (Free and Shaw et al., 2009). 
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1.2.1 Gold Nanoparticle Uptake 
1.2.1.1 Cellular Uptake of Gold Nanoparticles 
As described in section 1.1.1, the success of any biomedical application 
employing NPs is dependent on the uptake of the particles into the cell 
body. The interplay between the size, shape and surface chemistry of 
the particle play a key role in determining this uptake 
AuNPs can have a range of size dependent and tuneable 
physicochemical properties, such as surface reactivity, surface plasmon 
resonance, and surface functionalisation (Chithrani and Ghazani et al., 
2006.,Liu and Shipton et al., 2007.,Free and Shaw et al., 2009.,Nel and 
Madler et al., 2009.,Chithrani, 2010.,Cho and Cho et al., 2010.,Decuzzi 
and Godin et al., 2010.,Lee and Huh et al., 2010.,Cebrian and Martin-
Saavedra et al., 2011.,Oh and Delehanty et al., 2011.,Kumar and Ma et 
al., 2012a.,Zhao and Zhao et al., 2012). Studies have shown that 
AuNPs are readily taken up by cells by both passive (diffusion) and 
active mechanisms (endocytosis) (Figure 1-1), however the actual 
mechanisms have not been fully elucidated as of yet, and a mix of the 
latter two in Figure 1-1 appears most likely (Chithrani and Chan, 
2007.,Chithrani, 2010.,Ma and Wu et al., 2011.,Oh and Delehanty et 
al., 2011). 
1.2.1.2 Influence of Nanoparticle Properties on Cellular Uptake 
Non-specific interaction between the AuNPs and serum proteins, termed 
‘opsonisation’, during cell culture has been suggested to have a major 
effect on the rate of uptake (Chen and Xu et al., 2008). Opsonisation 
results in the coating of the nanoparticle surface with proteins that are 
free in the cell media (via FCS/FBS). Many researchers pre-coat their 
NPs with a passivating ligand in an attempt to reduce this effect 
(section 1.1.2.1). For example, the addition of PEG to the surface of a 
AuNP prevents any non-specific interactions between the serum 
proteins and the functionalised AuNPs (Free and Shaw et al., 2009) 
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It should also be noted that the type of reactive group attached to the 
NP will result in a different surface chemistry layer, with functional 
groups such as COOH and NH2 inducing significantly different rates of 
uptake (Clift and Rothen-Rutishauser et al., 2008). However, Ehrenberg 
et al found that incubation in FCS/FBS for several hours levels out the 
differences in the uptake rates for these functional groups in vitro 
(Ehrenberg and Friedman et al., 2008). In comparison Giljohan et al 
(2007) produced AuNPs (13nm) with a mixed monolayer of 
oligonucleotides. They observed that greater amounts of 
oligonucleotides on the particle surface increased cellular uptake upon 
serum exposure in vitro (Giljohann and Seferos et al., 2007). This could 
be due to the negative charge of the oligonucleotides no longer being 
masked by the passivating ligand, in turn creating a charged NP that 
directly interacts with serum proteins. 
The overall charge of the NP is also an important consideration for 
efficient uptake (Chompoosor and Han et al., 2008). The cell plasma 
membrane is negatively charged, and maintains a negative membrane 
potential for efficient ion uptake.  Due to this negative potential across 
the membrane a NP with a positive charge would be attracted to the 
membrane and uptake would be facilitated. Amine functional groups 
and peptides with arginine exhibit positive charges that have been used 
to alter the surface charge of the NP (Clift and Rothen-Rutishauser et 
al., 2008).  
In addition to the chemistry, NP size is known to influence uptake. The 
diameter of the NP core can heavily influence the rate of uptake. 
Chithrani et al (2006) observed that core sizes below 100nm allowed for 
a greater uptake of particles per cell, with sizes above 100nm having 
greatly reduced uptake in HeLa cells (Chithrani and Ghazani et al., 
2006).  The actual NP shape is also known to influence cellular uptake.  
AuNPs can be made into a vast array of shapes, however data has 
indicated that spherical AuNPs have the greater uptake potential than 
rod shaped particles (Chithrani and Ghazani et al., 2006). A report by 
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(Alkilany and Nagaria et al., 2009) indicated a greater cytotoxic effect 
exhibited by rods in comparison to spherical gold. 
1.2.1.3 Endosomal Uptake  
Cellular uptake of AuNPs results in endosomal localisation. This can be 
problematic due to the acidic nature of the endosomal environment, 
that can range from ~pH6 in the early endosome to ~pH4.5 in the late 
endosome (Sorkin and Von Zastrow, 2002). This low pH can therefore 
cause the degradation of any attached drug or gene cargo. Thus, much 
effort is concentrated on tracking and localising NPs within the cell 
body. The time taken for cellular uptake to occur has been reported for 
different cell lines and particle types, with the uptake being described 
with as short as 30 seconds incubation (Sorkin and Von Zastrow, 2002).  
1.2.1.4 Nanotoxicology 
With the exponential use in NP bioapplications and the implications for 
human health, The Royal Society and The Royal Academy of 
Engineering published a report in 2004 dedicated entirely to the 
opportunities and potential dangers of NPs. The report concluded that 
all newly synthesised NPs must be viewed as a new chemical and all the 
necessary precautions must be taken (Dowling and Clift et al., 2004). 
The report led to the creation of a new discipline; nanotoxicology. 
Nanotoxicology aims to assess the safety issues concerned with the use 
of NPs, by evaluating the risks involved in exposure to NPs and the 
mechanisms involved in NP toxicity (Fischer and Chan, 
2007.,Oberdorster and Maynard et al., 2005).  Nanotoxicological studies 
are of a pressing concern at present, as multiple NPs are entering the 
clinical trial phase. The need for studies is compounded by growing 
public concern and awareness of NPs in everyday items, such as sun 
creams, food packaging and cosmetics, and their potential impact on 
the environment and our health (Miller, 2006). 
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Nanotoxicology studies to date have produced mixed results, with a 
review by Sanvicens and Marco reporting effects at the cellular, 
subcellular, protein and gene levels (Sanvicens and Marco, 2008). 
Lovric et al (2005) found green mercaptopropionic acid-coated CdTe 
QDs (2nm diameter) damaged not only the plasma membrane but also 
the mitochondria and nucleus (Lovric and Cho et al., 2005). AuNPs have 
also been assessed in terms of nanotoxicology (Alkilany and Murphy, 
2010). A report by Su et al (2007) described a toxic dose dependant 
effect of Au-nanoshells in BALBc mice (Su and Sheu et al., 2007). 
However a subsequent study by Qian et al (2008) showed that 
PEGylated AuNPs administered to mice produced no cytotoxic effects or 
tissue damage, demonstrating the importance of passivating NP ligands 
(Qian and Peng et al., 2008). The NP size of gold has created some 
concern that cellular barriers would not be able to stop AuNP infiltration 
into cells, which could potentially lead to unintended cytotoxic 
effects(Connor and Mwamuka et al., 2005) . Based on these concerns, a 
group by Pan et al (2007) demonstrated that AuNP cytotoxicity is 
indeed size dependant. Four cell lines were studied: Hela (cervical 
carcinoma epithelial cells), Sk-Mel-28 (melanoma cells), L929 (mouse 
fibroblasts), and J774A11 (mouse monocytic/macrophage cells). The 
authors systematically increased the size of the AuNPs and observed for 
signs of toxicity. Results indicated that AuNPs with a diameter of 1-
2nms displayed high levels of cytotoxicity (Pan and Neuss et al., 2007). 
Another study by Chen et al indicated that AuNPs with a diameter of 
15nm were not toxic in human hepatoma cell culture (Chen and Xu et 
al., 2008). 
There are other studies that have highlighted additional factors such as 
NP concentration (Kirchner and Liedl et al., 2005), geometry (Cui and 
Tian et al., 2005), ligand side chains (Goodman and McCusker et al., 
2004) and surface modifications (Hoshino and Manabe et al., 2007) all 
play a crucial role in the potential nanotoxicity of a AuNP. 
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The nanotoxic properties must be assessed on a particle-to-particle 
basis, using adsorptions tests, distribution analysis, particle excretion, 
metabolism and the physiochemistry or toxicological properties of the 
AuNP in vitro (Sanvicens and Marco, 2008). This allows for a quick and 
easy assessment of NP toxicology, before moving into more complex 
risk assessment with in vivo studies. This conclusion was echoed by 
Conner et al (2003), who emphasised that AuNPs nanotoxicity was 
dependant on AuNP size and surface coating.   
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1.2.2 Regulation of Cells by RNA 
1.2.2.1 RNA Interference (siRNA) 
RNA interference, (RNAi) is a natural function of the intra-cellular 
machinery affecting gene expression (Figure 1-4) (Fire and Xu et al., 
1998). Originally thought of as ‘co-suppression’ and attributed to 
another mechanism of antisense silencing (van der Krol and Mur et al., 
1990.,Napoli and Lemieux et al., 1990). However in 1998, Fire and 
Mello proved that this ‘co-suppression’ idea was incorrect and that this 
new mode of silencing was something new. They concluded that dsRNA 
sequences are understood in eukaryotic cells as specific signals that can 
inhibit mRNA expression (Fire and Xu et al., 1998). This revelation 
resulted in both Fire and Mello receiving the Nobel Prize in Physiology or 
Medicine in 2006 (Zamore, 2006).   
Double-stranded RNA (dsRNA) >30nucleotides (nt) in length are 
exported by exportin 5 from the nucleus into the cytoplasm and cleaved 
by DICER (a ribonuclease enzyme), into 21-23nt fragments of small 
interfering RNAs (siRNAs) (Bernstein and Caudy et al., 2001.,Elbashir 
and Harborth et al., 2001.,Ohrt and Merkle et al., 2006.,Lommatzsch 
and Aris, 2009). In the cytoplasm, these siRNAs interact with the RNA-
induced silencing complex, RISC (Rand and Ginalski et al., 2004), 
becoming single stranded (Matranga and Tomari et al., 2005) and 
binding with complete complementary to the mRNA sequence (Ameres 
and Martinez et al., 2007).  Argonaute 2 (AGO2), a multi-functional 
protein found within RISC, is responsible for cleaving the bound mRNA 
between the 10th and 11th nucleotide from the 5’ end (Whitehead and 
Langer et al., 2009a). Cleaving and degrading the bound mRNA 
transcript effectively silences the gene.  
Over recent years RNAi has become the favoured method for gene 
knockdown studies in research. The advantages of RNAi over more 
traditional methods include the ability to target a broader range of 
genes and portions of regulatory code than classical drug inhibition 
33 
 
would facilitate. This is due to the very nature of RNAi, as any known 
portion of genetic code can be used to design a set of perfectly 
complimentary double stranded siRNA sequences (Huang and Li et al., 
2008).    Chemical inhibitors can be very time-consuming to produce, 
costly and are generally more toxic than RNAi sequences.  These 
advantages have led RNAi to emerge as an attractive therapeutic tool 
for clinical treatment of human genetic disease caused by abhorrent 
gene expression (Kurreck, 2009). 
1.2.2.2 MicroRNA 
MicroRNAs (miRNAs) were first discovered in 1993 in C.elgans, and 
have since become a key frontier for biomedical research, particularly in 
diseases such as cancer, but also in regenerative medicine using stem 
cells (Figure 1-3). 
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Figure 1-3. Timeline of major advances for miRNA studies, with 
particular focus on stem cells and osteogenesis (personal image). 
MiRNA differs from siRNA in the method of generation, as summarised 
in Figure 1-4. Where siRNA is normally double stranded and produced 
outside of the cell, miRNA is produced within the nucleus. It is exported 
and processed from pre-miRNA into a mature miRNA form. Both siRNA 
and miRNA form RISC complexes with AGO2 to target mRNA. However 
miRNA primarily represses mRNA transcript translation and only induces 
degradation when bound with a high degree of complementarity (Guo 
and Ingolia et al., 2010), whereas siRNA only acts to degrade mRNA 
transcripts with perfect complementarity,  
As described previously, siRNA binds with complete complementarity to 
its intended mRNA transcript, whereas miRNAs bind imperfectly to the 
3’ untranslated region (UTR) of mRNA. The UTR region is important for 
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mRNA stability and sub-cellular location. This miRNA/mRNA interaction 
represses the translation of a whole family of mRNA transcripts, 
providing less specificity, but a broader range. Translational repression 
by miRNA depends on the binding free energy of the first 8 nucleotides 
located at the 5′ end of the miRNA and the target mRNA (Doench and 
Sharp, 2004). MiRNAs have a major role in the regulation of many 
cellular processes; such as apoptosis, stem cell differentiation and 
proliferation (Zeng and Qu et al., 2012.,Wu and Xie et al., 2012.,van 
Wijnen and van de Peppel et al., 2013.,Sun and Wang et al., 
2009b.,Seca and Almeida et al., 2010.,Sartipy and Olsson et al., 2009). 
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Figure 1-4 Diagram comparing antagomir, miRNA and siRNA pathways and routes. SiRNA and antagomirs are made 
exogenously. A) Antagomirs enter the cell and bind to miRNA, blocking miRNA expression. B) MiRNA made in the nucleus 
are processed into hairpin structures, exported from the nucleus and cut with dicer to silence mRNA. C) SiRNA enters the 
cell and is processed by dicer, cutting the double stranded RNA into single stranded RNA. This RNA is loaded into the 
RISC complex silencing mRNA targets. Routes A and C will be used in this thesis. Adapted from (Rana, 2007).
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1.2.2.3 Blocking miRNA with Antagonists 
Recent advances in our understanding of small RNAs have shown the 
wide-ranging and dynamic effects that these small RNAs have on cells; 
from disease progression through to cell growth and apoptosis. From 
this new understanding people have sought to target miRNAs with 
possible therapeutic potential. To date, two methods of miRNA targeting 
have been successfully trialled:  
 Morpholinos; modified nucleic acid analogues containing a 
morpholino ring (Kloosterman and Lagendijk et al., 2007) 
 Antagomirs; usually containing a 2'-methoxy group or 
phosphorothioates as a method to prevent sequence degradation 
(Krutzfeldt and Rajewsky et al., 2005b) 
Morpholinos and antagomirs act by similar principles of blocking, that is 
to say that they tightly bind to the guide strand of the mature miRNA 
and prevent access of the miRNA to the mRNA (Schöniger and Arenz, 
2013). 
1.2.2.4 Delivery of Therapeutic siRNA and miRNA/Antagomirs 
Using siRNA therapeutically relies upon the transfection of mammalian 
cells with designed doubled stranded sequences that can bind to and 
silence the target genes’ mRNA with perfect complementarity. 
Sequences of siRNA are designed and created ex-vivo, however 
generally these sequences have a short half-life and are easily 
degraded. An alternative to conventional double stranded siRNA is 
short-hairpin RNA (shRNA) (~29nt long), which is capable of providing a 
longer lasting and higher stability of silencing (Shi, 2003.,Huang and Li 
et al., 2008.,Siolas and Lerner et al., 2005). ShRNA can be produced 
inside the cell with a DNA construct, but requires a viral vector. As with 
other viral technologies, the presence of the virus limits the potential 
clinical use of the shRNA.  In 2010 Ryou et al reported the successful 
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silencing of the p53 gene in HEK293 cells using shRNA against p53 
conjugated to gold nanoparticles. Due to the lack of viral DNA, 
knockdown decreased from 97% to 35% after 72 hours.   
MiRNAs and antagomirs can be synthesised into single strands and 
subsequently delivered into the cells. However as with siRNA, naked 
miRNAs have a short half-life and are also easily degraded. To bring this 
technology into more widespread therapeutic use, a reliable, non-viral 
and non-toxic method for siRNA and miRNA/antagomir delivery must be 
developed with a view for potential use in vivo, as the half-life and 
degradation of naked siRNA is a major hurdle to overcome. This method 
of delivery must: 
1) Protect the sequence from degradation once introduced into the body 
(Dykxhoorn and Lieberman, 2005.,Kim and Yeom et al., 2011),  
2) Be able to target specific cells e.g. the disease phenotypic cells  
(Derfus and Chen et al., 2007.,Doench and Sharp, 2004) 
3) Mask the negative charge of the sequences for efficient membrane 
crossing (Akhtar and Basu et al., 1991.,Wittung and Kajanus et al., 
1995.,Suh and Lee et al., 2013),  
4) Avoid endosomal degradation (Lee and Huh et al., 2010.,Ghosh and 
Singh et al., 2012)  
NPs therefore offer the ideal platform for delivery of such small 
regulatory molecules. The ability of NPs to meet and surpass the four 
criteria mentioned above creates numerous opportunities for biomedical 
science. However some challenges still need to be meet. For example, 
rapid excretion by the kidney, complex extracellular matrices, poor 
vascular permeability and clearance of NPs by the reticuloendothelial 
system (a collection of phagocytic cells that target and remove foreign 
objects) present complex challenges for the systemic delivery of 
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therapeutic payloads (Barry, 2008.,Juliano and Alam et al., 2008.,Gao 
and Dagnaes-Hansen et al., 2009).  
Within the cell, efficient delivery requires both (i) efficient cellular 
uptake levels, and (ii) availability of free siRNA within the cell to allow 
interaction with the RISC complex, which may depend on endosomal 
escape (Juliano and Alam et al., 2008). Creating a multi-functional 
vehicle to deliver therapeutic payloads such as siRNA or miRNA could be 
the panacea needed to overcome the aforementioned technical 
problems. Moderate success has been achieved by using some 
transfection methods (liposomal, polymer capsules) delivering siRNA  in 
vivo.  Indeed, Hepatitis B has been treated by reducing the FAS protein 
in mice by delivering an injection of siRNA with no delivery vector 
intravenously (Song and Lee et al., 2003). Although successful, this 
study required large volumes of siRNA to achieve protein knockdown, 
which in a clinical setting would be prohibitively expensive, with the 
potential for numerous off-target effects. Injection of siRNA into tissue 
can induce some limited therapeutic benefit (e.g. slow cancer 
progression), however a systemic approach to siRNA delivery and 
administration using a delivery vector could significantly enhance the 
therapeutic potential, and reduce the associative cost of delivery 
(Kurreck, 2009). 
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1.2.3 Nanoparticle-Mediated Delivery of Oligonucleotides 
Progress within gene discovery and analysis, has begun to investigate 
the link between gene dysfunction and disease phenotype. As the 
previous section has shown, targeting diseases at the genetic level is an 
attractive opportunity currently receiving a lot of attention within 
medical research. However, problems surrounding the delivery and 
functional activity of the oligonucleotide payload have to date hindered 
the developing technology. 
The combination of therapeutic siRNA with the adaptability of AuNPs 
creates an attractive platform for successful and targeted gene therapy. 
To date, there have been many studies to this effect. Derfus et al 
demonstrated that one siRNA per particle conjugated with >15 tumour 
homing peptides (F3) produced optimal knockdown and targeting 
(Derfus and Chen et al., 2007). Subsequently, Lee et al (2008) reported 
that PEG-siRNA (against GFP) complexes conjugated to AuNPs 
functionalised with amines group, could efficiently enter the cell whilst 
significantly knocking down the expression of GFP in carcinoma cells 
without producing any severe cytotoxicity (Lee and Bae et al., 2008). 
Other reports have shown that siRNA attached to AuNPs by thiol linkage 
are efficiently uptaken by cells and consistently knockdown the 
expression of the targeted gene. A report by Acharya et al (2013), 
developed a AuNP conjugated with KDEL peptides and siRNA against 
Nox4, delivered to C2C12 myoblasts. The authors reported a 55% 
knockdown of Nox4 at the gene level at 24 hours (Ryou and Kim et al., 
2010.,Giljohann and Seferos et al., 2009.,Dreaden and Mackey et al., 
2011). Therefore the potential for using NPs to deliver therapeutic 
siRNA is apparent. 
The delivery of multivalent NPs has also been achieved. Kim et al 
successfully demonstrated the potential of targeting cells using a 
combination of folate (FOL) and PEG attached to polyethylenimine (PEI) 
to significantly reduce GFP gene expression by siRNA (targeted against 
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GFP) loaded into polymer NPs (PEI-PEG-FOL) (Kim and Mok et al., 
2006). When applied to folate expressing cells these NPS were more 
readily uptaken as compared to control NPs lacking any folate or PEG. 
Despite the differences in NP type, cell type, study time courses etc, 
when taken together, along with the multiple other studies in this field, 
there is certainly promise for siRNA functionalised NPs in nanomedicine.  
Some studies have been advanced to the in vivo stage. For example 
Schiffelers et al (2004) created self-assembling polymer NPs with PEI-
PEG, in addition to the RGD ligand, to enhance delivery of siRNA into 
cancer cells in mice. The authors reported successfully reducing the 
VEGF R2 oncogene, and in vivo prevented an increase in tumour size. 
(Schiffelers and Ansari et al., 2004).  
Ghosh et al (2013) addressed a number of issues surrounding miRNA 
delivery. Most miRNAs require expensive modifications to increase 
stability, and some delivery method such as lipofectamine, which is 
toxic to cells. The author’s developed a system using AuNPs, conjugated 
with PEG and miRNA (mir-31,-1323), attached by ionic bonds to the 
gold surface. They reported a higher payload density than 
lipofectamine, efficient uptake and low cytotoxicity compared to 
lipofectamine (~98% cell survival). In 2011 Kim et al, developed a 
system that targeted mir-29b with antisense RNA (antagomir-29b). The 
antagomirs were conjugated to AuNPs (13nm) and delivered to HeLa 
cells. The authors reported an increase of MCL-1 at the protein and 
mRNA level upon addition of the antagomir-AuNPs. However the 
authors did not report the use of any polymer coating, which could have 
limited the success of the delivery (Kim and Yeom et al., 2011). 
Conde et al (2013) developed upon this system for targeting miRNAs. 
Using AuNPs (~15nm) they targeted mir-21 with antisense RNA and 
protected the AuNP with PEG. The antisense RNA was created as a 
hairpin structure with the 3’ end containing a cy- dye and the 5’ end 
containing a thiol group allowing for covalent attachment to the AuNP. 
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The authors successfully reported a ~89% knockdown of mir-21 by RT-
qPCR in HCT-116 cells (a colorectal carcinoma). 
These studies are excellent examples of the scope of using NP 
multifunctionality to successfully deliver siRNA and miRNA/antagomirs. 
1.3 Targeting Cancers Using an siRNA-Nanoparticle 
Delivery Platform 
1.3.1 Targeting Genetic Disease  
Damaged or disregulated expression of one or more genes is 
responsible for a wide range of human diseases. Nanomedicine is 
currently geared towards the targeting and treatment of known genetic 
aberrations in disease. Huntington’s disease has received a lot of media 
attention as an autosomal dominant disorder caused by lengthening of 
a CAG repeat sequence in the genetic code (Walker, 2007). Additionally 
cystic fibrosis is an autosomal recessive disorder in humans, produced 
by mutations in the gene cystic fibrosis transmembrane conductance 
regulator (CFTR) (Lommatzsch and Aris, 2009). With Duchenne 
muscular dystrophy, a mutation in the dystrophin gene produces an x-
linked recess disorder (Odom and Banks et al., 2010). One method of 
facilitating treatment is the delivery of novel oligonucleotides, to either 
silence or replace the dysfunctional genes. 
Conjugating cholesterol directly to siRNA, targeting ApoB (a gene 
associated with heart disease), was found by Soutshek et al (2004) to 
enhance the pharmokinetics of the siRNA and increase cellular uptake of 
the siRNA (Soutschek and Akinc et al., 2004).  This increase although 
impressive, was overshadowed by Zimmerman et al (2006), who 
conjugated siRNA onto stable nucleic acid lipid particles (SNALPs). 
These SNALPs were capable of even greater silencing in the same ApoB 
mouse model used by Soutschek et al (2004). Zimmerman et al (2006) 
demonstrated that a SNALP based delivery method was capable of 
reducing ApoB mRNA by up to 90% in non-human primates.  
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The above conditions, although serious, are fairly rare in comparison to 
global rates of cancer, which account for 13% of all deaths per year, 
thus cancer remains one of the major treatment goals in nanomedicine 
(Ferlay and Shin et al., 2010). 
Cancer is a multipoint disease, with many genetic mutations resulting in 
unregulated cell growth and consequential formation of tumours 
(Santarius and Shipley et al., 2010). Within the human genome 
approximately 600 proposed genes are involved in cancer formation and 
progression. These genes are linked to angiogenesis, apoptosis, cell 
cycle control, DNA repair, metastasis (Pawaiya and Krishna et al., 
2011). 
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1.3.2 C-Myc Protein and Cancer 
The C-Myc gene was first reported in a Burkett’s Lymphoma patient 
(Dalla-Favera and Bregni et al., 1982). Since its discovery, the gene has 
been cloned (C-Myc) and has become one of the most studied 
oncogenes to date (Beroukhim and Mermel et al., 2010). C-Myc is an 
essential transcription factor that regulates signal transduction for 
proliferation pathways. Whilst being vital to healthy cell survival, 
deregulated C-Myc has been found in approximately 95% of human 
cancers (Figure 1-5) (Beroukhim and Mermel et al., 2010).  
 
 
Figure 1-5. Effect of stimuli on C-Myc expression in healthy and 
dysregualted cells. Figure adapted from (Cassinelli and Supino et al., 
2004) 
In healthy cells C-Myc expression is highly regulated by multiple 
feedback loops such as Arf and p53. Transcribed C-Myc forms a dimer 
with another transcription factor ‘max’. This C-Myc/max complex can 
then bind to DNA (C-Myc-E Box 5’-CACGGTG-3’), activating a host of 
target genes (Liao and Dickson, 2000). To determine the exact number 
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of C-Myc target genes, a number of genome wide studies can be 
conducted (Li and Van Calcar et al., 2003.,Zeller and Zhao et al., 2006). 
A study by Li et al (2003), found that approximately 726 binding sites 
bound to C-Myc. This was corroborated by another study by Zeller et al 
(2006) that found 700 genes responded to C-Myc activation (Zeller and 
Zhao et al., 2006). Zeller et al (2006) used ChIP-PET (chromatin 
immunoprecipitation pair end tags) to map C-Myc binding sites. 
However a study by Ji et al (2011), identified a C-Myc core group of 50 
gene targets by combining and correlating genome wide ChIP-chip, 
ChIP-seq and microarray data from multiple cell types (Ji and Wu et al., 
2011). 
In 2012 a review by Dang, concluded that the majority of C-Myc studies 
suggested that C-Myc functioned as a master regulator, which was 
capable of affecting a broad spectrum of genes involved in energy 
metabolism, replication and division (Dang, 2012). Due to the high 
occurrence of C-Myc over-expression found in multiple types of 
cancerous cells, and the central role it plays in cell cycle regulation and 
proliferation, C-Myc is a very interesting candidate for gene therapy. 
Such a targeted approach should aim to normalise C-Myc levels and as 
a consequence slow down or halt the tumour formation and 
progression. 
1.3.3 C-Myc Oncogene Addiction  
A new approach for targeted cancer therapy is based on the theory that 
cancer cells become dependent on the expression of one main oncogene 
(Luo and Solimini et al., 2009). This theory has been dubbed ‘oncogene 
addiction’, and has been described as the Achilles heel of cancer 
(Weinstein, 2002).  C-Myc has been shown to be one of the major 
oncogenes that cells can become addicted to. To investigate this theory, 
Jain et al (2002) created a transgenic mouse model that, in the 
presence of doxycycline (dox) (an antibiotic that has shown promising 
anti-cancer properties), activated C-Myc expression. Their study found 
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that a brief inactivation of C-Myc lead to tumour regression and the 
transformation of osteogenic sarcoma cells to differentiate into mature 
osteocytes. Interestingly the authors noted that reactivation of C-Myc 
did not lead to the reactivation of the malignant tumour cells. They 
have proposed that the brief C-Myc inactivation has altered certain 
epigenetic features, desensitising the cells to C-Myc lead tumorigenesis 
(Jain and Arvanitis et al., 2002). This study reinforced the theory that 
temporarily targeting key oncogenes can have a long-term beneficial 
therapeutic outcome. The limits for this study come from a clinical point 
of view, where oncogenes could not be manipulated by dox treatment 
alone. However sustained delivery of dox produces toxic off-target 
effects in normal cells. This type of off target effect is reduced in RNAi 
treatments, as there are a lot of overlapping and complementary 
molecules regulating essential pathways in healthy cells. So from a 
clinical aspect oncogene addiction treated by oligonucleotides offers a 
therapeutic with very limited side effects, facilitated by some form of NP 
delivery vehicle. 
1.3.4 Targeting the C-Myc Protein by RNAi-siRNA 
Fire and Mello used C.elgans treated with specific dsRNA molecules that 
resulted in potent and significant silencing (Fire and Xu et al., 1998). 
Many studies afterwards have reiterated Fire and Mellos work, that 
dsRNA >30nts can silence genes in eukaryotes, such as D.melanogaster 
(Kennerdell and Carthew, 1998), and plants (Hamilton and Baulcombe, 
1999). The breadth and diversity of life that exhibited some form of 
RNAi lead researchers to consider using RNAi to target human genes.  
In mammalian cells however, the longer dsRNAs (>30nts) were found 
to produce a severe interferon (IFN) immune response, making them 
unacceptable for use in human targeted RNAi studies (Manche and 
Green et al., 1992). This problem was solved in 2001, using small 
artificial, exogenous dsRNA molecules of approximately 21nts in length 
(Elbashir and Harborth et al., 2001).  The smaller lengths were able to 
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silence the intended genes whilst preventing any IFN immune response. 
Since then, the increase in bioapplications utilising RNAi has been 
exponential, growing into a multimillion-dollar business (Castanotto and 
Rossi, 2009).  
Within 6 years from initial discovery in 1998, the first RNAi-based 
clinical trials began in 2004. The trial conducted by Acuity 
Pharmaceuticals targeted the expression of a VEGF receptor in the eye 
(Cand5) with siRNA, to treated patients with a form of macular 
degeneration that leads to adult blindness. The siRNA therapy reached 
phase III clinical trials and was reported by Bumcrot et al to reduce 
lesion size and improve near vision (Bumcrot and Manoharan et al., 
2006). This success led Acuity Pharmaceuticals to investigate if Cand5 
silencing could be used to treat diabetic macular edema (DME).   Other 
companies such as Merck-siRNA Therapeutics also started to bring their 
own versions of RNAi based therapeutics to clinical trials (Castanotto 
and Rossi, 2009). Alnylam Pharmaceuticals targeted respiratory 
syncytial virus (RSV) infections, using siRNA to reduce viral replication. 
They were the first antiviral siRNA therapy to make it to clinical trials 
(Castanotto and Rossi, 2009). To date, however, the therapies that 
have achieved clinical trial status mainly target easily accessible tissue, 
such as the lungs or the eyes, for siRNA delivery, and have not yet 
targeted more challenging tissue or diseases. 
As explained previously, successful delivery of therapeutic siRNA to 
challenging sites within the body that cannot be reached by direct 
injection or inhalation, requires a suitable delivery vector, such as NPs. 
These NPs must protect the RNAi from degradation within the body; 
remain in the bloodstream without being cleared by the kidneys 
(Dykxhoorn and Lieberman, 2005);  target a specific tissue or area 
(Derfus and Chen et al., 2007) and be easily taken up by the target 
cells (Akhtar and Basu et al., 1991.,Wittung and Kajanus et al., 1995). 
Bumcrot et al (2006) cite the ‘Lipinski Rules’ (a set of rules used to 
denote small molecule drug behaviour by the pharmaceutical industry), 
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for the poor uptake of siRNA into cells without the aid of a delivery 
vector. One of the rules states that: an octanol-water coefficient should 
be less than or equal to 5 and a molecular weight less than 500 Daltons 
(Da) are needed for successful uptake. SiRNA molecules break this rule 
with molecular weights of approximately greater than 13kDa and so 
require a delivery vector to circumvent this issue (Bumcrot and 
Manoharan et al., 2006).  
However siRNA have further issues, including their size, mainly that 
they are easily degraded in vivo, and rapidly excreted by the kidneys 
(Gao and Dagnaes-Hansen et al., 2009). It addition, siRNA permeates 
poorly through vascular tissue and extracellular matrices, and is cleared 
rapidly by phagocytes in the reticuloendothelial system (RES) (Barry, 
2008.,Juliano and Alam et al., 2008).  Due to these drawbacks, naked 
siRNA molecules have very little practical applications for RNAi therapy. 
Therefore the design of a multifunctional NP has become key to 
resolving the above issues before RNAi therapy can become a wide 
scale therapeutic option. 
1.3.5 Nanoparticles as siRNA Delivery Vehicles for Cancer 
Zukiel et al (2006) clinically trialled RNAi therapy to treat human 
glioblastoma multiform brain tumours. The results concluded that 
although direct, localised injections of siRNA inhibited cancerous cells, 
there were differences in patient response. Additionally some patients 
had sections of the tumour removed, making direct comparisons of 
tumour regression difficult. The procedure itself was invasive and 
required a surgical team (Zukiel and Nowak et al., 2006).   
A growing volume of evidence indicates that attachment of siRNA onto a 
NP enhances siRNA administration and uptake (Bumcrot and Manoharan 
et al., 2006). Numerous delivery agents have been studied, from 
liposomes to organic polymers and inorganic nanoparticles. Liposome 
delivery has been used within the last decade from ovarian cancer 
treatment (Halder and Kamat et al., 2006.,Landen and Chavez-Reyes et 
49 
 
al., 2005) to liver metastasis in mice (Yano and Hirabayashi et al., 
2004). Cancerous bone tissue was administered with atelcollagen 
loaded with siRNA (Takeshita and Minakuchi et al., 2005). However 
liposomal delivery has a number of significant drawbacks as 
summarised by Gabizon et al (2006): i) encapsulation of cargo can be 
difficult, ii) delivery and release is effected by serum proteins and can 
‘leak’ through the liposomal layer, iii) cell targeting specificity, iv) half-
life (Gabizon and Shmeeda et al., 2006)   
Conde et al (2012) created a multifunctional AuNP conjugated with 
siRNA against C-Myc, PEG to shield the siRNA and to stabilise the NP, 
biotin for imaging of the NP (via streptavidin linked flurophores) and an 
RGD binding motif to increase cell uptake by integrin binding. The 
authors were the first to establish a NP system whereby functional 
siRNA was successfully delivered in three different models; in vitro 
human cell lines, a simple in vivo hydra model and an in vivo mouse 
model (Conde and Ambrosone et al., 2012). With up to a 65% reduction 
of native C-Myc levels being reported by this delivery vector.  
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1.4 MiRNA and Mesenchymal Stem Cells 
Aside from targeting disregulated gene expression in disease, NPs also 
have potential for use in regenerative medicine.  
1.4.1 Stem Cells 
Stem cells are a unique and highly valuable subset of cells. By definition 
stem cells have the ability to self-renew in an undifferentiated state 
indefinitely, whilst simultaneously being able to differentiate into 
multiple highly specialised cells upon receiving the correct cues.  Stem 
cells can have different levels of potency (Keller, 1995.,Pittenger and 
Mackay et al., 1999.,Williams and Hilton et al., 1988.,Clarke and 
Johansson et al., 2000). Pluripotent stem cells can develop into any cell 
type within the three germ layers of mesoderm, ectoderm and 
endoderm, whereas multipotent stem cells can develop into multiple cell 
types but are limited by the lineage they form. 
Stem cells have been classified into 3 main categories: 
 Adult stem cells 
 Embryonic stem cells 
 Induced pluripotent stem cells 
Adult stem cells were first identified in the 1960s from bone marrow 
samples, and were further classified into hematopoietic stem cells 
(HSCs) and mesenchymal stem cells (MSCs) (Becker and McCulloch et 
al., 1963); the differentiation capabilities of each is summarised in 
Table 1-1. 
 Origin Differentiation
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Table 1-1. Stem cell type, tissue of origin and differentiation potential. 
Name Tissue of 
Origin 
Differentiated Cell 
Types 
Hematopoietic Bone marrow All blood cells 
Osteoclasts 
Mesenchymal 
 
Adipose tissue 
Bone marrow 
Umbilical Cord 
 
Bone 
Cartilage 
Connective tissue 
Fat 
Muscle 
Nerve 
 
Embryonic stem cells (ESCs) were first isolated from mouse embryos in 
1981; a discovery that lead to the subsequent detection of stem cells in 
human embryos (Evans and Kaufman, 1981.,Martin, 1981.,Thomson 
and Itskovitz-Eldor et al., 1998).  More recently, the reprogramming of 
somatic cells into stem cells, known as induced pluripotent stem cells 
(iPSCs), became an area of intense study. However it was only with 
Yamanaka et al (2007) that real progress was made. The authors 
identified 4 key transcription factors (oct-3/4, sox2, klf-4 and C-Myc) 
that were required for reprogramming somatic cells back into a stem 
cell like state (Takahashi and Yamanaka, 2006.,Yu and Vodyanik et al., 
2007). The initial studies used viral based vectors to introduce the 
reprogramming factors. Although this method was very efficient at 
reprogramming, it did however create several hazards including 
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increased oncogene activation and dangerous mutations caused by viral 
genome integration.  
Recent advances for iPSC generation have moved away from viral based 
delivery methods and towards using RNAi. Although these methods are 
less risky, they also have much lower efficiencies (Kaji and Norrby et 
al., 2009.,Kim and Kim et al., 2009.,Woltjen and Michael et al., 
2009.,Zhou and Wu et al., 2009.,Kim and Thier et al., 2012).  Stem 
cells, although unique, are not a homogenous population. Differences 
exist between the location of stem cells, their local niche 
microenvironment, the capacity to form different cell types and their 
suitability for regenerative applications. These differences have been 
summarized in Table 1-2. 
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Table 1-2. Advantages and disadvantages of different stem cell types and their origins. 
Stem Cells Origin Potency Advantages Disadvantages 
Adult Stem Cells 
 
Adipose tissue 
Bone marrow 
Umbilical cord 
Multipotent Accessible 
Autologous 
Easy to culture 
Less ethical issues 
Multipotent 
Spontaneous 
differentiation 
Embryonic Stem 
Cells 
 
Inner cell mass of a 
blastocyst 
 
Pluripotent Pluripotent Complicated cell 
culture 
Ethical issues 
Immune rejection 
Tumorigenic 
Induced Pluripotent 
Stem Cells 
Reprogramming of somatic 
cells 
Pluripotent Autologous 
Pluripotent 
Low efficiency 
Tumorigenic 
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Both ESCs and iPSCs can generate all three germ layers, a 
characteristic known as pluripotency. Pluripotency is seen as a very 
attractive tool for regenerative medicine research. ESCs culture well and 
multiply in vitro, however in vivo, these cells can form tumours 
including teratomas, due to unchecked division, and may produce an 
immune reaction. Additionally the ethical issues that surround ESCs 
make them unsuitable for therapeutic use. 
Adult stem cells have several distinct advantages over ESCs and iPSCs. 
Adult stem cells such as mesenchymal stem cells (MSCs) are 
autologous, easily accessible for extraction and eliminate the risk of an 
immune response (Uccelli and Moretta et al., 2008). Despite all these 
advantages, adult stem cells are more prone to spontaneous 
differentiation when cultured in vitro, from a stem cell state into a more 
fibroblast phenotype (Sherley, 2002.,Sarugaser and Hanoun et al., 
2009). 
1.4.2 Mesenchymal Stem Cells (MSCs) 
MSCs have been discovered in adipose tissue, umbilical cord blood and 
Wharton’s jelly of the umbilical cord tissue, however, the most studied 
and best-characterised population of MSCs to date are derived from the 
bone marrow (Zuk and Zhu et al., 2001.,Lee and Kuo et al., 
2004.,Wang and Hung et al., 2004). MSCs appear as large cells with a 
fibroblast-like morphology. Whilst the cells were initially discovered in 
HSC cultures, MSCs were noted to behave differently, by adhering to 
the to tissue culture plates and forming clonogenic colonies known as 
colony forming unit-fibroblasts (CFU-Fs) (Becker and McCulloch et al., 
1963.,Friedenstein and Gorskaja et al., 1976.,Owen, 1988.,Owen and 
Friedenstein, 1988).  Much work subsequently concentrated on 
improving the isolation and characterisation of MSCs. 
55 
 
The discovery of a definitive marker of MSCs is currently an elusive goal 
for stem cell scientists. At present MSCs are defined by a presence or 
absence of a range of cellular markers (cell surface receptors or intra-
cellular protein expression), the main ones of which are highlighted in 
Figure 1-6 and Table 1-3. Positive markers include numerous surface 
markers (CD44, CD271), cell adhesion molecules (ALCAM) and cell 
surface proteins (Stro-1) (Casado-Díaz and Pérez et al., 2011). Stro-1 
is the most widely used marker to isolate MSCs from bone marrow, 
found in approximately 10% of the total cell population (Simmons and 
Torok-Storb, 1991.,Bakopoulou and Leyhausen et al., 2013.,Stewart 
and Monk et al., 2003). 
Table 1-3. Common MSC stem cell markers used in biomedical research 
as described by Casado-Díaz et al (2011). Positive markers highlighted 
in yellow, are markers that have been selected and used for the 
experimental work carried out for this investigation. 
Positive Markers Negative Markers 
CD29, CD44, CD71, CD73, 
CD90, CD105, CD106, CD120a,  
CD124, ICAM-1, MHC1, CD166 
(ALCAM),CD271, STRO-1 
CD11, CD14, CD18, CD34, CD40, 
CD45, CD80, CD86, MHCII 
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Figure 1-6. Differentiation potential of MSCs harvested from bone 
marrow, showing the most established stem cell positive cell markers  
MSCs reside within a highly ordered environment known as the bone 
marrow niche. Within this area two individual niches exist; the 
endosteal niche (near the osteoblast lined endosteal bone, which 
supports MSC quiescence and self-renewal) and a peri-vascular/peri-
sinusoidal niche (near blood vessels, supporting proliferation and 
differentiation). The endosteal niche, described by Zhang et al (2003) 
(Zhang and Niu et al., 2003) is composed of multiple cell types 
including osteoblasts, HSCs, MSCs and endothelial cells (Wang and 
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Zhang et al., 2012) (Figure 1-7). Signaling from the bone marrow can 
induce cycling of HSCs from the sinusoid to the outer bone marrow 
(Figure 1-7). Environmental signals ranging from the material stiffness 
and topography of the extracellular matrix to cell signaling (eg. 
cytokines, small RNAs and excreted proteins) can influence the 
proliferation, differentiation and migration of the MSCs (Laine and 
Hentunen et al., 2012.,Orford and Scadden, 2008). 
 
Figure 1-7. Interplay between the endosteal and sinusoid niches, in 
bone marrow. The endosteal niche is located near the osteoblast lined 
endosteal bone, which supports MSC quiescence and self-renewal. The 
sinusoidal niche normally located near blood vessels, supports 
proliferation and differentiation. HSCs migrate and bind to the nestin 
markers on MSCs. Blue cells show MSCs, pink indicate HSCs, Green 
osteoblasts and yellow endothelial capillary cells. Image adapted from 
Zhang et al (2003)  
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1.4.2.1 MSC Differentiation  
MSCs are derived from the mesoderm layer. It is possible with 
chemically defined signals to induce MSC differentiation, to form a 
multitude of cell types ranging from adipocytes to chondrocytes, 
fibroblasts, myoblasts and osteoblasts (Figure 1-6) (Pittenger and 
Mackay et al., 1999.,Majumdar and Thiede et al., 2000.,Gang and Hong 
et al., 2004).  
Controversially some evidence has indicated that MSCs may have the 
potential to transdifferentiate across germ layers into ectoderm or 
endoderm cell types, potentially increasing the differentiation potential 
(Tropel and Platet et al., 2006.,Woodbury and Schwarz et al., 
2000.,Wang and Bunnell et al., 2005.,Jiang and Jahagirdar et al., 
2002). 
1.4.2.2  Osteogenesis 
MSC differentiation into a mature bone cell type requires a multistep 
process, from MSC to pre-osteoblast and finally to a mature osteoblast. 
The process of cellular differentiation reduces the rate of proliferation 
but increases the secretion of extracellular matrix proteins such as 
fibronectin (FN) and type I collagen. Osteoblast-type cells produce 
specific cell markers, including the enzyme alkaline phosphatase, and 
bone mineralisation proteins (in particular osteopontin and osteocalcin) 
(Stein and Lian et al., 1990) . Key signalling pathways have since been 
identified, that are critical for osteogenesis, collated together in Figure 
1-8.  
Wnt (cell surface receptor) signalling was noted to alter osteogenic 
proteins levels, with Wnt3a thought to repress osteogenesis and 
increase proliferation (Boland and Perkins et al., 2004.,Siddappa and 
Fernandes et al., 2007).  
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The TGF-beta/BMP (bone morphogenic protein) pathway has also been 
identified to be critically important to the development of stem cells to a 
bone cell state (Linkhart and Mohan et al., 1996.,Rickard and Sullivan 
et al., 1994). 
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Figure 1-8. Osteogenic pathways found in hMSCs, combining BMP, Hedgehog, MAP and Wnt signalling. Red circles 
indicated a phosphorylated protein and red arrows indicate protein inhibition. This diagram is not an exhaustive list, and 
highlights only some of the complexity of signalling during osteogenesis. The area within the blue dotted line corresponds 
to the events within the nucleus, outside this represents the cytoplasm and the two parallel lines signify the plasma 
membrane. 
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1.4.2.3 Self-Renewal 
Self-renewal in MSCs is currently not well understood at the molecular 
level. Self-renewal in vivo is governed by complex signals within the 
niche, such as mechanical properties of the extracellular matrix, cell 
cycle and hormonal signals. Within the niche, stem cells undergo either 
symmetrical division; whereby one stem cell divides creating two stem 
cells, and/or asymmetrical cell division; whereby one stem cell is 
produced and retained in the niche whilst a progenitor cell exits the 
niche and differentiates (Kiel and Morrison, 2006).  
Asymmetrical cell division is thought to maintain tissue homeostasis 
and stem cell population within the niche environment, whereas 
symmetrical cell division is predominantly observed following an injury 
or during tissue development (Wilson and Laurenti et al., 2008).  
Internal and external signalling controls both symmetrical and 
asymmetrical division. Factors within the cell such as the mitotic 
spindle orientation to the niche, the presence of differentiation factors 
and cell polarity are crucial to the choice of division (Wodarz, 
2005.,Beier and Rohrl et al., 2008.,Yamashita, 2009). Outside the cell, 
signals such as differentiation factors relatively closer to one daughter 
cell can produce an asymmetric division.  
However, when cultured in vitro, MSCs are not subjected to this 
dynamic environment. MSC are traditionally cultured on a flat two-
dimensional surface, with a steady supply of nutrients and growth 
factors. As a result, MSCs in culture tend to undergo asymmetric 
divisions, typically referred to as spontaneous differentiation. These 
daughter cells usually form a fibroblast-like cell, which over time 
deplete the stem cell population (Banfi and Muraglia et al., 
2000.,Muraglia and Cancedda et al., 2000.,Siddappa and Licht et al., 
2007). Due to this loss of potency, the clinical potential of MSCs is 
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dependant on low passage numbers (Sherley, 2002.,Siddappa and Licht 
et al., 2007.,Sarugaser and Hanoun et al., 2009). 
1.4.3 Artificial Control of MSC Differentiation 
As mentioned previously, MSCs can respond to their environment 
through interactions with the extracellular matrix and signalling 
molecules. However MSCs can be artificially induced to differentiate by 
mimicking the properties of the extracellular matrix or by inducing 
chemical or small molecule signals. 
1.4.3.1 Chemical induction 
Dexamethasone (Dex) is a synthetic glucocorticoid that induces 
osteogenesis in MSCs. Although the pathway is still not fully understood 
several studies have linked Dex with regulation of hedgehog signalling 
(Siddappa and Licht et al., 2007.,Rickard and Sullivan et al., 1994). 
Other media supplements can stimulate adipogenesis with a 
combination of dexamethasone and indomethacin (Scott and Nguyen et 
al., 2011) or chondrogenesis  using GSK-3 (glycogen synthase kinase-
3) inhibitors in MSCs (Eslaminejad and Karimi et al., 2013). 
1.4.3.2 Topographical induction 
Cells, when cultured on surfaces, are capable of ‘reading’ topographies 
on surfaces just as they would identify and bind with extracellular 
matrix proteins. Controlling induction and differentiation by using 
specific topographical patterns is an exciting and rapidly advancing area 
of biomaterials. Authors Dalby et al (2007) found that disordered, 
nanoscale features (topographies) can alter MSC differentiation (Dalby 
and Gadegaard et al., 2007.,). McMurray et al (2011) later 
demonstrated that these designed nanoscale topographies can maintain 
MSC self-renewal or produce osteoblast cells from MSCs (McMurray and 
Gadegaard et al., 2011). Other groups demonstrated topographies 
improving cell adhesion, (Le Guehennec and Lopez-Heredia et al., 
2008.,Biggs and Richards et al., 2009), gene expression(Gasiorowski 
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and Liliensiek et al., 2010.,McNamara and McMurray et al., 2010) and 
proliferation (Milner and Siedlecki, 2007).  
1.4.4  Targeting MSC Differentiation by MiRNAs 
As mentioned previously miRNAs regulate a plethora of metabolic and 
regulatory networks (Guo and Zhao et al., 2011b.,Melton and Blelloch, 
2010.,Sartipy and Olsson et al., 2009.,Houbaviy and Murray et al., 
2003.,Dong and Yang et al., 2012) These can be transiently altered to 
target MSCs to undergo differentiation or to maintain multipotency (Wu 
and Xie et al., 2012.,Laine and Hentunen et al., 2012.,Deng and Wu et 
al., 2013.,Shi and Lu et al., 2013.,van Wijnen and van de Peppel et al., 
2013)  
Zeng et al (2013) found that under expressing mir-100 (a microRNA 
that regulates differentiation) induced an increase in osteogenesis, 
whereas overexpressing mir-100 significantly inhibited osteogenesis. 
Using duel luciferase reporter genes in vitro BMPR2 (bone morphogenic 
protein receptor 2), a protein kinase was found to interact with and be 
inactivated by mir-100. The mir-100 mimic and its inhibitor were 
transfected with Lipofectamine, into adipose derived MSCs (Zeng and 
Qu et al., 2012). However, as mentioned with siRNA delivery, 
lipofectamine as a delivery agent tends to be cytotoxic and reduce the 
long term viability of the cells. 
Deng et al 2013, furthered our understanding of the complexity 
between miRNAs and MSC differentiation (Deng and Wu et al., 2013).  
They reported a regulatory mechanism whereby mir-31 (microRNA 
involved in proliferation and osteogenesis) expression inhibited 
osteogenesis through RUNX2 (an early time point osteogenic 
transcription factor) and SATB2. As MSC cultures grew and 
differentiated into bone they found a progressive decrease in mir-31 
levels, with inhibition of mir-31 dramatically increasing alkaline 
phosphatase levels (a known bone protein marker, produced as a by-
product of osteoblasts). Mir-31 overexpression was induced by the 
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introduction of plasmids encoded with the miRNA. Although plasmid 
vectors are highly effective delivery mechanisms the possibility of off-
target effects, such as genome integration precludes this vector from 
clinical studies. 
In the same year Suh et al (2013), attempted to promote osteoblastic 
differentiation by targeting mir-29b (an anti-apoptotic and osteogenic 
miRNA) (Suh and Lee et al., 2013). Mir-29b was found to target anti-
osteogenic factors and the authors hoped delivery of the miRNA into 
hMSCs would instigate bone formation.  As with most RNA therapeutics, 
delivery was an issue, which the authors attempted to solve by creating 
a cell penetrating peptide that complexed with double-stranded miRNA 
using thiol bonds. Osteogenesis was confirmed with Alizarin red and 
osteocalcein staining.   
MiRNA delivery to MSCs to maintain multipotency or induce a certain 
cell type is a very new, novel and dynamic frontier.  The dosage of the 
miRNA, the duration of the dosage and the delivery vector are elements 
that need to be systematically investigated, to ensure we are 
developing successful and robust therapeutics for the clinic. 
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1.5 Project Outline and Aims 
With regards to cell engineering, medical research advances in the last 
twenty years have focused on tissue engineering and materials science. 
However the advent of stem cell research and nanotechnology, in 
particular NPs, and the pace at which both research areas are moving, 
allows for the opening of new avenues in nanomedicine and 
therapeutics. 
The mechanism of NP delivery is still an issue and there is still huge 
debate surrounding the potential toxicity of NPs in vivo. Delivery and 
release of the NPs cargo requires more optimisation, as there is 
significant difference between cell types, which affect the stability, and 
functionality of the cargo. Current research aims to resolve these issues 
and bring NP-mediated delivery of small molecules to the clinic. 
This project concentrated on using AuNPs as a delivery platform for 
small regulatory RNAs into bone tissue. All AuNPs were designed and 
synthesised in collaboration with chemists in Zaragoza (Spain) and 
Lisbon (Portugal). Two different cell types were employed in the 
project; the human osteosarcoma cell line, MG63, and primary human 
mesenchymal stem cells.  MG63s were chosen, as a cheap and easily 
cultured bone model. 
Chapter 3, the first experimental chapter, concentrates on C-Myc 
silencing in cancer cells via siRNA functionalised AuNPs. There are 
contradictions in recent literature as to the benefits conferred by the 
passivating ligand, and how these benefits actually depend on the 
ligand density and arrangement on the NP surface. Therefore, the main 
aims of this chapter were to: 
 Verify siRNA-AuNP delivery and uptake into MG63 cells 
 Identify C-Myc silencing (indicative of successful delivery of 
functional siRNA) 
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 Compare two different passivating ligand (PEG) densities on C-
Myc silencing. 
Chapter 4 and chapter 5 moved focus to the artificial control of MSC 
differentiation via delivering miRNAs. Based on Cell Engineering lab data 
and a literature search, mir-31 was selected as a target in this regard, 
as it has been established that mir-31 is involved in osterix (osteogenic 
transcription factor) regulation.  The AuNPs designed for this part of the 
project were functionalised with an antagomir sequence against mir-31 
5’ or a sequence against mir-31 3’. Whilst the delivery of miRNAs is a 
very recent field of study, there have been no studies to date that 
compare the possible difference in directionality of the miRNA used (i.e. 
whether 5’ or 3’), therefore both sequences were used in both of these 
chapters. 
Chapter 4 was a proof of concept study, and employed MG63 cells as an 
initial target.  These cells are pre-osteoblastic cells, with relatively high 
levels of mir-31, and are therefore an excellent model to test the 
antagomir delivery. The main aims of this chapter were: 
 Verify antagomir-AuNP delivery and uptake into MG63 cells. 
 Assess osterix levels at the RNA and protein level (indicative of 
successful delivery). 
 Identify any difference in potency between the 5’ and 3’ 
antagomir sequences. 
Following the success of chapter 4, whereby osterix levels were altered 
with our antagomir-AuNPs, chapter 5 employed a more dynamic MSC 
population. Osterix is a major transcription factor in osteogenesis, 
therefore, any changes in osterix should lead to changes in stem cell 
phenotype. The main aims in this chapter were: 
 Verify antagomir-AuNP delivery and uptake into MSC cells 
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 Assess osterix levels in MSCs (RNA and protein level) 
 Assess long term (3 and 5 week) MSC phenotype following 
antagomir treatment (i.e. osteogenic differentiation).  
The ability to guide osteogenesis of MSCs into osteoblasts, is a 
major goal for regenerative medicine and offers exciting avenues 
for the treatment of diseases such as osteoporosis. 
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2 Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Antibodies 
Primary Antibodies 
 Anti-C-Myc antibody [9E10]     Abcam, UK 
Mouse ChIP Grade (ab32)  
Used for In-Cell Westerns 1:2000 
 Anti-GAPDH antibody                       Abcam, UK 
       Rabbit Monoclonal antibody (clone EPR6256) 
Used for In-Cell Westerns 1:2000 
 Amersham Monoclonal     GE Healthcare,            
.                                                                     UK (GE) 
        anti-Bromodeoxyuridine (clone BU-1) (murine) 
Used to detect BrdU at 1:100 
 Anti-Osterix (SP7, OSX) Antibody                      Abcam, UK 
Rabbit polyclonal  (ab22552) 
Used for In-Cell Westerns 1:2000 
 Anti-Osteocalcin (OCN) (sc-73464)                   Santa Cruz  
         Biotechnology,              
.                                                              USA    …….  
……………………………………………………………………………..(Santa Cruz)  
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Used for Immunofluorescence 1:50 
 Actin conjugated with Oregon Green            Life………      .    
……………………………………………………………..Technologies, .                   
……………………………………………………………  UK ( Life Tech) 
Used for Immunofluorescence 1:1000 
Secondary Antibodies 
 Biotinylated anti-mouse     Vector   
        Laboratories,Inc 
.                                                                     UK ( Vector) 
Used in BrdU assay at 1:50 
 Texas Red anti-mouse             Vector   
         
Used for Immunofluorescence assay at 1:50 
 Donkey anti-Mouse IR Dye 680    Li-cor, UK  
         
Used in In-Cell Western (C-Myv and GAPDH) at 1:2000 
 Donkey anti-Rabbit IR Dye 800   Li-cor, UK  
          
Used in In-Cell Western (C-Myc and GAPDH) at 1:2000 
 Donkey anti-Rabbit IR Dye 680    Li-cor, UK  
          
Used in In-Cell Western (C-Myc and GAPDH) at 1:2000 
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 Donkey anti-Mouse IR Dye 800   Li-cor, UK  
          
Used in In-Cell Western (C-Myc and GAPDH) at 1:2000 
 Cell Tag 700      Li-cor, UK  
          
Used in In-Cell Western at 1:500 
Tertiary Antibodies 
 Streptavidin-FITC      Vector   
         
Used in BrdU assay at 1:50 
2.1.2 Cell Culture 
Trypsin         Sigma, UK 
Versine                (made in house) 
Fetal Bovine Serum (FBS)      Lonza, UK 
Needle (1.2mm x 40mm)      BD Microlance 3,  
.                                                                              UK 
13mm glass coverslips               Chance Propper 
.     .                                                                         LTD, UK 
Incubator (CO2 water jacketed incubator)   Forma Scientific, 
.                                                                              UK 
Dulbeco’s Modified Eagle Medium (DMEM)   Sigma, UK 
L-Glutamine 200mM (100x) liquid     Invitrogen, UK 
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Sodium pyruvate  Life Tech    
Penicillin streptomycin       Sigma, UK 
MEM Non-Essential Amino Acids Life Tech            
Ficoll-Paque               GE  
Opti-MEM® I Reduced Serum Media    Invitrogen, UK 
Bone Marrow CD271+ Selected    Promocell, UK 
Easy Sep CD271+  Stem Cell…………  
Technologies, 
UK 
2.1.3 Electron Microscopy (EM) 
Thermanox coverslips  ThermoScientific 
, UK 
Gluteraldehyde (25% aqua Pure, EM Grade)   Sigma, UK 
Sodium cacodylate  Agar Scientific 
Ltd UK 
Osmium tetroxide  Agar Scientific 
Ltd UK 
Phosphate buffer  VWR 
International 
Ltd, UK (VWR) 
Uranyl acetate  Agar Scientific 
Ltd UK 
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Propylene oxide  VWR  
Resin (812 Kit E202)  TAAB Lab 
Equipment Ltd  
UK (TAAB) 
Methanol                                                                Sigma, UK 
Reynolds lead citrate  Agar Scientific 
Ltd UK  (Agar) 
Alcohol increments (30-100% (dry))  AnalaR 
NORMAPUR, UK 
Molecular sieve        Sigma, UK 
Hexamethyl-disilazane  TAAB  
Carbon coated grids  Agar  
2.1.4 General Reagents 
5-Bromo-2’-deoxyridine (BrdU)     Calbiochem, UK 
Dimethyl sulfoxide  (DMSO)      Sigma, UK 
 
Ethanol (absolute)  AnalaR 
NORMAPUR, UK 
Lipofectamine 2000       Invitrogen, UK 
LIVE/DEAD® Viability/Cytotoxicity kit    Invitrogen, UK 
Methanol, analytical reagent grade     Fisher Scientific, 
.                                                                              UK 
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3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  Sigma, UK………            
bromide, a tetrazole (MTT)  
Nitric acid (70%), analytical reagent grade   Fisher Scientific, 
.                                                                              UK 
Hydrochloric acid, analytical reagent grade   Fisher Scientific, 
.                                                                              UK 
Rhodamine phalloidin                                             Invitrogen         .                                                                             
.                                                                          Molecular Probes        
,                                                                              ,UK 
siRNA (C-MYC and nonsense) + miRNA Thermo 
Scientific 
Dharmacon 
Phosphate Buffer Solution(PBS) tablets    Sigma, UK 
Sucrose         Fisher Scientific  
.                                                                              , UK 
Sodium Chloride (NaCl)  AnalaR 
NORMAPUR, UK 
Magnesium Chloride hexahydrate (MgCl2)  AnalaR  
NORMAPUR, UK  
Hepes         Fisher Scientific  
.                                                                              , UK  
Triton® X-100        Sigma, UK 
Formaldehyde (40%)       Fisher Scientific  
.                                                                              , UK  
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Bovine serum albumin (BSA)                    Sigma, UK 
Tween® 20        Sigma, UK 
Sodium deoxycholate       Sigma, UK 
Sodium Dodecyl Sulphate (SDS)     BDH, UK 
Protease inhibitor (10X)      Roche, UK 
Phosphatase inhibitor (10X)      Roche, UK 
ß-mercaptoethanol       BDH, UK 
Powdered milk (dried, skimmed)     Marvel, UK 
Glycine         BDH, UK 
Potassium Chloride (KCl)      BDH, UK 
D-Glucose         Fisher Scientific, 
.                                                                              UK 
Ethylenediaminetetraacetic acid (EDTA )   Sigma, UK 
Phenol red         Sigma, UK 
Sodium Hydroxide (NaOH) (powder)    Fisher Scientific 
2.1.5 Microscopes 
Axiovert 25 light microscope      Zeiss, UK 
Axiophot fluorescence microscope     Zeiss, UK 
Leitz DMRB fluorescence microscope    Leica, UK 
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LSM 510 META confocal microscope    Zeiss, UK 
Leo 912 AB TEM        Zeiss, UK 
Tecnai T20         FEI, USA 
Jeol 6400 SEM        Jeol Ltd, UK 
2.1.6 Quantitative Real-Time PCR (qRT-PCR) 
RNeasy® Micro kit       Qiagen, UK 
QuantiTect® Reverse Transcription kit    Qiagen, UK 
Taqman® master mix  Applied 
Biosystems, UK 
Primers and Probes  Eurofins MWG 
Operon, UK 
Abi Prism 96-well plates  Applied 
Biosystems, UK 
Real-time PCR, 7500 System  Applied 
Biosystems, UK 
2.1.7 Scientific Instruments 
Inductively Coupled Plasma Mass Spectroscopy (ICP-MS)      THERMO 
X Series II, UK 
NanoDrop-1000 V3.7.1  Thermo 
Scientific, UK 
Plate reader (Ch.3) Dynatech 
MR7000, UK 
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Plate reader (Ch.4 & 5) FLUOstar 
Omega,BMG 
Labtech, UK 
Vortex  Fisions 
Whirlimixer, UK 
Zetasizer         Malvern, UK 
Odessey SA Li-cor, UK 
2.2 General Solutions 
PBS 
1 x PBS tablet dissolved in 200ml H2O 
Permeabilising buffer 
100ml PBS; 10.3g sucrose; 0.292g NaCL; 0.06g MgCl2 (hexahydrae); 
0.476g Hepes. 
pH adjusted to 7.2, followed by the addition of 0.5ml Triton X. 
Fixative 
90ml PBS; 10ml (38%) formaldehyde; 2g sucrose. 
PBS/BSA 
100ml PBS, 1g BSA. 
PBS/Tween 
100ml PBS; 0.5ml Tween 20. 
RIPA buffer 
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45ml H2O; 150mM NaCl; 50mM TRIZMA® base; 0.5ml Triton 1% (t-
Octyl phenoxy polyethoxy ethanol); 0.5g Sodium deoxycholate 1%; 
0.05g SDS 1% (Sodium Dodecyl Sulphate). 
Make up to 50ml with water (H2O). 
Protein Extraction Buffer (PEB) 
1ml RIPA buffer; 100μl Protease inhibitor (10X stock); 100μl 
Phosphatase inhibitor (10X stock). 
Blocking buffer 
50ml PBS-Tween; 1.5g Marvel milk. 
Versine 
1L H2O; 8g NaCl; 0.4g KCl; 1g glucose; 2.38g Hepes; 0.2g EDTA; 2ml 
0.5% phenol red. 
Adjusted to pH 7.5 with 5M NaOH, dispensed into 20ml aliquots and 
autoclaved. Stored at 4°C. 
Electron Microscopy fixative (EM fixative) 
1.5% gluteraldehyde in 0.1M sodium cacodylate 
2.3 Cell Culture 
2.3.1 Human Cell Lines 
Fibroblast: 
 MG63 Osteosarcoma     Sigma, UK 
 MCF-7 Breast Cancer     Sigma, UK 
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 HeLa Cervical Cancer     Gifted by Prof. 
..................................................................Gwyn Gould 
2.3.2  Primary Culture 
Human Osteoprogenitor Stem Cells: 
 Human Mesenchymal Stem Cells   Promocell, UK 
 Bone Marrow from patients (hip surgery)         Gifted by Mr    
Dominic Meek 
2.3.3 Media 
MG63 cells were expanded in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 1% penicillin streptomycin. 
All stem cells were expanded in Dulbecco’s Modified Eagle Medium 
(DMEM+) supplemented with 10% FBS and 1% penicillin streptomycin, 
1% 100mM Sodium Pyruvate and 1% Non Essential Amino Acids. 
Cells were cultured in T75 flasks in complete medium and passaged by 
trypsinisation when 80-90% confluent. Cells were cultured at 37°C with 
5% CO2. 
2.4 General Methods 
2.4.1 Synthesis and Functionalization of Gold Nanoparticles.  
All gold nanoparticles (AuNPs) were prepared and characterised by 
collaborators in Zaragoza (C-Myc studies) and Lisbon (antagomir 
studies). 
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2.4.1.1 Synthesis of citrate-gold nanoparticles 
Gold Nanoparticle Synthesis. Gold nanoparticles (AuNPs), with an 
average diameter of 14.4±2.0 nm, were synthesized by the citrate 
reduction method, as described previously. Briefly, 225 mL of 1 mM 
hydrogen tetrachloroaureate (III) hydrate (Sigma) (88.61 mg) 
dissolved in 500 ml of distilled water were heated to reflux while 
stirring. Then, 25 mL of 38.8 mM sodium citrate dihydrate (285 mg) 
were added and refluxed for additional 30 minutes with vigorous stirring 
and protected from light. The resulting red solution was cooled down 
and kept protected from light. Citrate capped AuNPs were characterized 
by transmission electron microscopy (TEM) and UV-Vis spectroscopy 
(Figure 2-1).  
 
Figure 2-1. Gold nanoparticle characterization. (A) TEM image of citrate-
gold nanoparticles (scale bar = 100 nm). Inset: size distribution 
histogram showing an average diameter of 14.4±2.0 nm. (B) UV-Vis 
spectra of the synthesized gold nanoparticles with a characteristic 
surface plasmon resonance (SPR) peak at 519 nm. Provided by J. Conde 
(2015). 
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PEG Functionalization. Briefly, 10 nM of the AuNP solution were mixed 
with 0.003 mg/mL of a commercial hetero-functional poly (ethylene 
glycol) (PEG MW 2000) [O-(2-Mercaptoethyl)-O’-methyl-hexa (ethylene 
glycol), C15H32O7S, 356.48 Da, Sigma] in an aqueous solution of SDS 
(0.028%). Then, NaOH was added to a final concentration of 25 mM 
and the mixture incubated for 16 hours at room temperature. Excess 
PEG was removed by centrifugation (21.460 ×g, 30 min, 4ºC), and 
quantified by a modification of the Ellmans’ Assay (Conde and 
Ambrosone et al., 2012). Briefly, Ellman's reagent (5,5'-dithiobis-(2-
nitrobenzoic acid) quantifies the concentration of thiol bonds by being 
broken into 2-nitro-5-thiobenzoate (TNB−), which in the presence of 
water, forms the TNB2− ion. This ion is yellow in colour and can be read 
on a spectrometer. The Ellman’s method is a stoichiometric reaction, 
allowing for direct evaluation of the number of PEG molecules bound to 
the AuNP 
The excess of thiolated chains in the supernatants is quantified by 
interpolating a calibration curve set by reacting 200 μL of stock solution 
of the O-(2-Mercaptoethyl)-O’-methyl-hexa (ethylene glycol) in 100 μL 
in phosphate buffer 0.5 M (pH 7) with 7 μL 5 5’-dithio-bis(2-
nitrobenzoic) acid (DTNB, Sigma) 5 mg/mL in phosphate buffer 0.5 M 
(pH 7), and measuring the absorbance at 412 nm after 10 minutes. The 
linear range (see Figure 10 A-B) for the O-(2-Mercaptoethyl)-O’-methyl-
hexa(ethylene glycol) chain obtained by this method is 0.0002-0.035 
mg/mL (Abs412 = 26.229×[HS-PEG, mg/mL] + 0.0671). The number 
of exchanged chains is given by the difference between the amount 
determined by this assay and the initial amount incubated with the 
AuNPs. There is a point at which the nanoparticle becomes saturated 
with a thiolated layer and is not able to take up more thiolated chains - 
maximum coverage per gold nanoparticle, i.e. 0.01 mg/mL of O-(2-
Mercaptoethyl)-O’-methyl-hexa (ethylene glycol) (Figure 10C). The 
AuNPs were functionalized with 0.003 mg/mL of O-(2-Mercaptoethyl)-
O’-methyl-hexa (ethylene glycol) corresponding to 30% of PEG 
saturation of AuNPs’ surface (200.16 ± 15.01 chains per nanoparticle). 
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Biotin was attached by EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide) (Sigma) and sulfo-NHS (sulfo-
hydroxysuccinimide) (Sigma) chemistry at pH 6.1 (25 mM MES).  
 
Figure 2-2. (A) Absorbance spectra of DTNB after reaction with the 
thiolated PEG. (B) Standard calibration curve for PEG chains, whose 
concentration can be calculated via the following equation Abs412 = 
26.229×[HS-PEG, mg/mL] + 0.0671. (C) Variation of the excess of PEG 
thiolated chains as a function of the initial concentration in the 
incubation with 10 mM AuNPs. The dashed vertical line indicates the 
100% saturation, i.e. the PEG concentration above which no more PEG 
can be bonded to the AuNPs surface. (D) Ratio between non-aggregated 
(at 520 nm) and aggregated NPs (at 600 nm) of AuNPs after 
functionalization with increasing amounts (0-0.035 mg/mL) of thiolated 
PEG. Provided by J. Conde (2015). 
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Finally, AuNP functionalisation with siRNA (Thermo Scientific 
Dharmacon) took place using thiolated siRNA incubated with NPs 
containing 0.028% SDS and 0.1 M NaCl. Excess siRNA was removed by 
centrifugation at 4oC. The siRNA quantification was carried out by 
fluorescence measurement (Perkin-Elmer LS55) using a GelRed 
(Biotium) acid nucleic intercalator. 
2.4.1.2 NP Characterisation 
A 2μl aliquot of each NP sample (0.1mg/ml in MilliQ H2O) was dried 
onto a carbon-coated grid and viewed under the TEM at 120kV, at 
40,000x magnification. In addition, NP size and charge were 
characterised by dynamic light scattering (DLS) and zeta potential 
respectively on a Malvern Zetasizer following manufacturers guidelines. 
2.4.2 Toxicity Testing (MTT Assay) 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is 
a yellow tetrazole (550nm). The MTT assay is a colorimetric assay for 
measuring the activity of enzymes that reduce MTT to formazan dyes, 
producing a purple colour. The strength of this enzymatic activity and 
resulting purple colour is used to indicate cellular metabolic activity, 
viability, and indicate any cytotoxicity caused by a test substance, such 
as NPs. This technique is a quick and high throughput method to detect 
toxicity. 
Cells were seeded at 1 x 104 cells per well in a 96 well plate and allowed 
to adhere overnight. AuNPs were diluted in appropriate cell media to a 
final working concentration per well and incubated with the cells for 1, 
24 and 48 hours (control cells were incubated with media alone). After 
treatment incubation, cells were washed with warmed PBS; 100μl MTT 
solution was added per well (0.5mg/ml MTT powder in PBS) and cells 
were incubated for 1.5 h at 37°C. MTT solution was removed, and 
replaced with 100μl DMSO. Cells were left for 10 min at room 
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temperature and then the absorbance (Abs) was subsequently read via 
spectrophotometry at 550nm (Dyntech MR7000). 
MTT data analysis: Percentage viability was calculated using the 
following equation: (Absorbance of NP-treated cells / Absorbance of 
control cells) x 100 = % viability) [n=3]. 
2.4.3 Uptake Analysis  
2.4.3.1 Transmission Electron Microscopy (TEM) 
TEM was used to observe the cells in cross section after NP treatment, 
to verify AuNP uptake into the cell body. Cells were seeded at 1 x 105 
cells per well on Thermanox coverslips in a 24 well plate and allowed to 
adhere overnight. NP treatments were added to cells grown on 
coverslips at a stated concentration and incubated for 1, 24 or 48 hours 
(control cells were incubated with media alone). Following treatments, 
the cells were fixed in 1ml of 1.5% gluteraldehyde in sodium 0.1M 
cacodylate buffer at 4°C for 1 hour, then post fixed in 1% osmium 
tetroxide in phosphate buffer for 1 hour, followed by 0.5% uranyl 
acetate for 1 hour and then dehydrated through a series of alcohol 
increments (30 – 100%) and left in propylene oxide:Epon 812 resin 
araldite mix (1:1) overnight. At this point Margaret Mullen from the EM 
unit, continued the processing procedure. Samples were put into pure 
resin and kept in an oven for 24 hour to cure (at 60oC). Blocks were 
then cut into ultrathin sections, stained with 2% methanolic uranyl 
acetate and Reynolds lead citrate, and viewed under the TEM at 120kV 
for the LEO 912 (Chapter 3) and 200kV for the Tecnai T20 (Chapter 4 
and 5). 
2.4.3.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS, also known as element analysis, is a branch of mass 
spectrometry that can measure and quantify trace levels of a specified 
element. It is highly quantitative compared to microscopy. To facilitate 
this work, collaboration was set up with the chemistry department at 
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the University of the West of Scotland (UWS) in Paisley and Scottish 
Universities Environmental Research Centre (SUERC) in East Kilbride. 
Cells were seeded at 1 x 104 in a 96 well plate and allowed to adhere 
overnight. Cell media was replaced with NP treatments the following 
day and the cells were cultured for a further 24 hours at 37oC in 
5%CO2. After incubation, the treatment media from each sample was 
removed and washed with sterile PBS, to remove extracellular AuNPs. 
Samples were treated 400 μl RIPA buffer, the lysate was put into a tube 
and a wash with 100 μl of sterile miliQ water was added to the wells 
and combined with the relevant tubes. To each tube 500 μl of miliQ 
water was added to get a volume of 1ml. To this, 1ml of AquaRegia was 
added (3:1 mix of HCL and 70% nitric acid) and then heated in a water 
bath at 70°C overnight. After heating, samples were cooled and then 
diluted to 50ml with H2O (MilliQ H2O used throughout). Samples were 
analysed by collaborators using ICP-MS at either the UWS or the 
SUERC. 
2.4.4 Functional Assays 
2.4.4.1 In-Cell Westerns (ICW) 
Cells were seeded at 1 x 103 cells per well on a 96 well plate and 
allowed to adhere overnight. The AuNP treatments were added to 
coverslips at a stated concentration and incubated for a specified time 
(control cells were incubated with media alone). Cells were 
subsequently ﬁxed in fixing buffer for 15 min at 37oC, and 
permeabilised for 5 min at room temperature. Non-speciﬁc binding sites 
were blocked by incubation with 1% (w/v) milk protein in PBS at 37oC 
for 1.5 hours. The PBS/milk Protein was removed and samples co-
incubated with primary antibodies at 37oC for 1 hour. Free antibody was 
removed by washing three times in Tween/PBS (5 min/wash). Samples 
were co-incubated with Li-cor secondary antibodies, in PBS-1%milk 
protein and 0.2% Tween at 37oC for 1 hour, then washed three times in 
PBST (5 min/wash). 
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The plates were imaged by scanning simultaneously at 700 and 800 nm 
with an Odyssey SA at 100μm resolution, medium quality, focus offset 
of 3.53 mm, and an intensity setting of 7 for both 700- and 800-nm 
channels. 
2.4.4.2 Fluidigm Analysis 
Cells were seeded at 1 x 105 cells per well on glass coverslips in a 24 
well plate and allowed to adhere overnight. The AuNP treatments were 
added to coverslips at a stated concentration and incubated for a 
specified time (control cells were incubated with media alone). After 
this, AuNPs were removed and RNA was extracted using an RNeasy Mini 
Kit. Reverse transcription was performed using a SuperScript III 
Reverse Transcriptase (Invitrogen). Each qRT-PCR reaction contained 
10ng of cDNA. The cDNA was pre-amplified with a pool of selected 
100µM forward and reverse primers. After pre-amplification the samples 
were then treated with Exonuclease I treatment, to clean up any 
unincorporated primers. After Exonuclease I treatment the amplified 
samples were diluted in TE buffer (TEKnova, PN T0224). The samples 
were prepared as two technical replicates for every three biological 
replicates. Samples were pre-mixed with 2xSsoFast Evagreen Supermix 
(Bio Rad, PN 172-5211) and 20x DNA binding dye sample loading 
reagent (Fluidigm, PN 100-3738). The stock primers, detailed in Table 
2-1, were prepared separately, with 100µM of forward and reverse 
primers to a final concentration of 5µM in loading reagent. The plate 
was primed using an IFC controller MX and loaded with samples on one 
side and primers on the other. Afterwards the plate was run using the 
BioMark Fluidigm system. Data was obtained by Fluidigm Real-Time PCR 
Analysis Software. Heatmaps were produced using the software 
PermutMatrix v.1.9.3. 
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Table 2-1. Primer list used for fluidigm analysis, detailing the gene 
function and the forward and reverse sequences used. Those with * 
indicate housekeeping genes. 
Primer Function Sequence (5’ to 3’) 
β-Actin* 
Housekeeping 
Gene 
Forward 
GTGGGCCGCCCTAGGCACCAG 
Reverse 
CACTTTGATGTCACGCACGATTTC 
RUNX2 
Transcription 
factor associated 
with osteoblast 
differentiation 
Forward  
CAGCAGCAGCAACAGCAG 
Reverse  
GGCGATGATCTCCACCAT 
ACVR1A 
Binds BMPs to 
then form 
complexes with 
SMADs 
Forward  
GCCAAGGGGACTGGTGTAAC 
Reverse 
GAGAATAATGAGGCCAACCTCCA 
SMAD1 
Mediates signals 
with BMPs by 
receptors 
Forward  
GCTGCTCTCCAATGTTAACCG 
Reverse 
CACTAAGGCATTCGGCATACAC 
SMAD2 
Mediates signals 
with BMPs by 
receptors 
Forward 
CCACGGTAGAAATGACAAGAAGG 
Reverse 
GATTACAATTGGGGCTCTGCAC 
SMAD3 
Mediates signals 
with BMPs by 
receptors 
Forward  
GTCTGCGTGAATCCCTACCAC 
Reverse 
GGGATGGAATGGCTGTAGTCG 
GNB2L1* 
Receptor for 
activated C kinase 
1 
Forward  
TCCATACCTTGACCAGCTTG 
Reverse  
GCAGATTGTCTCTGGATCTC 
SMAD4 
Common 
mediator SMAD, 
enhances SMAD 
signaling 
Forward 
GGGTCAACTCTCCAATGTCCAC 
Reverse  
GTCACTAAGGCACCTGACCC 
SMAD5 
Mediates signals 
with BMPs by 
receptors 
Forward 
TGGGTCAAGATAATTCCCAGCCT 
Reverse 
GGCTCTTCATAGGCAACAGGC 
SMAD6 
Inhibitory SMAD, 
block R-SMAD 
activation 
Forward  
CTCCCTACTCTCGGCTGTCT 
Reverse  
AGAATTCACCCGGAGCAGTG 
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SMAD7 
Inhibitory SMAD, 
block R-SMAD 
activation 
Forward  
CCATCACCTTAGCCGACTCT 
Reverse  
CCAGGGGCCAGATAATTCGT 
SMAD9 
Mediates signals 
with BMPs by 
receptors 
Forward 
CTTATCATGCCACAGAAGCCTCT 
Reverse 
GCTCCTCGTAACAAACTGGTCG 
BMPR1A 
Bone 
morphogenetic 
protein receptor, 
type IA (CD292) 
Forward 
ACGCCGGACAATAGAATGTTGTC 
Reverse 
GAGCAAAACCAGCCATCGAATG 
TWY1* 
Wyosine 
biosynthesis 
protein 
Forward 
ATTGTCATCAAGACGCAGGGC 
Reverse  
GTTGCGAATCCCTTCGCTGTT 
BMPR1B 
Bone 
morphogenetic 
protein receptor 
type-1B 
(CDw293) 
Forward 
GGTTCAGACTTCTGCTGATTCAT 
Reverse  
CGCAAAAGCATGTTATCAAGG 
BMP2-EL 
Osteoinductive 
cytokine, linked to 
hedgehog 
pathway and TGF 
beta signaling 
Forward  
CTTCTAGCGTTGCTGCTTCC 
Reverse  
AACTCGCTCAGGACCTCGT 
BMP2-HW 
Osteoinductive 
cytokine, linked to 
hedgehog 
pathway and TGF 
beta signaling 
Forward  
AGACCTGTATCGCAGGCACT 
Reverse 
CCACTCGTTTCTGGTAGTTCTTCC 
BMPR2 
Serine/threonine 
receptor kinase 
that binds bone 
morphogenetic 
proteins 
Forward  
AGCCTCTCACACCCACTCC 
Reverse  
GCAGAACAACCGTGAGAGG 
ACVR1B 
Binds ACVR2A or 
ACVR2B to recruit 
SMADS 2/3. 
Forward 
GACATTGCCCCGAATCAGAGG 
Reverse 
GCCCGAGGGCATAAATATCAGC 
BMP4 
BMP4 is found in 
early embryonic 
development 
Forward 
CAGCACTGGTCTTGAGTATCCT 
Reverse  
AGCAGAGTTTTCACTGGTCCC 
CYCR* 
Bacterial 
housekeeping 
gene with 
adenylate cyclase 
activity 
 
Forward 
ACTGCGGGAAGGTCTCTACTT 
Reverse 
GGGTGCCATCGTCAAACTCTA 
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BMP7 
Phosphorylates 
SMAD1 and 
SMAD5 
Forward  
CAGGCCTGTAAGAAGCACGA 
Reverse  
TGGTTGGTGGCGTTCATGTA 
BMP10 
Involved in the 
trabeculation of 
the heart 
Forward 
ACCCACCAGAGTACATGTTGG 
Reverse  
GCCCATTAAAACTGACCGGC 
Nestin 
A type VI 
intermediate 
filament, mainly a 
nerve stem cells 
marker 
Forward  
GCTCAGGTCCTGGAAGGTC 
Reverse  
AAGCTGAGGGAAGTCTTGGA 
CD63 
A transmembrane 
protein, signaling 
cell growth, 
development and 
motility  
Forward  
CCCTTGGAATTGCTTTTGTT 
Reverse  
TATTCCACTCCCCCAGATGA 
ALCAM 
(CD1660) A 
transmembrane 
glycoprotein, 
mediating 
adhesions  
Forward 
TTCCAGTCCCTCTACTCAGAGC 
Reverse  
GCTAAGAAGGACTCGCAGGA 
Osterix 
A master 
regulatory 
transcription 
factor for 
osteogenesis 
Forward  
TGGGCTCCCAACACTATTTC 
Reverse  
GGGAAGACTGAAGCCTGGA 
UBE2D2* 
Ubiquitin-
conjugating 
enzyme E2 D2 
Forward 
CCATGGCTCTGAAGAGAATCC 
Reverse 
GATAGGGACTGTCATTTGGCC 
RUNX1T1 
A zinc finger 
transcription 
factor, that blocks 
hematopoietic 
differentiation 
Forward  
ATCACAACAGAGAGGGCCAA 
Reverse  
CTGCAGGTTTCACTCGCTTT 
SMURF1 
E3 ubiquitin-
protein ligase 
regulates SMAD 
proteins 
Forward  
ATGCAGTTCGTGGCCAGATA 
Reverse  
CAGGCCCGGAGTCTTCATAC 
SMURF2 
E3 ubiquitin-
protein ligase 
regulates SMAD 
proteins 
Forward  
GACAGGATCCTCTCGAGTGC 
Reverse 
AGCTTTCATAGGGTGGAATGTCT 
INHBA 
Inhibin beta A, a 
differentiation 
factor 
Forward  
AAGTCGGGGAGAACGGGTAT 
Reverse  
GGTCACTGCCTTCCTTGGAA 
Chapter 2   89 
 
ACVR2A 
Forms a dimer to 
activate TGF-Beta 
pathway. 
Forward  
ACCATGGCTAGAGGATTGGC 
Reverse  
GCCAACCCAAAGTCAGCAAT 
ACVR2B 
Forms a dimer to 
activate TGF-Beta 
pathway. Binds 
with a 3-4 higher 
affinity than 
ACVR2A 
Forward  
CTGCAACGAACGCTTCACTC 
Reverse  
CAGGACGATGAGGGAAAGGC 
RNF20* 
E3 ubiquitin-
protein ligase 
BRE1A 
Forward 
GGTGTCTCTTCAACGGAGGAA 
Reverse 
TAGTGAGGCATCATCAGTGGC 
TGFB1 
Cytokine of the 
TGF-beta 
superfamily, that 
controls cell 
growth, 
differentiation and 
proliferation  
Forward 
CGACTCGCCAGAGTGGTTATC 
Reverse 
GTTATCCCTGCTGTCACAGGAG 
TGFBR1 
The receptor for 
TGFB1, that 
transduces further 
signalling 
Forward  
CGTTCGTGGTTCCGTGAGG 
Reverse 
TAATCTGACACCAACCAGAGCTG 
TRAF6 
Tumor necrosis 
factor receptor, 
transduces 
signaling for 
MAP3K pathways 
Forward 
CGCACTAGAACGAGCAAGTGA 
Reverse  
GCCACACAGCAGTCACTTTCA 
SNAIL2 
Regulator of 
osteoblast 
differentiation 
Forward  
TCCTTCCTGGTCAAGAAGCA 
Reverse  
GGTATGACAGGCATGGAGTA 
Vimentin 
A type III 
intermediate 
filament protein 
expressed in MSC 
Forward  
GGAGAAATTGCAGGAGGAGA 
Reverse  
TGCGTTCAAGGTCAAGACGT 
IL-08 
Chemokine 
involved in 
immune response 
and angiogenesis 
Forward 
GTGTGAAGGTGCAGTTTTGCC 
Reverse  
GTGGTCCACTCTCAATCACTC 
B2M* 
MHC class I 
molecule present 
on all nucleated 
cells 
Forward  
TTGTCTTTCAGCAAGGACTGG 
Reverse  
ATGCGGCATCTTCAAACCTCC 
CathepsinB 
Marker for cell 
death and 
inflammation 
Forward  
TGTGTATTCGGACTTCCTGC 
Reverse  
TTAAAGAAGCCATTGTCACCC 
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CathepsinD 
A lysosomal 
aspartyl protease 
Forward  
GGTGCTCAAGAACTACATGG 
Reverse  
ATTCTTCACGTAGGTGCTGG 
CathepsinG 
Protease found 
mainly in immuno 
cells 
Forward  
AACAGATACACTCCGAGAGG 
Reverse  
ACGACTTTCCATAGGAGACG 
CathepsinL 
Lysosomal 
endopeptidase 
enzyme initiating 
protein 
degradation 
Forward  
GACTCTGAGGAATCCTATCC 
Reverse  
CTTAGGGATGTCCACAAAGC 
CathepsinS 
lysosomal 
cysteine protease 
Forward  
GCGTCATCCTTCTTTCTTCC 
Reverse  
CCAGCTGTTTTTCACAAGCC 
GAPDH* 
Enzyme 
catalyzing a step 
of the glycolysis 
pathway 
Forward  
TCAAGGCTGAGAACGGGAA 
Reverse  
TGGGTGGCAGTGATGGCA 
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2.4.4.3 Brdu Analysis via Fluorescence 
Cells were seeded for 24 hours at 1x105 cells per ml in DMEM, AuNPs 
were incubated for 42 hours. After this time 1mM, Brdu solution in 
DMEM was added and left for 6 hours. Media was removed and washed 
in PBS, Cells were ﬁxed in fixative for 15 min at 37oC, and 
permeabilised for 5 minutes at room temperature. Non-speciﬁc binding 
sites were blocked by incubation with 1% (w/v) milk protein in PBS at 
37◦C for 1.5 hours.  The BrdU primary antibody  (1:100 cell proliferation 
kit RPN20,) diluted in DNase I, was added for 2.5 hours at 37oC.  
Samples were subsequently washed 3 times (5 min/wash in PBS-
Tween) before incubating with anti-mouse Texas red secondary 
antibody (1:50) for 1 hour at 37oC, before co-staining with DAPI loaded  
mounting media (Vector Laboratories). All images were view under a 
Zeiss Axiophot fluorescence microscope. 
2.4.5 Osteocalcin Nodule Formation via Fluorescence 
The hMSCs (from Promocell) were seeded for 24 hours at 1x103 cells 
per cm2 in DMEM+ on glass cover slips. AuNPs were added to cultures 
at 50nM, and left for 3 and 5 weeks. Media was changed every 3 days. 
Cells were ﬁxed for 15 minutes at 37◦C, and permeabilised for 5 min at 
room temperature. Non-speciﬁc binding sites were blocked by 
incubation with 1% (w/v) milk protein in PBS at 37◦C for 1.5 hours.  
The osteocalcin primary antibody (1:50) was added for 1 hour at 37oC, 
simultaneously with Oregon green phalloidin (1:1000) for F-actin 
staining, before incubating with anti-mouse Texas red secondary 
antibody (1:50) for 1 hour at 37oC, before mounting with DAPI loaded 
mounting media (Vector Laboratories). All images were viewed under a 
Zeiss Axiophot fluorescence microscope. 
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3 Chapter 3: Gold Nanoparticle-mediated 
Knockdown of C-Myc in the Osteosarcoma Cell 
Line MG63 via siRNA 
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3.1 Introduction 
SiRNA are double stranded RNA’s approximately 20-25 nucleotides long 
and are key components, involved in the RNA interference (RNAi) 
pathway (Chiu and Rana, 2003).  They bind specifically and with 
complete complementarity to a target sequence. This complementarity 
forms a tightly bound unit that halts RNA expression by preventing 
access to the RISC complex (see section 1.2.2.1). This form of silencing 
offers a robust and attractive method of gene therapy (Whitehead and 
Langer et al., 2009b). 
Our fundamental knowledge of siRNAs and their effect on cell 
phenotypes and disease remediation has been exponentially increasing 
in the last decade. However this breadth of information has not been 
translated into the clinic, mainly due to technical limits of therapeutic 
delivery. As described in chapter 1, the successful delivery of active 
siRNA involve four keys steps; (i) cellular localisation and binding, (ii) 
cell internalisation, (iii) subcellular trafficking and endosomal escape 
and (iv) release of functional siRNA, capable of interaction with the 
RISC complex (containing the cells machinery for silencing to progress) 
(Grigsby and Leong, 2010). Resolving the outlined issues will require 
the design of a multifunctional delivery vehicle and NPs have been 
postulated as meeting these challenging conditions. In this study we 
focus on the use of AuNPs, which have become very popular within 
biomedicine due to their unique physical and chemical properties as 
outlined in the introduction (Lévy and Shaheen et al., 2010). AuNPs are 
bio inert with the added benefit of being easily synthesized and stable, 
allowing precise control of size and shape, with a multitude of ligands to 
choose from (Lévy and Shaheen et al., 2010).  
Derfus et al (2009) concluded that one single siRNA molecule per 
particle conjugated with cell penetrating peptides >15 produced optimal 
silencing conditions(Derfus and Chen et al., 2007).  However, whilst 
ligand-based NPs are championed as holding great potential in future 
Chapter 3   94 
 
cancer diagnosis and therapy, to date they deliver inconsistent results. 
One of the major factors contributing towards this is thought to be the 
differences in PEG density and conformation coating the NPs (Stefanick 
and Ashley et al., 2013).  
As described in the introduction (section 1.1.2.1), polyethylene glycol 
(PEG) has been successfully used to passivate AuNPs due to it being 
inherently protein repulsive. PEG can be used at various molecular 
weights that in turn can influence the conformational arrangement of 
the PEG on the surface of the AuNP.  A high molecular weight produces 
long thin chains that fold back on themselves forming mushroom-like 
structures. However these are unordered and can sterically hinder a 
release of additional ligands, such as therapeutics. Shorter PEG 
molecular weight molecules maintain a linear conformation, which 
confer stability under physiological conditions (Stefanick and Ashley et 
al., 2013).  It is noted that the innate ability of PEG to repel protein 
adsorption does not depend on the chemical method of attachment, be 
it ionic or covalent (Karakoti and Das et al., 2011). 
As alluded to earlier, intracellular release of a functional therapeutic 
such as siRNA from the AuNP surface is a critical consideration when 
designing a delivery vector. Functional attachments are made to the 
gold surface with the aid of a thiol bond, and it’s the exploitation of the 
thiol bond that allows for the efficient disassociation and release of the 
NP therapeutic (Oishi and Nakaogami et al., 2001a). The thiol bond is 
cleaved by the intracellular antioxidant glutathione (GSH), located 
within the cytoplasm in the milimolar range, whilst in the extracellular 
space it is virtually absent (Lushchak, 2012).  
Previous studies in our group have confirmed that AuNPs functionalised 
with siRNA were able to silence the cancer gene C-Myc in HeLa cells 
(Conde and Ambrosone et al., 2012).PEG was used as a passivating 
ligand with these AuNPs, and it has been postulated in the literature 
that as well as the PEG length and presentation on NP surface, the PEG 
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ligand density also plays a role in NP uptake into cells, however to date 
this has not been studied. Therefore we designed AuNPs with two 
differing PEG densities, 40% and 25%, with a view to determining 
whether the ligand density would affect the silencing ability of the NPs. 
In addition, it is known that different cell types may have differing 
levels of intracellular GSH, thereby also affecting the silencing. Our 
previous studies employed HeLa cells, which have relatively high levels 
of GSH, so in this study we sought to test the robustness of the AuNP 
design by selecting a cancer cell line with a relatively low GSH 
concentrations.   
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3.2 Materials and Methods 
3.2.1 Synthesis and Functionalisation of Gold Nanoparticles.  
 
AuNPs with a diameter of 14nm were synthesised by our collaborators 
in Zaragoza by the citrate reduction method described by Turkevich and 
Frens and in chapter 2.4.1.1 (Frens, 1973.,Turkevich and Stevenson et 
al., 1951.,Lee and Meisel, 1982). Subsequently, a mixture of AuNPs, 
0.028% SDS, and HS-EG(8)-(CH2)2-COOH (Iris-Biotech) (MW 458 Da) 
and HS-(CH2)3-CONH-EG(6)-(CH2)2-N3 (MW 452 Da) in a 1:1 ratio (7 
and 10.5 µM of each chain for 25% and 40% respectively) was 
combined under basic conditions for 16 hours.  
AuNP functionalization with siRNA (Thermo Scientific Dharmacon) took 
place using thiolated siRNA previously reduced with dithiothreitol (DTT) 
incubated with AuNPs followed by the addition of 0.028% SDS and NaCl 
at a final concentration of 0.1 M (25% saturated AuNPs) or 0.3 M (40% 
saturated AuNPs). Excess siRNA was removed by centrifugation at 4oC. 
SiRNA quantification was carried out by fluorescence measurement of 
supernatants (Perkin-Elmer LS55) using GelRed (Biotium), an acid 
nucleic intercalator. The panel of four AuNPs employed in this study, 
with PEG chain densities, are detailed in Table 3-1 and Figure 3-1. 
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Table 3-1. The AuNPs used in this chapter with the corresponding PEG 
ligand densities and siRNA strands per nm2. Please note that B denotes 
biotin and S denotes siRNA      
 Nanoparticle Acronym 
PEG Ligand 
Density (Chains 
per nm2) 
siRNA Density 
(strands per 
nm2) 
1 Au-B-25% PEG ~ 2.03 2.26x10-2 
2 Au-B-S-25% PEG ~ 2.03 2.26x10-2 
3 Au-B-40% PEG ~ 2.99 2.26x10-2 
4 Au-B-S-40% PEG ~ 2.99 2.26x10-2 
 
 
Figure 3-1 Panel of the four types of AuNP used: 1) Au-B-25% PEG, 2) 
Au-B-S-25% PEG, 3) Au-B-40% PEG, 4) Au-B-S-40% PEG. 
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3.2.2 Cell Culture          
The human osteosarcoma cell line MG63, the human breast cancer cell 
line MCF-7 and HeLa cells were cultured in DMEM growth medium (10% 
FBS, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL 
streptomycin) and maintained at 37oC in 5% CO2 until ~90% confluent, 
after which time they were passaged and counted with a 
haemocytometer. The cells were seeded at a density of 1x104 cells per 
ml for experiments unless stated otherwise. The cells were cultured for 
24 hours before the addition of both the 25% and 40% PEG AuNP 
treatments at 2nM and 15nM. The concentrations of 2nM and 15nM 
were used throughout the experiments 
3.2.3 Glutathione (GSH) Assay 
The three cancer cell lines, MG63 (osteosarcoma), MCF-7 (breast 
cancer) and HeLa (cervical cancer), were assessed for their relative 
cytoplasmic levels of GSH. Cells were cultured and harvested (1x106 
cells were collected for each cell line) to determine cytoplasmic GSH 
levels. The cells were lysed by lysis buffer (GSH kit obtained from 
AbCam), incubated on ice for ten minutes and centrifuged at 13000g for 
ten minutes. A standard GSH curve was prepared alongside the 
samples. Monochlorobimane (McBeath and Pirone et al.), a dye that 
forms an adduct with GSH, was added to the well and the plate was left 
for 1 hour at 370C. The fluorescence was measured on a plate reader 
with an EX/EM= 360/420 nm. 
MG63 cells were deemed to have the lowest levels of GSH. With this in 
mind our aim for future studies was to test the robustness of siRNA 
release from AuNPs in a low level GSH cell type.  Therefore MG63s were 
employed throughout the remainder of the study. 
3.2.4 Nanoparticle Toxicity 
The possible MG63 cytotoxicity response was assessed by standard MTT 
assay, as described in section 2.4.2. 
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3.2.5 Cellular Uptake of Gold Nanoparticles 
3.2.5.1 Transmission Electron Microscopy (TEM) 
MG63 cells were seeded at a density of 4x104 cells per mL onto 
Thermanox coverslips (13mm diameter) and cultured to develop a 
confluent monolayer of cells. At this point the AuNPs were added and 
cells further cultured for 24 hours.  Cells were subsequently processed 
for TEM as described in chapter 2, section 2.4.3.1.  
3.2.5.2 Inductively Coupled Plasma Mass Spectrometry     
The MG63 cells were seeded (100 L/well) in a 96 well plate and 
incubated for 24 hours. AuNPs were added to cells for 48 hours and the 
cells were processed for ICP-MS as described in chapter 2, section 
2.4.3.2. The converted values for gold uptake were averaged (n=3) and 
used for statistical analysis. 
3.2.6 In Cell Western (ICW) 
MG63 cells were seeded in a 96 well plate in triplicate, challenged with 
the AuNPs for 24 and 48 hours, then ﬁxed, permeabilised and blocked 
as in chapter 2, section 2.4.4.1. Samples were then co-incubated with 
primary antibodies (1:10000 mouse anti-C-Myc, [9E10] - ChIP Grade 
(ab32), AbCam  and 1:10000 rabbit anti-GAPDH, Epitomics) at 37◦C for 
1 hour. Following Tween washing, samples were subsequently co-
incubated with secondary antibodies (1:10000 donkey anti-mouse 
IR680RD, Licor, UK and 1:10000 donkey anti-rabbit IR800CW, Licor, 
UK) at 37◦C for 1 hour. All samples were finally washed three times in 
PBS/Tween (5 min/wash). The plates were imaged by scanning 
simultaneously at 700 and 800 nm with an Odyssey SA at 100 μm 
resolution, medium quality, focus offset of 3.53 mm, and an intensity 
setting of 7 for both 700- and 800-nm channels. 
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3.2.7 Brdu Proliferation assay       
MG63 cells were seeded onto 13 mm glass coverslips for 24 hours, and 
incubated with AuNPs for a further 42 hours. Cell proliferation was 
analysed via BrdU incorporation, as section 2.4.4.3. Cells were imaged 
using an Axiovert 200m ﬂuorescence microscope (Carl Zeiss, Jena, 
Germany) equipped with ImagePro Plus Version 6.01 software (Media 
Cybernetics) and a sideport Evolution QEi Monochrome CCD camera 
(Media Cybernetics). 
3.2.8 Statistics 
Statistical analysis was performed in Graphpad using a one-way ANOVA 
with a Dunnett's test. In all figures * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001 and **** = p < 0.0001.  Two tailed T-Tests were 
performed where specifically mentioned, a welchs correction was used, 
♯ = p < 0.05, ♯ ♯ = p < 0.01 
3.3 Results 
3.3.1 Intracellular GSH Levels 
The AuNPs were designed based on the established AuNP/GSH 
interaction within the cell cytoplasm, whereby GSH cleaves the thiol 
bonds that will in turn release the thiolated siRNA from the gold core. 
The levels of GSH in three established cancer cell lines were determined 
(Figure 3-2). MG63 cells were found to have relatively low GSH levels in 
comparison to both MCF-7 and HeLa cells, with Hela approximately 4 
times higher. 
In previous studies we have demonstrated that C-Myc knockdown in 
HeLa cells using thiol exchange via GSH was achievable, therefore 
MG63 were selected to test the level of functionality we can achieve 
from our siRNA-AuNPs with a cancer cell line of known lower GSH 
concentration. 
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Figure 3-2.  Glutathione (GSH) levels in MG63, MCF-7 and HeLa cancer 
cell lines. Cell number was normalised to 1x106 cells and values were 
plotted onto a GSH standard curve (n=3).  Crosses indicate GSH 
standards, whilst the squares correspond to the cell type. Dashed areas 
around cell type indicate standard deviation. MTT Assay 
The AuNPs were found to have no cytotoxicity over 24 hours incubation, 
as demonstrated with the MTT assay, showing no statistical difference 
between treatments (Figure 3 3). 
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Figure 3-3. MTT analysis of MG63 cells treated with 15 nM and 2 nM of 
each AuNP, with 40% or 25% PEG coverage for 24 hours. (B = biotin; S 
= siRNA) (n=3; error bars indicate SD). 
3.3.2 Cellular Uptake of AuNPs via TEM 
AuNPs were initially screened for uptake using the biotin ligand attached 
to PEG on the AuNP, via streptavidin linked FITC (Supplemental figure 
1, section 3.6 page 114)). However, this only provided images allowing 
confirmation of AuNP-cell interaction or attachment, to verify NP uptake 
had occurred, TEM was used with cross-sectional imaging. 
At the lower 25% PEG saturation, the AuNPs were all distinctly located 
in the cell cytoplasm, as shown in Figure 3-4. The higher concentration 
(15nM) clearly demonstrated more tightly packed endosomes, reflecting 
the greater number of AuNPs present (Figure 3-4). The 40% PEG 
saturation proved similar, with AuNPs evident in the cell body (Figure 
3-5). Therefore, after 24 hours incubation, NPs were clearly visible at 
both concentrations and both PEG densities within the cytoplasm, either 
free in the cytoplasm or packaged into endosomes. 
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Figure 3-4. TEM images of MG63 cells treated with 15 nM and 2 nM 
AuNPs, with 25% PEG after 24-hour incubation. Clusters of the AuNPs 
are evident within the cell body. Scale bar = 1 µm. 
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Figure 3-5. TEM images of MG63 cells treated with 15 nM and 2 nM 
AuNPs, with 40% PEG after 24-hour incubation. As with the 25%, 
clusters of the AuNPs are evident within the cell body.  
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3.3.3 ICP-MS 
In parallel to qualifying AuNP uptake into cells, the amount of AuNPs 
within the cells was also quantified after 24 hours using ICP-MS to 
determine elemental gold levels in lysed cell. samples (Figure 3 6).  The 
AuNPs were clearly uptaken into the cells (ANOVA analysis p<0.0001), 
with the higher concentration producing higher levels of internalised 
gold, verifying the methodology. Following an unpaired t-test, no 
significant difference was found between the different AuNP species with 
different PEG coverage.   
Figure 3-6. ICP-MS analysis of MG63 cells treated with 2nM and 15 nM 
of AuNPs, with 25% or 40% PEG coverage for 24 hours (each lysate has 
n=3, error bars denote SD). All values have been normalised to 
ultrapure water. ANOVA analysis comparing all treatments to MG63s 
without AuNPs, found a significant increase in elemental gold within 
cells treated with AuNPs p<0.0001. 
3.3.4 siRNA-mediated C-Myc Knockdown 
Following verification and quantification of AuNP uptake into MG63 cells, 
the efficiency of siRNA-mediated C-Myc silencing was evaluated by ICW. 
The higher concentration of siRNA (15 nM) produced clear knockdown, 
at both PEG densities (40% and 25%), as indicated in the left side of 
the graph in Figure 3-7. The lower 25% PEG density also produced 
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strong down regulation of C-Myc protein, as indicated on the right side 
of the graph. The optimal silencing was achieved with a combination of 
both approaches, using the higher concentration (15 nM) and a lower 
PEG density (25%). There was also a significant reduction in C-Myc 
protein noted for one of the controls, Allstar nonsense siRNA with 
lipofectamine, however this may be due to the lipofectamine causing 
issues with cell viability. 
  
Figure 3-7. ICW data comparing C-Myc protein levels in MG63 cells with 
AuNP treatments, normalised to GAPDH. Cells were serum starved for 
24 hours before treatment to synchronise cell division.  The NPs were 
added at both 2nM and 15nM, with both 25% and 40% PEG coverage. 
The standard control reflects cells without AuNPs added, additional 
controls included lipofectamine treatment, C-Myc siRNA with 
lipofectamine (CL), Allstar nonsense siRNA with lipofectamine (AL), or 
C-Myc siRNA or Allstar siRNA added directly to the media (CN & AN) 
(n=6; error bars denote standard error, asterisk denotes significance 
based on Anova analysis, with a Dunnet post test normalising to 
control. Hash marks relate to an unpaired two tailed t-test, with a 
welchs correction ♯♯ =p< 0.005 , ♯♯♯ = p<0.0005). 
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3.3.5 BrdU Analysis 
The synthetic nucleoside BrdU was used to analyse cells entering S-
phase in the cell cycle, thus giving an indication of cell division in the 
sample population, allowing an estimation of cell proliferation rates. As 
shown in Figure 3-8, there were a higher proportion of cells in S-phase 
(red) in the standard control cells (no AuNPs) and cells treated with the 
additional control NPs (biotin & PEG only)., in contrast to the lack of cell 
division recorded in cells treated with the siRNA AuNPs (Figure 3-7). To 
quantify this, ten images were taken from each cell sample (n=3 
samples). The proportion of cells in S-phase were determined using 
CellProfiler, which calculated the ratio of red (BrdU stained cells) to blue 
(nucleus) staining (Figure 3-9). Results demonstrated a significant 
decrease in cells entering S-phase when treated with siRNA at the 
higher concentration (15nM) at both densities (25% and 40%), but was 
only noted at the lower PEG density (25%) when tested at 2nM. 
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Figure 3-8. BrdU incorporation into cells treated with 2 nM and 15 nM of 
AuNPs, with either 40% or 25% PEG coverage for 48 hours. Cells were 
stained for nuclei (DAPI:blue) and actively dividing cells (BrdU:red). 
Additional controls included C-Myc with lipofectamine (CL), Allstar 
nonsense siRNA with lipofectamine (AL), or C-Myc and Allstar siRNA 
added directly to the media (CN & AN). Scale bar = 20 µm. 
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Figure 3-9. Graphical representation of the BrdU images as determined 
by CellProfiler, normalised to nuclei number, comparing the level of 
MG63 cells in S-phase with different treatments. Control cells are 
MG63s with AuNPs. CL= C-Myc siRNA with lipofectamine, CN= C-Myc 
siRNA only, AL= Allstar siRNA with lipofectamine, AN= Allstar siRNA 
only. Results from 10 images per sample, n=3 replicates, error bars 
denote standard error, asterisk denotes significance based on Anova 
analysis, with a Dunnet post test compared to control. Hash marks 
relate to an unpaired two tailed t-test, with a Welchs correction p< 
0.05). 
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3.4 Discussion 
The use of intracellular GSH as a release mechanism has been 
capitalised upon to date with a view to thio-tethered ligand release from 
the surface of AuNPs. While there have been several recent studies into 
the influence of the PEG chain length and ligand release (Stefanick and 
Ashley et al., 2013) the mixed reports on the effect of PEG density 
prompted this study; with a shorter chain length and higher density 
having been considered optimum for both ligand release and 
maintenance of the PEGylated NP stealth properties (Karakoti and Das 
et al., 2011). 
Previous work involving our group has shown that PEGylated AuNPs 
functionalized with siRNA against C-Myc can produce knockdown in 
HeLa cells (2 nM with a PEG ligand density of 25%) (Conde and 
Ambrosone et al., 2012). This study was designed to assess both the 
potency of the AuNPs, by assessing the knockdown in a cancer cell line 
with a lower intracellular GSH level, and also the influence of PEG chain 
density on C-Myc knockdown. The NPs were PEGylated at both 25% and 
40% saturation, and were used at two concentrations, 2 nM and 15 nM. 
Following cellular toxicity and AuNP uptake assessment, C-Myc 
knockdown was determined. 
When investigating C-Myc knockdown at the protein level, the higher 
concentration (15 nM) achieved clear knockdown at both 25% and 40% 
PEG densities, with the lower 25% density achieving a significantly 
higher level of knockdown (Figure 3-7). Meanwhile, the lower 
concentration (2 nM) also achieved knockdown, but to a lesser extent. 
At the physiological level, however, when determining changes in cell 
proliferation, a comparable reduction was again noted for both higher 
concentration densities (ie. 15 nM at 40% and 25%), but with the lower 
concentration (2 nM) only the lower 25% PEG density indicated a 
reduction in proliferation. These results indicate that a variation in 
knockdown may be observed when adopting differing PEG saturation 
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densities, which may have consequences with regards to the 
therapeutic potential of siRNA. 
GSH is an abundant thiol-cleaving antioxidant located within cells. 
During normal cellular processes GSH exists in two distinct forms, an 
oxidised (GSSG) and a reduced state (GSH). The oxidised form makes 
up <2% of total GSH levels (Meister and Anderson, 1983). GSH is used 
in many processes within the cells such as detoxification, removal of 
hydroperoxides and maintaining oxidation of protein sulfhydryls (Wu 
and Fang et al., 2004.,Lei, 2002.,Fang and Yang et al., 2002). Healthy 
cells tend to have GSH levels within 1-10 mM range, an order higher 
than the extracellular environment (Meister, 1988). Our AuNPs are 
designed with a view towards GSH interaction with the AuNP core, 
cleaving the thiol bound siRNA. In this study we have selected to use a 
cell type with a low concentration of intracellular GSH, to assess the 
robustness of our siRNA-NP delivery system. Despite this, C-Myc 
silencing was clearly observed in our MG63 cell line, indicating that the 
GSH concentration was perfectly sufficient to access and cleave the 
siRNA. 
With our results we noted a difference in the potency of knockdown 
between siRNA concentrations, which cannot therefore be due to the 
low GSH concentration. Instead, we believe that increasing the PEG 
length, or in our case the PEG density, towards saturation can 
complicate access to the thiol (Stefanick and Ashley et al., 2013), with 
greater ligand density or higher molecular weight polymers preventing 
GSH access to the core (Kah and Wong et al., 2009). This is reflected in 
the results section 3.3.5, where a significantly better knockdown is 
recorded for the 15nM AuNPs at 25% density (as opposed to 40%), and 
also in section 3.3.6, where a significantly lower cell proliferation rate is 
noted for the 2nM AuNPs at 25%. Once released, the double stranded 
siRNA molecule is successfully loaded into the RISC complex. Within the 
RISC complex Ago2 cleaves the sense strand and dissociates it from the 
complex, where it will ultimately be degraded(Rana, 2007). The anti-
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sense strand, which is complementary to the target mRNA, will remain 
bound to the RISC complex until it recognises the target sequence. 
Ago2 mediates the cleavage of the target mRNA ~10-11 nts upstream 
of the guide strands 5’ end. After degradation the components of the 
RISC complex are recycled (Li and Rana, 2012). 
As discussed in the introduction, the PEG chain length is known to 
influence the NP-cell interactions, however it is also well established 
that the PEG density on a NP surface can also affect the protein 
repelling capacity of the resultant NPs, and therefore influence the 
particles stealth properties (Unsworth and Sheardown et al., 
2005.,Knop and Hoogenboom et al., 2010). The PEG density has also 
been identified as being key in determining cell uptake (Stefanick and 
Ashley et al., 2013), although in this study, the AuNPs with 40% PEG 
coverage demonstrated marginally higher uptake levels to the 25% 
AuNPs (as demonstrated by ICP-MS results), and the TEM images 
indicated clear availability of the 40%-NPs in the cell cytoplasm. Thus, 
the 40% density did not appear to be hindering cellular uptake.  
In summary, it is well established that ligand surface coverage, density 
and conformation on functionalized NPs is of critical importance to the 
success of the NP delivery system, however to date it is rarely reported. 
Until only very recently, data on ligand densities on AuNPs (in the 10-
100 nm range) were seldom supplied (Hinterwirth and Kappel et al., 
2013). This may be due in part to the technical difficulties in 
determining such data, with X-ray crystallography and density 
functional theory studies being performed to derive theoretical 
considerations (Hakkinen, 2012). In this study, we surmise that the 
lower coverage of PEG potentially allowed greater access of the siRNA 
to the intracellular environment and the RISC complex, which was 
reflected in (i) the significantly higher C-Myc protein knockdown levels 
recorded with the 25% at 15 nM (Figure 3 6), and (ii) the reduction in 
cell proliferation observed with the 25% PEG at 2 nM whilst the 40% 
was similar to control levels (Figure 3-9). The most pronounced C-Myc 
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knockdown occurred using the increased concentration and the 25% 
PEG in tandem, producing better protein reduction than the positive 
control C-Myc Lipofectamine. 
3.5 Conclusion 
For siRNA to realise its therapeutic potential, it must be functional and 
freely available within the cell cytoplasm to interact with the RISC 
complex. When relying on a glutathione-based release strategy, this 
study highlights the importance of both particle design, in terms of 
passivating ligand densities such as PEG, and also intracellular 
glutathione levels, which differ between cell types. To tackle this, a 
multidisciplinary approach is strongly recommended, allowing a 
feedback loop between the cell biologists and synthesis chemists in 
order to redesign aspects of the NP, with a view to tailoring the particles 
for a specific cells and tissues. 
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3.6 Supplemental 
Due to the expense of determining AuNP uptake via TEM, preliminary 
uptake studies were performed via fluorescence microscopy. Several 
AuNPs were selected to trial uptake in MG63s, after 24 hours incubation 
the cells were fixed and the particles were stained using streptavidin-
FITC binding to the biotin attached to PEG on AuNP surface. The results 
indicated good uptake of the AuNPs into the cells, however, whether the 
NPs were internalised or merely attached onto the cell surface could not 
be determined by this method, thus uptake was measured qualitatively 
by TEM and quantitatively by ICP-MS. 
Supplemental Figure 1. Fluorescent localisation of AuNPs, at 2nM, after 
24-hour incubation. The green indicates the streptavidin-FITC binding to 
the biotin on the AuNPs  (nucleus: blue). Scale bar =5µm. 
 
 
A) 2nM Au-B-40% PEG B) 2nM Au-B-S-40% PEG 
 
D) 2nM Au-B-R-S-40% 
PEG 
 
C) No AuNPs 
 
   115    
 
4 Chapter 4: Gold Nanoparticle-mediated Blocking 
of Mir-31 to Influence Osterix Expression in the 
Osteosarcoma Cell Line MG6
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4.1 Introduction 
MicroRNA’s (miRNA) are single stranded RNA molecules approximately 
20 nucleotides long, involved in the RNA interference (RNAi) pathway. 
MiRNA, unlike short interfering RNA (siRNA), do not innately bind with 
complete complementarity to targeted RNA sequences. This lack of 
complementarity allows miRNA to bind and halt the expression of a 
number of mRNA transcripts, thus offering an attractive mechanism for 
broad silencing of target genes. 
Thompson et al (2006) performed the first global analysis of miRNA 
levels. Mature miRNAs were analysed and showed widespread post-
transcriptional regulation of mRNAs (Thomson and Newman et al., 
2006).  They have been shown to regulate a wide spectrum of biological 
processes from differentiation, (Bhushan and Grünhagen et al., 
2013.,Xie and Wang et al., 2014) to tumorigenesis (Sun and Wang et 
al., 2009b.,Liu and Li et al., 2011b). Until lately, most miRNAs have 
been used diagnostically to identify cancerous cells in a number of 
tissues (Table 4-1). More recently, however, research is beginning to 
investigate miRNAs for their potential as therapeutic tools, with a view 
to influencing cell homeostasis and stem cell differentiation 
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Table 4-1 Specific miRNAs involved in different cancer types. 
Cancer 
Tissue 
Types 
Associated 
miRNAs with 
Cancer Cell Types 
Reference 
Bone mir-31, mir-125b Baglìo and DeVescovi et al. 
(2013) 
Liu and Li et al. (2011a) 
Brain mir-21, 221,181 Ciafre and Galardi et al. 
(2005) 
 
Breast mir-
125b,145,21,155 
Iorio and Ferracin et al. 
(2005) 
Lymphatic mir-15,16 Calin and Ferracin et al. 
(2005)  
Cimmino and Calin et al. 
(2005) 
Colorectal mir-143,145 Michael and SM et al. (2003) 
Hepatocellular mir-
18,224,199,195, 
200,125 
Murakami and Yasuda et al. 
(2006) 
Lung mir-17, mir-31 Zhong and Dong et al. 
(2013) 
Mouth mir-31 Chang and Kao et al. (2013) 
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Prostate mir-31 Lin and Chiu et al. (2013) 
Testicular mir-372, 373 Voorhoeve and le Sage et al. 
(2006) 
Thyroid mir-
221,222,146,181 
He and Jazdzewski et al. 
(2005) 
Pallante and Visone et al. 
(2006) 
 
MiRNAs are known to play a crucial role in bone formation and 
regulation (Lian and Stein et al., 2012.,Ell and Kang, 2014).  Bone 
tissue is made of several cell types, including osteogenic cells (stem 
cells); osteoblasts (form bone matix); osteocytes (maintain bone) and 
osteoclasts (resorb bone). Each different cell type has a miRNA profile, 
as detailed in Table 4-2. The osteogenic cells have sub-divisions of cell 
types, such as mesenchymal stem cells (MSCs) within the bone marrow, 
and pre-osteoblasts, which are cells that have begun to differentiate 
from MSCs and proliferate rapidly. As they proliferate, they mature into 
osteoblasts, reducing proliferation and creating layers of extracellular 
protein matrix. These cells can mature further into osteocytes, as they 
begin to mineralise and form functional ossified bone. 
A final class of bone cell are osteoclasts, which are important for bone 
remodelling and are capable of digesting mineralised bone. Osteoclasts 
are slightly different, as they are generated from a hematopoietic stem 
cell (HSC; blood stem cells) cell maturing into a monocyte. The 
monocyte interacts with osteoblasts presenting the Receptor activator 
of nuclear factor kappa-B ligand (RANKl) protein. This protein-receptor 
interaction induces the monocyte to mature into an osteoclast (Lian and 
Stein et al., 2012). 
Chapter 4   119 
 
Table 4-2 Role of miRNAs in the different  bone cell types. Adapted from 
Lain and stein et al, 2012 and Baglìo and DeVescovi et al, 2013. 
Bone Cell Type Role miRNAs 
 
MSCs Proliferation and 
homeostasis 
Mir-135, mir-138, mir-
23a, mir-30c, mir-31, 
mir-196a, mir-204, mir-
206, mir-335 
Pre-osteoblast Proliferation Mir-23, mir-29, mir-34, 
mir-30, mir-31 mir-210 
mir-218 
Osteoblast Matrix Maturation Mir-125b, mir-138, mir-
637, mir-29c 
Osteocytes Mineralization Mir-23a~27a~24-2, mir-
204, mir-205, mir-217, 
mir-133, mir-135 
Osteoclast Bone remodelling Mir-155, mir-223, mir-21 
 
Due to this wide range of regulation, miRNAs have recently become a 
potential target for future therapeutics. Mir-31 in particular has been 
linked to tumorigenesis, as mentioned in Table 4-1 (Zhong and Dong et 
al., 2013.,Hung and Tu et al., 2014.,Hua and Xiaotao et al., 2012.,Feng 
and Huang et al., 2013.,Chang and Kao et al., 2013.,Valastyan and 
Weinberg, 2011), angiogenesis (Liu and Cheng et al., 2011) and 
Duchene muscular dystrophy (Cacchiarelli and Incitti et al., 2011). More 
recently however mir-31 has been indicated to influence stem cell 
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osteogenesis by suppressing the master osteogenic transcription factor 
osterix (Baglìo and DeVescovi et al., 2013.,Xie and Wang et al., 
2014.,Deng and Wu et al., 2013.,Deng and Zhou et al., 2013). A recent 
study by Baglio et al (2013) introduced antagonists of mir-31 into the 
osteosarcoma cell line MG63s (pre-osteoblast), using linear sequences 
with a cholesterol attachment to aid cellular uptake, via the low density 
lipoprotein uptake pathway. Using quantities in the milimolar range, 
they demonstrated that by blocking mir-31, they increased the level of 
osterix in MG63s, and conversely, by increasing mir-31 they showed a 
reduction in osterix expression in SOAS-2 cells (a mature osteoblast 
cancer cell line). The authors concluded that osterix was a definite mir-
31 target. 
Another group in the same year linked mir-31 with the Runt-related 
transcription factor 2 (RUNX2) and Special AT-rich sequence-binding 
protein 2 (SATB2) regulatory network. The authors reported that mir-31 
expression was progressively decreased in human bone marrow derived 
stem cells undergoing differentiation (Deng and Wu et al., 2013). The 
authors used lipofectamine to transfect their cultures with mir-31, or 
mir-31 inhibitors. Increasing levels of mir-31 decreased SATB2 protein 
levels, however no notable changes were reported at the RNA level. The 
authors linked RUNX2, mir-31 and SATB2 together in a regulatory 
feedback system. By increasing RUNX2 levels (with transfected 
plasmids encoding RUNX2) they directly repressed mir-31. In addition, 
by overexpressing mir-31 they reduced osterix, osteocalcin, and 
osteopontin protein expression without effecting RUNX2 protein levels, 
suggesting that mir-31 can only target down stream targets of RUNX2.  
Using this collated evidence, I believe that mir-31 exists in a complex 
osteogenic pathway that represses several established factors (Figure 
4-1). 
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Figure 4-1. The interaction of mir-31 within an osteogenic pathway; 
green arrows indicate interacting factors, with a dashed line showing a 
simplified interaction, whilst red bars indicate an inhibitory effect 
(personal image). 
The exploitation of miRNAs and their antagonists for widespread clinical 
treatment has to date been setback by technical problems, in particular 
their cellular delivery. In a manner similar to siRNA, miRNA and their 
antagomirs cannot enter cells easily and are rapidly degraded in vivo. It 
is important therefore that a delivery vector is used. As with the 
delivery of siRNA, the optimal delivery vector needs to, (i) target cells, 
(ii) cross the plasma membrane and (iii) release the functional 
miRNA/antagonist so that it can interact with the RISC complex 
(Grigsby and Leong, 2010). As described in section 1.2, AuNPs are 
excellent candidates, meeting all essential criteria. Therefore, this 
section of work focuses on the synthesis of AuNPs, which are designed 
with the aim to functionally inhibit mir-31 via antagomir sequences 
attached to the NP surface, and can bind to the mature mir-31 
sequences by base-pair binding. The hypothesis therein being that such 
inhibition will lead to an increase in osterix expression. 
This chapter aims to test this hypothesis using the osteosarcoma cell 
line MG63 (the same cell line used in chapter 3). Osteosarcoma cells are 
derived from malignant bone tumours.  They share key osteoblastic 
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features, and are commonly used as osteoblastic models (Pautke and 
Schieker et al., 2004).  The study aims to assess osterix levels in MG63 
following treatment with antagomirs against mir-31 via AuNP delivery 
(Figure 4 1).  A further facet to this study will be to identify any possible 
influence the antagomir sequence directionality has on function. To 
date, there have not been any specific studies addressing this issue, 
which is surprising given the possible differences in binding potency. 
Therefore, both the thiolated 5’ and 3’ sequences were conjugated onto 
the AuNP surface and tested independently. 
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4.2 Materials and Methods 
4.2.1 Synthesis and Functionalisation of Gold Nanoparticles.  
All AuNP synthesis and characterisation was carried out by our 
collaborators Professor Pedro Baptista and Dr. Joao Conde, based in 
Caparica, Portugal ( section 2.4.1). 
4.2.1.1  Assembly of Antagomirs to PEGylated gold nanoparticles 
Four sets of NPs-Antagomirs were prepared using modified 2’-ACE (2′-
bis(2-acetoxyethoxy)methyl) protected RNA oligonucleotides. 2’ACE is 
an orthoester group used to protect the 2′-OH of RNA monomers from 
degradation and can used to store RNAs for extended periods prior to 
use. Three oligos sequences were synthesised as described in Table 4-
3. 
First, the RNA oligos were deprotected by adding 400 L of 2’-
Deprotection buffer (100 mM acetic acid, adjusted to pH 3.8 with 
TEMED), dissolving the oligo completely by vortexing and centrifuge 10 
seconds. Then, the oligos were incubated at 60ºC for 30 minutes and 
SpeedVac to dryness before reduction and purification of thiol groups. 
Briefly, the thiolated RNA oligonucleotides were suspended in 1mL of 
0.1M dithiothreitol (DTT), extracted three times with ethyl acetate and 
further purified through a desalting NAP-5 column (Pharmacia Biotech) 
using 10 mM phosphate buffer (pH 8) as eluent. Following 
oligonucleotide quantification via UV/Vis spectroscopy, each RNA 
oligonucleotide was added to the AuNP@PEG in a 100:1 ratio. AGE I 
solution (2% (w/v) SDS, 10 mM phosphate buffer (pH 8)) was added to 
the mixture to a final concentration of 10 mM phosphate buffer (pH 8), 
0.01% (w/v) SDS, sonicated for 10 seconds using an ultrasound bath 
and incubated at room temperature for 20 minutes. Afterwards, the 
ionic strength of the solution was increased sequentially in 50 mM NaCl 
increments by adding the required volume of AGE II solution (1.5 M 
NaCl, 0.01% (w/v) SDS, 10 mM phosphate buffer (pH 8)) up to a final 
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concentration of 10 mM phosphate buffer (pH 8), 0.3 M NaCl, 0.01% 
(w/v) SDS. After each increment, the solution was sonicated for 10 
seconds and incubated at room temperature for 20 minutes. The 
solution was allowed to rest for an additional 16 hours at room 
temperature. Then, the functionalized NPs-Antagomirs were centrifuged 
for 20 minutes at 21.460 ×g, the oily precipitate washed three times 
with DEPC-treated H2O, and redispersed in the same buffer. The 
resulting NPs-Antagomirs, as listed in Table 4-4, were stored in the dark 
at 4 °C until further use. 
Table 4-3. Oligomer sequences used for AuNPs-antagomir 
functionalization. GC % relates to the melting temperature, the greater 
the GC content the higher the melting temperature. Antagomir-31 5’, is 
designed to bind with perfect complementarity to the corresponding 
mir-31 5’ sequence. The same principle relates to antagomir-31 3’, 
which binds with perfect complementarity to the mir-31 3’ sequence. 
Antagomirs Sequences 
GC
% 
Melting 
Temperature 
(ºC) 
antagomir  
non-targeting 
SSGGAGAUUGGUUUUGACGUU
UA 
38 48.5 
Antagomir-31 
5’ 
SSAGCUAUGCCAGCAUCUUGCC
U 
52 54.4 
antagomir-31 
3’ 
SSAUGGCAAUAUGUUGGCAUA
GCA 
41 51.1 
 
Physical characterization of the NPs-Antagomirs was performed by 
Dynamic Light Scattering (Zetasizer, Malvern), Zeta Potential 
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(Zetasizer, Malvern), UV/Vis Spectroscopy and Transmission Electron 
Microscopy (see Table 4-4 and Figure 4-2). 
Figure 4-2. TEM image of antagomir-gold nanoparticles (scale bar = 
200 nm). Panel A  shows nonsense (NS)-AuNPs;  B shows 5A-AuNPs, 
and  C shows 3A-AuNPs.  
In summary, the panel of four AuNPs employed in this study, with 
associated acronyms and PEG chain densities, is detailed in Table 4-4.
A B C 
Chapter 4            126 
 
Table 4-4. Physical-chemical properties of the gold nanoparticles employed in this chapter. Please note that 5A denotes 
the 5’ end of the antagonist sequence of mir-31, and 3A denotes the 3’ end of the antagonist sequence of mir-31. NS is a 
nonsense strand used as a negative control. SPR corresponds to the AuNP surface plasmon resonance. 
a Determined by Dynamic Light Scattering (DLS). 
 b Nanoparticles analysed at a concentration of 2 nM in water in a total volume of 1 mL, with 0.1 M KCl 
NP Type Acronym SPR 
peak 
Size 
(nm)a 
Zeta-Potential 
(mV)b 
PEG per NP Antagomir 
(nM) per NP 
  Uncoated NPs 519 14.4± 2.7 -19.2± 4.2 NA NA 
Au-30% PEG PEG 521 18.5± 3.9 -25.2± 2.7 200.16 ± 15.01 NA 
Au-NS-30% PEG NS 523 39.75±1.2 -32.9± 1.4 200.16 ± 15.01 1123.81 
Au-5A-30% PEG 5A 523 37.12±2.4 -34.3± 2.9 200.16 ± 15.01 965.35 
Au-3A-30% PEG 3A 523 38.84±3.1 -32.3± 1.6 200.16 ± 15.01 1058.53 
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4.2.2 Cell Culture          
The human osteosarcoma cell line MG63 was employed in this chapter, 
because of its innately high levels of mir-31.  The cells were cultured in 
DMEM growth medium and maintained at 37oC in 5% CO2 until ~90% 
confluent; after which time they were passaged and counted with a 
haemocytometer. The cells were seeded at a density of 1x104 cells per 
ml for experiments unless stated otherwise. The cells were cultured for 
24 hours before the addition AuNPs treatments at 50nM of oligo.  
4.2.3 Toxicity 
MG63 cytotoxicity in response to the antagomir-AuNP treatments was 
assessed by standard MTT assay, as described in Chapter 2.4.2. 
4.2.4 Cellular Uptake of Gold Nanoparticles 
4.2.4.1 Transmission Electron Microscopy (TEM) 
Cellular uptake of AuNPs was verified via TEM. MG63 cells were seeded 
at a density of 4x104 cells per mL onto Thermanox coverslips (13mm 
diameter) and cultured to develop a confluent monolayer of cells. At 
this point the AuNPs were added and cells further cultured for 24 hours.  
Cells were subsequently processed for TEM as described in chapter 2, 
section 2.4.3.1.  
4.2.4.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
Cellular uptake of AuNPs was further quantified via ICP-MS. The MG63 
cells were seeded (100 L/well) in a 96 well plate and incubated for 24 
hours. AuNPs were added to cells for 48 hours and the cells were 
processed for ICP-MS as described in chapter 2, section 2.4.3.2. The 
converted values for gold uptake were averaged (n=3) and used for 
statistical analysis. 
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4.2.5 Fluidigm Analysis of Osterix and Related Gene RNA Levels 
Analysis of MG63 cell RNA levels in response to antagomir-31-AuNP 
incubation was performed using the Fluidigm Biomark HD system. This 
system allows for automated PCR reactions to be carried out, using less 
samples and reagent, via a microfluidic design. This particularly suits 
experiments using NPs due to the typically large volumes required, and 
the expense this can lead to in terms of ordering sequences etc. A 
48x48 array was used, allowing for multiple RNA targets to be assessed 
alongside several house keeping genes. The targets used are detailed in 
section 2.4.5.2. Aside from the principal target osterix, these additional 
primers were selected based on their possible link to mir-31 through 
osteoblast-like pathways including RUNX2, the bone morphogenic 
proteins (BMPs) and Mothers Against Decapentaplegic Homolog  
(SMADs) (intracellular signalling proteins). 
To investigate the functionality of the antagomirs at the RNA level a 
fluidigm 48x48 well array was used, which quantified multiple targets 
after 48 hours of AuNP treatment. This robust, high throughput 
technique produced a snap shot of the effects of the AuNPs on selected 
RNA transcripts, including osterix, expressed in the MG63 cells (2.4.4.2, 
Table 2-1). From the qPCR data a heat map was created of the delta 
delta CT values :  
((CT(target,untreated)−CT(ref,untreated))−(CT(target,treated)−CT(ref,
treated)) 
From the samples normalised to multiple housekeeping genes, 
indicating increases or decreases in expression. MG63 cells were grown 
at 1 x 105 cells per well in a 24 well plate and allowed to adhere 
overnight. AuNP treatments were added (50nm oligo on AuNP surface) 
and incubated with the cells for 48 hours (control cells were incubated 
with media instead). After 48 hours samples were processed for 
fluidigm as per chapter 2, section 2.4.5.2. 
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4.2.6 In Cell Western Analysis of Osterix Protein Levels 
The level of osterix protein in MG63 cells post AuNP treatment was 
further analysed via in-cell westerns. This allowed for both specific and 
high throughput analysis. Cells were seeded in a 96 well plate in 
triplicate, challenged with the AuNPs for 24 and 48 hours, then ﬁxed, 
permeabilised and blocked as in section 2.5. Samples were then co-
incubated with primary antibodies (1:2000 mouse OSX and 1:5000 Cell 
tag 700) at 37◦C for 1 hour. Following Tween washing, samples were 
subsequently co-incubated with secondary antibody (1:2000 donkey 
anti-mouse IR800CW, Licor, UK) at 37◦C for 1 hour. All samples were 
finally washed three times in PBS/Tween (5 min/wash). The plates were 
imaged by scanning simultaneously at 700 and 800 nm with an Odyssey 
SA at 100 μm resolution, medium quality, focus offset of 3.53 mm, and 
an intensity setting of 7 for both 700- and 800-nm channels. 
4.2.7 Theoretical Binding of Antagomir-31 Sequences 
Both the antagomir 5’ and antagomir 3’ ( 5A and 3A respectively)  with 
the nonsense RNA sequences were run through the RNAhybrid 
programme developed by M. Rehmsmeier. RNAhybrid predicts the 
minimum free energy hybridization of two RNA sequences, allowing for 
miRNA target prediction.  Hybridization is assessed by domain analysis 
with one sequence hybridized to the best fitting part of another 
(Rehmsmeier and Steffen et al., 2004). 
4.2.8 Statistics 
Statistical analysis was performed in Graphpad using a one-way ANOVA 
with a Dunnett's test. In all figures * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001 and **** = p < 0.0001.  Two tailed T-Tests were 
performed where specifically mentioned, a welchs correction was used, 
♯ = p < 0.05, ♯ ♯ = p < 0.01 
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4.3 Results 
4.3.1 Cell Toxicity : MTT Assay 
The antagomir functionalised AuNPs were found to have no cytotoxicity 
over 24 hours incubation, as demonstrated with the MTT assay, 
showing no statistical difference between treatments (Figure 4 3).   
Figure 4-3. MTT analysis of MG63 cells treated with each AuNP (50nM 
oligo, 30% PEG) type for 24 hours (PEG, NS, 3A, 5A) (n=3; error bars 
indicate SD). 
4.3.2 Cellular Uptake : TEM  
Cross-sectional imaging by TEM was used to qualitatively analyse the 
cellular uptake and the intracellular location of the AuNPs after both 1 
hour and 48 hour incubation. At the earlier time point of 1 hour, the 
AuNPs were observed interacting with the cell membrane and 
instigating cellular uptake, as denoted by arrowheads in Figure 4-4A, 
whilst at the latter 48-hour time point the NPs were clearly evident 
within the cell, mainly packaged into endosomes (Figure 4-4B).  
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Figure 4-4. TEM images of MG63 cells treated with AuNPs (50nM, 30% 
PEG) after 1 (A) and 48 hours (B). Black arrowheads denote AuNPs. 
Scale bar =0.2µm.  
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4.3.3 Cellular Uptake : ICP-MS 
In parallel to qualifying AuNP uptake into cells, the amount of AuNPs 
within the cells was quantified after 48 hours using ICP-MS to determine 
elemental gold levels in lysed cell samples. All four AuNPs types were 
recorded in the cells, with a notable increase in uptake with the 5A and 
3A AuNP species compared to NS and PEG (Figure 4-5). This is unlikely 
to be due to either NP size or charge, as the NS functionalised AuNPs 
are very similar in both regards to the 5A and 3A NPs (Table 4-4). A 
possibility may be that the interaction of the antagomirs, if still attached 
to the gold surface, with the target miRNAs may hinder possible 
exocytosis and NP turnover, in turn increasing the AuNP load within the 
cell. Repeat experiments at earlier time points would be required to 
verify this.  
 
Figure 4-5.  ICP-MS analysis of MG63s treated with AuNPs (50nM, 30%) 
for 48 hours. Each lysate has an n=3, error bars denote SD. 
4.3.4 Osterix and Related Gene Expression via Fluidigm 
From the raw fluidigm data, a hierarchical analysis was used to group 
the AuNPs together based on the similarity of the CT values (Figure 4-
6). This separated out the NPs based on the influence they had on the 
48 different target RNAs. The analysis identified a close relationship 
between 5A and 3A, with NS and PEG being more distantly related.  
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When considering targets that may be linked to mir-31, the 5A 
antagomir highly up regulated RUNX2 and SMAD3 after 48 hours in 
comparison to the other NP species; both of which were highlighted in 
Figure 4-6 as being involved in osteogenesis. Crucially however, osterix 
was not up regulated with 5A, yet the remaining three AuNPs (3A, the 
nonsense (NS) and PEG controls), appeared to upregulate osterix 
(Figure 4-6). This could be partly explained by off-target effects, as 
very few other osteogenic markers were up regulated. However, it may 
be due to the time point selected; 48 hours may be too late to identify 
changes at the RNA level. The RNA environment is highly dynamic, with 
many reactions and very quick RNA turnover. With this perspective it is 
possible that 5A may have up regulated osterix expression before the 
48 hour time point and had been constituently silenced by other 
intracellular factors balancing any changes, as seen in other pathways 
such as cyclin signalling; a pathway highly dependant on the interplay 
between positive and negative feedback loops (Murray, 2004). A study 
by Zhou et al (2012) have found that many miRNAs act in a bistable 
regulatory pattern, with transcription factors and miRNA levels 
oscillating in response to each other, as seen in cyclin signalling (Zhou 
and Cai et al., 2012).   
Interestingly, C-Myc expression (a proliferation gene; a target in siRNA 
studies in chapter 3) was only down regulated with 5A. C-Myc is 
typically highly overexpressed in cancer cell lines and undifferentiated 
cells. As MG63s are both a cancer cell line and a pre-osteoblast like cell, 
a reduction in C-Myc expression by 5A alongside an increase in RUNX2 
and SMAD3 could indicate that the cells were slowing proliferation to 
focus on enhancing commitment down the osteoblast lineage 
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Figure 4-6. Heat-Map of MG63s treated with the AuNPs for 48 hours 
(green reflects a decrease in expression, whilst red reflects an 
increase). The data was analysed using PermutMatrix and ordered into 
hierarchy based on expression similarity using McQuitty’s criteria. 5A 
and 3A are the most related. After 48 hours 3A appears to activate a 
wide array of osteogenic factors, whereas 5A has appeared to up-
regulate RUNX2 very strongly whilst down regulating C-Myc expression. 
Chapter 4   136 
4.3.5 Osterix Protein Levels via In-Cell Western 
Due to the dynamic nature of RNA production, it is essential to also 
measure protein levels further downstream to further understand the 
effect of the antagomir functionalised AuNPs. Therefore, In-Cell Western 
was carried out to elucidate any changes in osterix at the protein level 
(Figure 4-7). After 48 hours of AuNP treatment osterix was significantly 
increased with both 5A and 3A treatment, compared to MG63s treated 
with no AuNPs, PEG or nonsense controls. The breast cancer cell line 
MCF-7 was used as a negative control, as this cell line is known to 
contain low levels of osterix; no difference was noted between these 
cells and the MG63 cells alone, or those incubated with the NS and PEG 
AuNPs. This suggests that the MG63 cells maintain a low background 
osterix expression level, which was increased in response to the 
antagomir functionalised AuNPs.  
Figure 4-7. ICW data comparing osterix levels in MG63s after 48 hours 
with AuNP treatments normalised to cell number, and in MCF-7 cells. 
(n=6; error bars denote standard deviation) 
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4.4 Discussion 
4.4.1 Mir-31 : Osterix and Osteogenesis 
MiRNAs are becoming recognised as crucial regulatory molecules, as 
such, their dysregulation can lead to many disease phenotypes. Mir-31, 
for example, has been linked to numerous diseases including 
tumorgenesis (Liu and Sempere et al., 2010), as well as cellular 
processes such as adipogenesis (Sun and Wang et al., 2009a), and 
most recently osteogenesis (Xie and Wang et al., 2014.,Deng and Wu et 
al., 2013.,Guo and Zhao et al., 2011a.,Gao and Yang et al., 2011.,Deng 
and Zhou et al., 2013.,Baglìo and DeVescovi et al., 2013).  Current 
papers by Baglìo et al (2013) and Deng et al (2013) found that mir-31 
was linked to osterix expression; expression levels were generally found 
to decrease as a stem cell differentiates (Gao and Yang et al., 2011). 
This however is not the case for tumour cells lines, which had elevated 
levels of mir-31 in comparison to stem cells. This potential link with 
osteosarcomas has created a debate around mir-31 being described as 
both an oncogene (Liu and Sempere et al., 2010) and tumour 
suppressor (Lin and Chiu et al., 2013). The multifunctional aspect of 
miRNAs in general makes it possible that, depending on cell type and 
the point at which the dysregulation occurs, mir-31 may act as a 
tumour suppressor or oncogene and also influence osteogenesis.   
However the link between mir-31 and osteogenesis is not without some 
controversy. Baglìo et al detected in their human mesenchymal stem 
cell (hMSC) cultures that mir-31 was upregulated in their differentiating 
cells in comparison to their undifferentiating cells. This is at odds with 
both Gao et al (2011) and Xie et al (2011), who both demonstrated that 
mir-31 decreases as a MSC continues down the osteogenic lineage. 
These conflicting results could be due to simple variation between 
experimental designs, for example differences in stem cell donor type, 
cell passage number, cell seeding density, culture times, culture media 
additives (eg. ascorbic acid), media changes and practices may have 
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produced such differences. Although this chapter employed MG63 cells 
as a proof of concept for our delivery system, the results in this chapter 
support the latter Gao and Xie papers, whereby when we block mir-31 
via antagomir-AuNP delivery, we see an increase in osterix protein. This 
certainly suggests that the two are linked, and indicates that it may be 
possible to direct cells down an osteogenic lineage. 
4.4.2 Antagomir Sequence Directionality: 5A Vs 3A 
A further complication, when comparing research papers utilising 
miRNAs is the possible variation in the sequence origin. This study, 
whilst aiming to identify a link between mir-31 and osterix levels in a 
standard tumour cell line, also compared the differences between 
antagomir sequences with 5’ (denoted 5A) and 3’ (3A) directionality. 
Although both the 5A and 3A antagomir are antagonists of mir-31, the 
two species are from different sections of the mir-31 sequence. It 
appears from the fluidigm data and the ICW experiments that the two 
sequences behave slightly differently despite their origin. With this 
noted, questions about the binding of the sequences were raised. 
To investigate the antagomir binding potentials the RNAhyrbid 
programme (designed by Rehmsmeier et al (2004)) was used, to 
determine the type and the strength of bond that both antagomirs 
would form with the corresponding and opposing strand (Rehmsmeier 
and Steffen et al., 2004). The results are shown in Figure 4-8. Binding 
energies for both antagomirs to their respective mir-31 sequences (mir-
31-5’ with 5A and mir-31-3’ with 3A) formed strong bonds that required 
< ~-40kcal/mol for dissociation. The antagomir 3’ sequence (ie. 3A) 
was predicted to form a strong bond with the corresponding 5’ 
sequence of mir-31 (-22.9kcal/mol), whilst the 5’ antagomir sequence 
(5A) was predicted to form a weaker structure with the opposing 3’ mir-
31 sequence (-12.6kcal/mol). Weaker still were the nonsense strand’s 
ability to bind to mir-31. This was expected, but was it was noted that a 
degree of potential binding was possible.   
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This differential between binding energies of the 5A and 3A with the 
different mir-31 stands could be a reason for the range of responses. A 
report by Chan et al (2013), found a range of concordant and 
disconcordant responses of mir-31 by shifting the sequence by one 
nucleotide; which was reported to repress dicer activity, whilst the 
nonshifted sequence could not. Recognising that other mechanisms 
apart from the seeding region can induce drastic change in properties 
by subtle variations in sequence length and position. This improved 
perspective could lead to better design of miRNA therapeutics.  
The difference between 5A and 3A in binding could also be due to 
differences in the structure of the primary RNA sequences, which, based 
on the minimum free energy method, are shown in Table 4-5. Mir-31 5’ 
and the corresponding 5’ antagomir (5A; the highest potency 
antagomir) form single stranded structures with large open unbound 
sequences of  ~9 bp in length.  This unbound section could allow for 
easier binding with targets, resulting in more efficient knockdown. 
Very few antagomir studies focus on the origin of the sequence 
employed, and the possible differences having a sequence that targets 
the passenger strand over the guide strand might produce (Zhong and 
Dong et al., 2013) (Chang and Kao et al., 2013) (Chan and Lin et al., 
2013). This is certainly a facet of such studies that requires attention in 
future work.  
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Table 4-5. The predicted structures of the single stranded RNA sequences, based on the minimal free energy (MFE) 
method (an established method to predict RNA structure). Complimentary regions are evaluated to predict the most 
energetically stable molecule. The stability of the structure is given in kcal/mol, the more negative the value equates to a 
more stable structure.  
 
Name Sequence MFE for 
optimal 
2o 
structure 
kcal/mol 
MFE structure drawing 
encoding base-pair 
probabilities 
 
Frequency of MFE 
structure 
hsa-mir-31-5’ AGGCAAGAUGCUGGCAUAGCU 
 
 -2.00   
 
18.96  
0 1
A
GGCAA
G
A
U G
C UG G C
A
U
A
GCU
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Name Sequence MFE for 
optimal 
2o 
structure 
kcal/mol 
MFE structure drawing 
encoding base-pair 
probabilities 
 
Frequency of MFE 
structure 
hsa-mir-31-3’ UGCUAUGCCAACAUAUUGCCAU -1.10   
 
39.35  
antagomiR-
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AGCUAUGCCAGCAUCUUGCCU -1.20  
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encoding base-pair 
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Figure 4-8. miRNA binding sequence geometries based on base pairing 
and minimum free energy using RNAhybrid. The stability of the 
structure is measured in kcal/mol (ie. the energy required to break the 
structure). The greater the energy needed the more stable the 
structure. Linearity infers stability, whilst loops indicate incompatibility 
and lack of binding. The antagomirs and their corresponding miRNA 
sequence form the strongest and most stable structure. 
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4.4.3  Off Target Effects 
Fluidigm data demonstrated a host of up- and down-regulations for 
primers other than osterix. For example, it was noted that the nonsense 
strand up-regulated several genes, despite being a negative control. 
This suggested a general cell reaction to the AuNPs at the RNA level, 
which were not related to the intended antagomir target (osterix).  This 
is not surprising, as the addition of NPs to the culture media, and their 
subsequent uptake into the cell would be expected to stimulate a 
variety of cell responses (Boisselier and Astruc, 2009). There is very 
little literature in this regard, as most reports using NPs focus on 
assessing functional delivery of the cargo, however recent work in our 
lab has noted several off target effects when using siRNA delivered to 
cells via AuNPs (Child et al, submitted). 
From the fluidigm data in Figure 4-6, it was also notable that the 3A 
AuNPs up-regulated most genes shown on the heat map, in direct 
comparison to the 5A AuNP, that down regulated everything apart from 
RUNX2, SMAD3 and CD63. Typically, miRNAs repress protein levels, so 
it could be said that 5A behaviour is more true to type (Lian and Stein 
et al., 2012).  The 3A antagomir may be non-specifically up regulating 
multiple RNAs by having more promiscuous binding, whilst 5A’s more 
conservative binding (i.e. binding to one target very strongly and 
binding only very weakly to any other sequence) might enable for 
better, more consistent targeting, producing more osteogenic like cells 
with higher osterix levels (Figure 4-7). 
The ICW data confirmed that blocking mir-31 with the antagomirs 
produced more osterix protein after 48 hours of treatment. The 3A 
indicated slightly less osterix in comparison to 5A, but both sequences 
significantly increased osterix levels in comparison to control cell 
populations.  
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4.5 Conclusion 
Interfering with intracellular miRNA levels for therapeutics provides an 
exciting alternative to current drug delivery formulations for many 
diseases. Using AuNPs as the delivery vector within this section of work 
provided a stable delivery platform with low toxicity. A functional 
response to blocking mir-31 was noted, with an increase in osterix level 
in MG63 cells at the protein level. However some off target effects were 
noted in this study at the RNA level, which could potentially, cause 
issues for future studies. This investigation highlighted clear differences 
in results when using different miRNA sequences, and more research is 
needed to tackle the lack of knowledge surrounding miRNA sequence 
binding and its effects. 
In spite of this, factors such as oligo concentration and duration of 
treatment proved challenging to achieve efficient silencing. With 
increased high throughput screening these variables could be fine-
tuned, increasing our understanding of the complexities of miRNA 
therapeutics and delivery.  
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5 Chapter 5:Gold Nanoparticle-mediated Blocking 
of Mir-31 to Influence Osterix Expression in 
Human Mesenchymal Stem Cells 
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5.1 Introduction 
The paradigm of using manmade synthetic materials to help support 
and restore functionality to injured tissues is being superseded by the 
potential of harnessing the body’s natural ability to heal itself. The main 
drive behind this shift has been the breadth of recent research with 
stem cells, and our subsequent expansion of knowledge. As described in 
chapter 1 (section 1.4.2), MSCs are a subset of stem cells that are 
mainly located in the bone marrow, within their specialised niche 
environment, and they have the potential to differentiate and heal 
damaged tissue in situ.  The more we understand about these 
processes, the better our chance of influencing MSC differentiation to 
our advantage to allow tissue regeneration and healing. 
To this end, an expanding field of MSC research is concerned with bone 
regeneration. The main pathways involved in osteogenic differentiation 
are summarised in Chapter 1, (section 1.4.2). Committing MSCs to an 
osteogenic lineage produces a mineralized extracellular matrix of 
collagen, calcium and phosphorus. It has been established that diseases 
such as osteoporosis and osteogenesis imperfecta are underpinned by 
the dysregulation of components in osteogenic pathways (Heggebo and 
Haasters et al., 2014).  To date research has involved creating new 
tissue (Eslaminejad and Karimi et al., 2013), repairing fractures (Chen 
and Deng et al., 2012), and attempting to further understand the 
mechanisms of osteogenesis with a view to increasing bone density for 
osteoporosis patients (Zhu and Friedman et al., 2012.,Qiu and Andersen 
et al., 2007.,Heggebo and Haasters et al., 2014.,Benisch and Schilling 
et al., 2012). 
MSCs are highly regulated cells, in terms of self-renewal and 
differentiation, and it is becoming increasingly evident that miRNAs play 
a critical role in this regulation. Several key miRNAs involved in 
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osteogenic differentiation were noted in chapter 1, section 1.4.4, with 
the key ones identified to date highlighted in Figure 5-1. 
 
Figure 5-1 Key miRNAs involved in MSC differentiation. Figure adapted 
from Guo et al (2011) and Baglìo et al (2013). 
As described in chapter 4, mir-31 has been linked to the inhibitory 
regulation of osterix in cells (Baglìo and DeVescovi et al., 2013). Based 
on this, we designed antagomirs against mir-31 and tested their 
functionality in a simple bone cancer cell (MG63) model, using AuNPs as 
a delivery platform. Despite the RNA data proving more complex, 
results did demonstrate that introducing mir-31 antagomirs to our cell 
population for 48 hours was sufficient to reverse this inhibition and 
cause an increase in osterix protein levels.  
When considering MSCs as a cell model as opposed to standard cell 
lines such as MG63, the effects of blocking a single miRNA which is 
known to affect osterix, may also affect other key factors in the 
osteogenic pathway.  Authors Deng et al (2013), found that mir-31 
expression was progressively decreased in human bone marrow derived 
stem cells undergoing differentiation (Deng and Wu et al., 2013). The 
authors used lipofectamine to transfect their cultures with mir-31, or 
mir-31 inhibitors. Increasing levels of mir-31 decreased SATB2 protein 
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levels, however no notable changes were reported from the RNA level. 
The authors linked RUNX2, mir-31 and SATB2 together in a regulatory 
feedback system. Increasing RUNX2 levels with transfected plasmids 
encoding RUNX2 directly repressed mir-31. Whereas overexpressing 
mir-31 reduced osterix, osteocalcin, and osteopontin protein expression 
without affecting RUNX2 protein levels. This suggested that mir-31 can 
only influence downstream targets of RUNX2.   
Dong et al (2015), investigated the role of SATB2 in MSCs. They found 
that the MSCs isolated from different sources had differential properties 
with regards to stemness, autophagy and senescence (Dong and Zhang 
et al., 2015). MSCs harvested from the cranio-facial region tended to be 
more osteogenic and had increased levels of autophagy proteins, 
compared to MSCs harvested from tibia bone marrow. Autophagy, the 
organised destruction and recycling of cellular components; is a process 
of cell survival mediated through internal cellular recycling of surplus 
proteins, lipids and organelles. The interplay between autophagy and 
stemness has been discussed in several reviews (Vessoni and Muotri et 
al., 2012.,Phadwal and Watson et al., 2013), with Oliver et al (2012), 
noting that reduction in the autophagy promoting protein Bcl-xL severly 
reduced cell survival (Oliver and Hue et al., 2012). Our stem cells 
should exhibit high levels of autophagy, as a reduction could indicate 
differentiation or apoptosis. 
The age of the patient derived MSCs is also an important factor, 
discussed by Heggrebo et al 2013. Differences in osteogenic potential 
by MSCs were noted from elderly patients compared to younger 
patients, in particular a lack of proliferation and osteogenic 
commitment. This presents a further challenge for patient specific tissue 
regeneration (Heggebo and Haasters et al., 2014). 
As the progressive loss of mir-31 has been demonstrated in 
differentiating MSCs (Deng and Wu et al., 2013), we hypothesised that 
blocking mir-31 with antagomirs at an early time point, could kick start 
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the process of osteoblastic differentiation. We therefore progressed to 
use our antagomir functionalised AuNPs from chapter 4 with MSCs, to 
identify whether we could influence osteogenic differentiation by 
increasing osterix expression in cells.  
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5.2 Materials and Methods 
The antagomir functionalised AuNPs were produced as described in 
Chapter 4, section 4.2.1.  
5.2.1 Cell Culture          
The human MSCs (hMSCs) were cultured in DMEM+ (section 2.3.3) 
maintained at 37oC in 5% CO2 until ~70% confluent, after which time 
they were passaged and counted with a haemocytometer. The cells 
were seeded at a density of 1x103 cells per cm2 for experiments unless 
stated otherwise. The cells were cultured for 24 hours before the 
addition AuNP antagomir treatments at 50nM.  
MSCs gifted by Mr Dominic Meek were isolated and processed from 
bone marrow extracted from patients undergoing knee or hip 
operations. The MSC’s were processed to remove any blood, fat or bone 
fragments present, by centrifugation with a ficoll-gradient. A 
heterogenous population of cells form an isolated band that contain 
MSCs. This band can be extracted and cultured in DMEM+ for a couple 
of days to allow cells to adhere. Adhered cells are further selected using 
the marker CD271, and a magnetic labelling separation kit (Cell 
technologies, UK), and seeded into a new flask. These MSCs were then 
treated as the MSCs from promocell. 
Pilot studies used MSCs gifted by Mr Dominic Meek. Whilst the 
experiments described in this thesis used MSCs from Promo cell. 
5.2.2 Toxicity 
The hMSC cytotoxicity in response to the antagomir-AuNP treatments 
was assessed by standard MTT assay, as described in Chapter 2 section 
2.4.3. 
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5.2.3 Cellular Uptake of Gold Nanoparticles 
5.2.3.1 Transmission Electron Microscopy (TEM) 
Cellular uptake of AuNPs was verified via TEM. The hMSCs were seeded 
at a density of 1x104 cells per mL onto Thermanox coverslips (13mm 
diameter) and cultured to develop a confluent monolayer of cells. At 
this point the AuNPs were added and cells further cultured for 24 hours.  
Cells were subsequently processed for TEM as described in chapter 2, 
(section 2.4.3.1).  
5.2.3.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
Cellular uptake of AuNPs was further quantified via ICP-MS. The hMSCs 
were seeded (100 L/well) in a 96 well plate and incubated for 24 
hours. AuNPs were added to cells for 48 hours and the cells were 
processed for ICP-MS as described in chapter 2 (section 2.4.3.2). The 
converted values for gold uptake were averaged (n=3) and used for 
statistical analysis. 
5.2.4 Fluidigm 
The hMSCs were cultured with antagomir functionalised AuNPs after 5 
days. Fluidigm (as explained in chapter 4, section 4.2.5) analysis was 
carried out as described in chapter 2 (section 2.4.4.2). 
5.2.5 In Cell Western 
The level of osterix protein in MSCs cells post antagomir-AuNP 
treatment was further analysed via in-cell western, as described in 
chapter 4 (section 4.2.6). 
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5.2.6 Osteocalcin Nodule Formation by Immuno Fluorescence 
The production of osteocalcin (OCN) nodules as a late marker for 
osteoblast cell phenotype was carried out as described in chapter 2 
(section 2.4.5).  
 
5.2.7 Statistics 
Statistical analysis was performed in Graphpad using a one-way ANOVA 
with a Dunnett's test. In all figures * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001  
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5.3 Results 
5.3.1 Cell Toxicity: MTT Assay 
MSCs exposed to antagomir functionalised AuNPs produced no 
statistical significant cytotoxic effect based on the MTT assay after 48 
hours incubation (Figure 5-2). In fact, cells appeared to be increasing 
their metabolic activity when compared to control cells. 
Figure 5-2. MTT analysis of hMSCs treated with each AuNP type (50nM 
oligo, 30% PEG saturation) for 48 hours (PEG,NS, 5A, 3A) (n=3; error 
bars indicate SD). 
5.3.2 Cellular Uptake : TEM 
The intracellular location of the AuNPs were qualitatively assessed by 
TEM after a 1 hour and 48 hour incubation. As with the MG63 cells, 
after 1 hour incubation the AuNPs appeared predominantly at the cell 
membrane, in the initial stages of uptake (Figure 5-3A). After 48 hours 
large accumulations of AuNPs can be seen within the cell (Figure 5-3B), 
in   endosomes or free within the cytoplasm.  
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Figure 5-3. TEM images of hMSCs cells treated with AuNPs (50nM, 30%) 
after 1 (A) and 48 (B) hours. PEG=Cells treated with AuNPs 
functionalised with PEG only. NS=AuNPs with PEG and nonsense 
antagomir strands. 5A= AuNPs with PEG and antagonist sequences 
targeting 5’ of mir-31. 3A=AuNPs with PEG and antagonist sequences 
targeting 5’ of mir-31. Scale bar =0.2µm.  Arrows indicate AuNP 
clusters. 
Chapter 5   157 
 
 
5.3.3 Cellular Uptake : ICP-MS 
To quantify the level of gold within the hMSCs, samples were incubated 
with AuNPs for 48 hours, and elemental gold levels were analysed by 
ICP-MS. All AuNP species were found within the hMSCs after 48 hours, 
with PEG-AuNPs demonstrating the highest level of uptake (Figure 5-4).  
  
Figure 5-4.  ICP-MS analysis of hMSCs treated with AuNPs (50nM, 30% 
PEG saturation) for 48 hours. Each lysate has an n=3, error bars denote 
SD. 
5.3.4 Osterix and Related Gene Expression via Fluidigm 
Changes at the RNA level were examined by a fluidigm 48x48 well 
array. This array was able to quantify multiple targets after 5 days of 
antagomir treatment. The data was expressed as a heat map, and sub-
divided into stem cell factors (Figure 5-5) and osteogenic factors (Figure 
5-6). The brighter the shade of red correlates to a greater abundance of 
RNA transcripts in comparison to the RNA levels measured in the control 
samples. The reverse is true for RNA transcripts coloured green, with 
brighter green signal correlating to a reduction in RNA in comparison to 
control (No AuNPs).   The heat map data was arranged into a hierarchy 
based on AuNP response similarity. The data from Figure 5-5 and Figure 
5-6 were taken from the same plate, but split into two separate figures 
for convenience. 
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When considering the day 5 data, overall the 5A, 3A and NS seemed to 
produce a similar down regulatory response of key stem cell markers, 
with PEG AuNPs producing the opposite (Figure 5-5). The fact that 
nestin, alcam, CD63 and CD44 (established MSC markers, chapter 1, 
Figure 5-6) are all decreased indicates a shift away from the retention 
of stem cell factors, whilst the decrease noted with C-Myc suggests the 
cells are reducing proliferation, which commonly occurs during 
differentiation (Figure 5-5). The 5A antagomir was the only treatment 
that demonstrated a decrease in vimentin, an intermediate filament 
expressed in mesenchymal cells which is considered a stem cell marker, 
again indicative of a shift away from ‘stemness’.  
However both the 3A and the 5A induced a general decrease in most 
osteogenic-related genes analysed (Figure 5-6). There were increases 
for the bone morphogenic protein receptors (BMPR-2 and BMP-R1A), 
which are co-involved in the early cell signalling pathways for 
osteogenesis amongst other roles, and this may suggest that at day 5, 
the cells are in the early stages of  osteogenesis, however this is purely 
hypothetical. A decrease in osterix was noted, across all AuNP 
treatments. As mentioned previously the RNA level is a very dynamic 
and ever changing environment. Further investigation would be 
required to see if this down regulation of osterix at the RNA level in 
comparison to control hMSCs, was a result of the time point selected or 
the cells reacting to the AuNPs in some manner. 
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Figure 5-5. Heat map of hMSCs treated with AuNPs for 5 days showing 
stem cell associated factors. The data was analysed using PERMUT and 
ordered into hierarchy based on similarity. 5A,3A and NS are the most 
related. After 5 days PEG appears to activate a wide array of stem cell 
associated factors. Whereas 5A was able to down regulate the stem cell 
markers. 
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Figure 5-6. Heat-Map of hMSCs treated with AuNPs for 5 days and 
showing oestogenic markers. The data was analysed using PERMUT and 
ordered into hierarchy based on similarity. 5A and 3A are the most 
related in terms of gene expression.  
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5.3.5 Osterix Protein Levels via ICW 
Following from the RNA analyses, which highlighted the difficulty in 
selecting the correct time point with hMSCs to detect changes in 
expression levels with differentiation, a time course experiment 
measuring the protein level of osterix was performed. The hMSC cells 
were cultured with the antagomir-AuNPs for 3, 5, 7 and 10 days, fixed 
and stained for osterix and normalised to cell number. The active AuNP 
treatments (5A, 3A and NS) were subsequently normalised to control 
NPs (ie. Au-PEG), with control cells (no AuNPs) acting as an osterix 
protein baseline level over time. 
During the time course, levels of osterix in control cells begins to 
increase at day 5, indicating that differentiation is starting to occur, 
rising at day 7 and beginning to plateau at day 10 (Figure 5-7A). 
However the trend is very different when the AuNPs are added. Osterix 
levels begin to rise immediately and rapidly, peaking by day 5. The 
levels subsequently drop down at day 7, before picking up again and 
returning to starting levels at day 10.  
This rapid and cyclic level of osterix expression, compared to the 
gradually rising expression found in control hMSCs (Figure 5-7B), may 
indicate an overall general cellular response to the presence of AuNPs, 
as the NS sequence also records an increase in osterix levels. This could 
potentially be due to some form of non-specific binding. However, both 
the 5A and the 3A had significantly higher levels osterix expression 
compared to the NS sequence. The cyclic nature of the response to the 
AuNPs is interesting, as it mimics many other gene expression 
responses to stimuli (Murray, 2004.,Zhou and Cai et al., 2012)  
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Figure 5-7. ICW data comparing osterix levels in hMSCs over several 
time points. A) AuNP treatments are shown as 5A= Red, 3A Green, NS= 
Purple (normalised to cell number and then PEG-AuNPs) B) Control cells 
(no AuNPs) normalised to cell number are shown in (n=6; error bars 
denote standard error).  
5.3.6 Osteocalcin Nodule Formation by Immunofluorescence 
The increase in osterix protein expression in response to the 5A and 3A 
(and the NS sequence) suggest that the antagomirs may be having an 
effect by blocking the mir-31 and therefore increasing osterix. Based on 
this, it was hypothesised that, with such a dramatic increase in MSC 
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osterix at day 5, this may in turn have effects further downstream, 
whereby the peak at day 5 may produce an earlier peak of late 
osteogenic markers. To assess this hMSCs were cultured with all AuNPs 
for both 3 and 5 weeks, and stained for osteocalcin, a late osteogenic 
cell marker. Figure 5-8 and Figure 5-9 demonstrate several example 
images at both time points, whilst Figure 5-10 is a graphical 
representation of a series of images to allow semi-quantification of 
osteocalcin staining. 
Osteocalcin is a downstream target of osterix and an established 
positive marker for osteogenesis.  Osteocalcin protein levels were 
determined by immunostaining and quantified via Fiji, with 
normalisation of osteocalcin nodules to cell number. The 5A antagomir 
functionalised AuNPs produced a dramatic increase of osteocalcin 
compared to the other AuNP treatments and to the control cells at week 
3  (Figure 5-10A). From the corresponding panel of images (Figure 5-9) 
the red osteocalcin can clearly be observed.  By 5 week the accelerated 
osteogenic effect of the 5A treatment remains, but it is less dramatic, 
suggesting that the increase has peaked and the other cell populations 
are slowly catching up (Figure 5-9 and Figure 5-10B).  
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Figure 5-8 Representative images from each replicate of AuNP 
treatment cultured with hMSCs after 3 weeks. Staining indicates actin 
(green), nucleus (blue) and osteocalcin nodules (red). Scale bar= 5µm. 
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Figure 5-9 Representative images from each replicate of AuNP 
treatment cultured with hMSCs after 5 weeks. Staining indicates actin 
(green), nucleus (blue) and osteocalcin nodules (red). Scale bar= 5µm. 
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Figure 5-10 Semi-quantification of osteocalcin staining in hMSCs after 
treatment with AuNPs for 3 and 5 weeks (A and B respectively). All 
treatments have been normalised to control cells treated with no 
AuNPs. (n=3, error bars denote SEM) ***= p < 0.001. 
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5.4 Discussion 
5.4.1 Influencing Differentiation 
MSC differentiation is a hugely important area of research. Studies have 
shown that chemical induction using dexamethasone and ascorbic acid 
can create osteoblast-like cells in vitro (Heggebo and Haasters et al., 
2014). Similarly, specific nanotopographies on cell growth surfaces have 
been proven capable of either maintaining stemness of hMSCs or 
producing accelerated osteogenesis (McNamara and McMurray et al., 
2010.,McMurray and Gadegaard et al., 2011). However, whilst both 
technologies are well established, neither is without its inherent 
difficulties. 
Chemical induction is limited predominately to in vitro studies, although 
some studies have shown the effectiveness of BMP-2 administered to 
patients to improve bone density (Rickard and Sullivan et al., 
1994.,Heggebo and Haasters et al., 2014). However the effectiveness of 
this treatment has been shown to be time dependant, with prolonged 
exposure diminishing any osteogenic effect produced within the first few 
days. 
The nanotopographies used by McNamara et al (2010) and McMurray et 
al (2011) produced clear effects on the hMSCs cultured on them. 
However, the influence of topography on cells is known to be highly cell 
density dependent, and as the cells proliferate and also begin to deposit 
extracellular matrix, the monolayer becomes more complex and the 
effects of the topography are weakened. Therefore, when used in vivo, 
this could prove challenging to the formation of functional bone around 
nano-patterened implants. Therefore, using miRNA therapeutics with a 
suitable delivery vector and targeting mechanism to influence stem cell 
differentiation, while in its infancy, holds great potential could solve the 
non-specificity of chemical induction and the lack of signal transduction 
experienced by topographies.  
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As alluded to previously, the location and source of the hMSCs plays a 
critical role in tissue regeneration, as not all MSCs are created equal 
(Heggebo and Haasters et al., 2014.,Dong and Zhang et al., 2015). The 
location of the MSC population has been shown to confer very specific 
differences in osteoblast formation, cell survival by the cellular process 
of autophagy and senescence (Dong and Zhang et al., 2015). The age 
of the patient is also crucial for effective bone formation. As a patient 
ages, the MSCs become less proliferative and have a reduced capacity 
to form functional bone tissue (Chen and Lee et al., 2012.,Baxter and 
Wynn et al., 2004). The elderly, therefore, are in much greater need of 
recapitulation of hMSC function, which primarily affects this section of 
the population e.g., osteoporosis. 
5.4.2 Why Do PEG AuNPs Affect MSC Cell Gene Expression? 
The fluidigm data indicated a wide range of general changes in gene 
expression responses for hMSCs when incubated with all of the AuNPs. 
Although gold is considered bio-inert, the very presence of the NPs and 
resultant AuNP-filled vesicles is likely to be producing a cellular 
response. It is conceivable that these vesicles could be altering an 
autophagy response or non-specifically influencing multiple pathways 
within the cell, in particular cellular trafficking.  
The PEG AuNPs have no attached RNA sequences, and therefore exhibit 
a more neutral charge when compared to the other AuNPs. This could 
potentially lead to a higher uptake (as observed in the ICP-MS data) 
and increased intracellular trafficking, degradation and recycling when 
compared to the 5A, 3A and NS AuNPs. TEM images from the hMSCs 
treated with PEG for 48 hours showed that the majority of the AuNPs 
were free in the cytosol, rather than packaged into endosomes as seen 
with the other AuNPs. This difference in spatial organisation could be 
responsible for this increased metabolic activity seen in Figure 5-5 and 
Figure 5-6 by putting the cell under some form of stress response. 
However further experiments would be required to validate this 
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assumption. Ding et al (2014) found a differential effect of AuNPs on 
human kidney cells (HK-2), with the AuNPs up regulating autophagy in 
normoxic conditions, whilst under hypoxic conditions an increase in 
reactive oxygen species and programmed cell death was noted (Ding 
and Li et al., 2014). With this information and the distribution of PEG 
AuNPs in the cytosol, it is conceivable that the PEG AuNP could be 
causing an increase gene expression by autophagy pathways as seen by 
the fluidigm data (Figure 5-6). 
5.4.3 The Variability Between Osterix RNA and Protein Levels 
The results in this chapter are variable. Fluidigm analysis at the RNA 
level did not demonstrate an increase in osterix levels with the 5A and 
3A antagomirs, however there was a suggestion of a cellular shift away 
from proliferation and towards differentiation when observing changes 
in other gene expression profiles. This may be due to the time points 
selected for analysis. As mentioned previously the RNA environment is a 
highly unstable and dynamic environment, with RNA’s having a half-life 
anywhere between a couple of minutes and a few days (Fabian and 
Sonenberg et al., 2010). This vast range means that there can be a lag 
time when comparing the RNA levels and the transcribed protein levels, 
with proteins tending to be far more stable. RNA transcription 
complexes can only produce one functional mRNA per read, however 
this mRNA can then go on to transcribe its protein a multitude of times, 
allowing for amplification. However mRNA can undergo many post-
transcriptional modifications, which can degrade, make them dormant 
or enhance their stability. This makes understanding the RNA 
environment extremely complex, with the outcome being that only 40% 
of RNAs that change at the RNA level correspond to a change at the 
protein level (Vogel and Marcotte, 2012). This discrepancy means that it 
is simply not sufficient to look at the RNA level for miRNA therapeutic 
studies but a range of levels, such as the protein and physiological 
level. To confuse matters further, Wang et al (2010) demonstrated that 
a proportion of the 60% of RNAs mentioned by Vogel et al (2012) did 
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correlate with a change at protein level when a lag time was included 
(Wang and Wang et al., 2010). This lag between the RNA and protein 
levels could be a reason for the seemingly contradictory results 
observed in the fluidigm and in-cell western data. 
Due to the variable RNA levels, the protein environment is also 
dynamic. Over time, protein levels can fluctuate in delayed response to 
RNA signals. It is therefore prudent to measure proteins of interest over 
time. From Figure 5-7, we can see a dramatic increase in osterix levels 
at day 5, which drop off by day 7 and then recover and start to rise 
again by day 10, producing a cyclical response to osterix over time.  
The control hMSC, without any NPs, produce a far more stable and 
steady increase in osterix, rising exponentially from day 7 to 10 where 
it begins to plateau off. It could be reasonable to assume that given a 
longer time series, we would have observed the control cells and AuNP 
treated cells equilibrating together, suggesting that the antagomir 
treatment allowed for an initial spike in osterix, where cells then 
returned to control conditions.  
5.4.4 Positive Downstream Effects of Increased Osterix 
Osterix is the master transcriptional regulator of osteogenesis, to assess 
whether the antagomirs, after instigating a spike in osterix protein 
levels at day 5, produced effects further down the pathway; we selected 
osteocalcin as a protein of interest. Osteocalcin is only present during 
calcium nodule formation; these nodules are crucial for functional bone 
formation. Other assays could have been deployed to assess the 
downstream effectiveness of the antagomirs, however the presence of 
gold inside the cells produced a level of complexity that had to be 
resolved. Von Kossa staining, a gold standard for osteogenesis uses 
silver nitrate to stain calcium found in nodules. This stain colours 
calcium black, thus it would have been impossible to differentiate AuNPs 
and Von Kossa staining, giving false positives. The same is true for 
Alizarin Red, a stain measured by absorbance. The AuNPs within the 
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cells would block some of the light, reducing absorbance and again 
producing false positives. It was therefore only possible to elucidate 
functional osteogenesis by immuno-staining of late osteogenic markers 
(Figure 5-8 and Figure 5-9) 
The staining showed a dramatic increase in 5A treatment of cells at 
week 3 and a sustained significant increase with 5A at week 5 of 
culture. This strongly suggests that the spike in osterix protein 
observed at day 5 was sufficient to accelerate those MSCs down the 
osteoblastic lineage at 3 and 5 weeks when compared to cells incubated 
with NS and PEG AuNPs, and control cells. This positive result is entirely 
novel, as to date no other studies have used AuNPs to delivery miRNA 
or antagomirs designed against specific miRNAs to influence MSC 
differentiation. 
As reminiscent with the results for MG63 cells in the previous chapter, 
whereby a difference in efficacy was noted between the 3A and 5A 
sequences, with 5A producing a higher increase in osterix. Again, in this 
chapter, the 5A sequence initiates the better cell response in terms of 
increased osterix than the 3A.  
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5.5 Conclusion 
The use of antagomirs against specific miRNAs known to be involved in 
stem cell differentiation has wide therapeutic potential. Whilst this study 
has indicated that such techniques should be possible, there are a 
number of issues that make successful deployment of antagomirs via 
NPs challenging. Elucidating the periodicity of the targeted miRNA is 
vitally important, in terms of when to apply the treatments and how 
long for; the length of exposure and duration of treatment must be 
systematically investigated. The direction of the antagomir sequence 
used should also be noted, as there are obvious differences in efficacy 
depending on whether a 5’ or 3’ sequence was used, both with a 
standard cells line (MG63 in chapter 4) and MSCs in this study. In 
addition, it should be noted that the variation of the cell type response 
must be considered, as identical cell types at different stages of aging 
can produce vastly different responses to the therapeutic. 
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6 Chapter 6: Discussion  
6.1 Gold Nanoparticles: A Future in Clinic? 
This thesis seeks to understand the practicality of delivering small 
molecules using gold AuNPs, and their potential therapeutic use in 
clinic. The underlying theme of the thesis has focused on the delivery of 
small RNAs with a view to influencing cellular behaviour in vitro. The 
initial experimental chapter 3 concentrated on reducing bone cancer cell 
growth, via delivery of siRNA against C-Myc, whilst the latter chapters 
(4 and 5) targeted an identified microRNA, mir-31, via antagomir 
delivery in both bone cancer cells and mesenchymal stem cells (MSCs) 
with a view to influencing osterix levels and ultimately stimulating bone 
differentiation.  Generally, in each case, the original objective was 
attained, and the desired cell outcome was determined. However, from 
the literature and our own experimental discoveries, it is clear that 
further primary research must be carried out in order to understand the 
relationship between AuNPs and their target cells and tissues. 
In order to conclude the thesis, the following section of writing aims to 
scope the current situation regarding the use of gold nanoparticles for 
clinical use, and determine whether the types of studies carried out 
during this PhD will indeed influence the future design of particles, 
based on their interaction at the cellular level. 
It is clear that environmental factors such as the frequency of media 
changes and the time points selected can greatly influence results. 
Differences in growth media can alter cellular physiology, in turn 
altering cellular metabolism. This alteration can silence or produce off 
target effects of small RNA therapeutics. This for example, may be a 
possible explanation for the decrease in mir-31 expression in hMSCs 
recorded in the Baglio study (Baglìo and DeVescovi et al., 2013). In this 
study the author’s pre-primed hMSCs with media supplemented with 
dexamethasone (an osteogenic initiator) until nearly confluent, before 
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changing to mineralisation media. This was in contrast to the Guo 
study, who used the same type of media throughout and whereby the 
reverse was noted for mir-31 levels (Guo and Zhao et al., 2011b). 
MiRNAs are regulated both temporally and spatially (Bratkovič and 
Glavan et al., 2012). Due to this, the duration of treatment during in 
vitro studies is highly important. If a miRNA is up-regulated for too long 
the cell could stall in a particular state. For example, induction media 
supplemented with BMP2 (a powerful osteoinductive cytokine) for 21 
days was noticed to have a drastically reduced osteogenic response in 
comparison to media only supplemented with BMP2 for 2-4 days 
(Heggebo and Haasters et al., 2014). Therefore, care should be taken 
when planning experiments. 
In addition, at the cellular level, the intracellular concentration of GSH 
can have a major impact on the successful delivery of our RNA cargos, 
based on thiol exchange release, which may bias any subsequent 
analysis of RNA therapeutics. Exploiting the thiol cleaving glutathione 
release mechanism for AuNP delivery of small regulatory RNAs requires 
understanding the intracellular GSH concentration, which in turn will 
dictate the necessary concentration of si/miRNA needed (Meister, 
1988.,Rosi and Giljohann et al., 2006.,Lushchak, 2012).  
Finally I have also learned that the RNA environment is a diverse and 
dynamic place, allowing only a small, and often undefined, timeframe to 
determine if an introduced RNA molecule has an effect on its supposed 
target; the difference of a few hours may mask any positive interaction 
with its target.  
At present only three AuNPs have made it to clinical trials, and of these 
three none are delivering siRNA or miRNA. At present, liposomal 
delivery appears to be the dominant choice for small RNA delivery. 
However liposomes, as discussed in section 1.1, are not without their 
inherent problems as they can be cytotoxic, difficult to make 
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multifunctional and can “leak” their cargo. AuNPs have been 
demonstrated in vitro to be relatively non-cytotoxic in short term 
experiments; are multivalent, allowing for additional ligands for 
visualisation and targeting; and are able to effectively protect their 
cargo from degradation prior to release in the cell. However there is a 
large gap in the literature surrounding the toxicity of AuNP delivery of 
small RNAs such as siRNA and miRNA in humans. The very limited 
nanotoxicology studies concerning AuNPs are only short term in vitro or 
in vivo with mice (Connor and Mwamuka et al., 2005).  Until the 
excellent advantages of AuNPs can be capitalised on in the clinic, their 
behaviour in vivo must be further studied. 
6.2 The Use of siRNA and miRNA in Current Therapies 
6.2.1 SiRNA Therapeutics  
Current siRNA therapeutics offers the potential to treat the  
“undruggable” diseases caused by RNA dysregulation. SiRNAs are 
designed to bind with perfect complementarity to their target, however 
siRNA are ultimately made from nucleotides and these nucleotide 
sequences can partially bind to other RNA sequences producing 
unknown and potentially dangerous off-target effects. This is a major 
drawback for siRNA therapeutics in comparisons to using or targeting 
innate miRNAs. Several studies (described in chapter 1.3.4) have shown 
the effectiveness of siRNA targeting oncogenes, including our own 
studies in chapter 3 (Li and Chono et al., 2008.,Conde and Tian et al., 
2013). The siRNA dosage must be carefully considered, as excess siRNA 
can overwhelm the endogenous RNAi machinery, which can lead to an 
inflammatory response (Kasinski and Slack, 2011). In spite of these 
challenges however, twenty two siRNA-based therapeutics have 
successfully made it to clinical trials, with a variety of outcomes, since 
2005. These trials have been summarised in Table 6-1. A conclusive list 
of current siRNA treatments undergoing clinical trials. All information 
was taken from clinicaltrials.gov. SNALPs (Stable Nucleic Acid Lipid 
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Particles) LODER polymer (biodegradable polymeric matrix). Several 
studies were terminated due to potential inflammatory immune 
responses, whilst others failed to progress into more advanced clinical 
trials. Rather disappointingly, to date, no siRNA treatment has left the 
clinic and made it onto the market. 
6.2.2 MiRNA Therapeutics 
As discussed previously miRNAs regulate a vast network of cellular 
processes and responses (section 1.2.2.2). This expansive array of 
miRNA offers the potential for a wide scope of therapeutics. Our 
understanding of miRNAs and their subsequent implication for treating 
diseases or influencing cell types is an area that is expanding 
exponentially and updated rapidly.  As such miRNAs have been 
implicated as a target for oncology studies and more recently their 
application for cellular engineering. 
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Table 6-1. A conclusive list of current siRNA treatments undergoing clinical trials. All information was taken from 
clinicaltrials.gov. SNALPs (Stable Nucleic Acid Lipid Particles) LODER polymer (biodegradable polymeric matrix). 
Date  
 
Candidate Disease target Delivery route Vehicle Phase 
stage 
Status Company Clinical Trial 
Identifier 
2005 Bevasiranib Age-related 
macular 
degeneration 
Intravitreal Free siRNA III Terminated Opko 
Health 
NCT00306904 
2006 AGN211745 Age-Related 
Macular 
Degeneration 
Injection  Free siRNA II Terminated Allergan NCT00395057 
2007 ALN-RSV01 Respiratory 
syncytial virus 
infections  
Nebulization Free siRNA IIb Completed Alnylam/ 
Cubist 
NCT01065935 
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Date  
 
Candidate Disease target Delivery route Vehicle Phase 
stage 
Status Company Clinical Trial 
Identifier 
2008 TD101 Pachyonychia  
congenita 
 
Intralesional Free siRNA Ib Completed TransDerm/ 
IPCC 
NCT00716014 
2008 I5NP Delayed graft 
function 
 
Intravitreal Free siRNA II Completed Quark 
Pharma 
NCT00802347 
2008 ALN-VSP02 Solid tumour Intravitreal SNALP I Completed Alnylan/ 
Tekmira 
NCT01158079 
2008 CALAA01 Solid tumor Intravitreal Polyplex I Terminated Calando 
Pharma 
NCT00689065 
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Date  
 
Candidate Disease target Delivery route Vehicle Phase 
stage 
Status Company Clinical Trial 
Identifier 
2009 SPC3649 Hepatitis C 
 
Subcutaneous LNA siRNA IIa Completed Santaris NCT00979927 
2009 QPI-1007 Non-arteritic   
anterior  
ischemic optic
neuropathy 
 
Intravitreal Free siRNA I Completed Quark 
Pharma 
NCT01064505 
2009 SYL040012 Intraocular 
pressure 
Eye drop Free siRNA II Recruiting Sylentis NCT02250612 
2009 TKM-ApoB High 
cholesterol 
Intravitreal SNALP I Terminated Tekmira NCT00927459 
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Date  
 
Candidate Disease target Delivery route Vehicle Phase 
stage 
Status Company Clinical Trial 
Identifier 
2009 ALN-TTR01 Transthyretin  
mediated  
amyloidosis 
 
Intravitreal SNALP I Completed Alnylam NCT01148953 
2009 Atu027 Advanced 
solid tumor 
Intravitreal Lipoplex I Completed Silence 
Therapeutic
s 
NCT00938574 
2010 siG12D 
LODER 
Advanced 
pancreatic 
cancer 
Intratumoral 
injection 
LODER 
polymer 
I Completed Silenceed 
Ltd. 
NCT01188785 
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Date  
 
Candidate Disease target Delivery route Vehicle Phase 
stage 
Status Company Clinical Trial 
Identifier 
2011 PF-4523655 Diabetic 
macular 
edema  
Intravitreal Free siRNA II Completed Quark/Pfize
r 
NCT01445899 
2011 SYL1001 Dry eye/ 
ocular pain 
Eye drop Free siRNA I Completed Sylentis NCT01438281 
2011 ALN-PCS02 LDL-
Cholesterol 
Intravitreal SNALP I Completed Alnylan NCT01437059 
2011 TKM-
080301 
(PLK1) 
Cancer Injection  SNALP  I Completed National 
Cancer 
Institute 
(NCI) 
NCT01437007 
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Date  
 
Candidate Disease target Delivery route Vehicle Phase 
stage 
Status Company Clinical Trial 
Identifier 
2012 EphA2 Cancer Injection  Liposomal I Recruiting M.D. 
Anderson 
Cancer 
Center 
NCT01591356 
2014  APN401 Cancer Injection  siRNA-
transfected 
peripheral 
blood 
mononuclear 
cells  
I Recruiting Comprehen
sive Cancer 
Center of 
Wake 
Forest 
University 
NCT02166255 
2014 DCR-MYC Cancer intravenous 
infusion 
Lipoplex Ib/II Recruiting Dicerna 
Pharmaceut
icals, Inc. 
NCT02314052 
Chapter 6          183 
 
Date  
 
Candidate Disease target Delivery route Vehicle Phase 
stage 
Status Company Clinical Trial 
Identifier 
2014 ND-L02-
s0201 
(HSP47) 
Hepatic 
fibrosis 
intravenous 
infusion 
Lipoplex Ib/II Recruiting Nitto Denko 
Corporation 
NCT02227459 
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6.2.3 Oncology 
Thousands of miRNAs have been screened by high throughput analysis. 
From these experiments hundreds of individual miRNAs have been 
found to cluster around specific genomic sections prone to cancerous 
mutations, suggesting that miRNAs from these areas could be potential 
targets for cancer treatments (Calin and Sevignani et al., 2004). In fact, 
miRNAs are becoming so associated with cancer diagnostics, that 
miRNA expression profiles are being used to identify the type and stage 
of certain cancers (Ryan and Robles et al., 2010.,Esquela-Kerscher and 
Slack, 2006.,Calin and Croce, 2006). This in itself offers a fantastic 
advantage in the initial early diagnosis and follow-up treatment. 
As described in section 1.3.3, cells can become addicted to certain 
oncogenes. Mir-21 over-expression has been reported in mouse models 
to induce multiple tumours and is found in many human tumour and 
serum samples (Medina and Nolde et al., 2010).   However, blocking 
mir-21 expression in the mice models induced complete tumour 
regression, validating the theory that cells become addicted to only a 
few oncomirs and their subsequent silencing can halt cellular 
dysregulation (Medina and Nolde et al., 2010).  
The therapeutic future of miRNAs looks promising with regards to 
oncology. Several studies in primates and mice have shown that miRNA 
degradation by antagomirs have limited side effects and can effectively 
silence metastatic cancers (Lanford and Hildebrandt-Eriksen et al., 
2010.,Tsai and Hsu et al., 2009.,Krutzfeldt and Rajewsky et al., 2005a) 
MiRNAs have also been linked to sensitizing tumours that are resistant 
to chemotherapies.  Supplementing mir-9 into cell growth media was 
noted to reduce SOX2 expression, which indirectly pumps out cytotoxic 
drugs used by chemotherapies. By increasing mir-9 expression 
aggressive cancerous cells became vulnerable to chemotherapies (Jeon 
and Sohn et al., 2011).  
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It is therefore clear that by understanding the particular mechanism of 
a miRNAs action will help us design specific treatments.  This can be 
difficult, as some miRNAs can appear to be oncogenic and 
oncosuppressive, depending on the context under which they are 
employed. For example mir-146 up regulation is associated with breast, 
thyroid and cervical cancer (Volinia and Calin et al., 2006.,Dahiya and 
Sherman-Baust et al., 2008). Conversely, however, over expressing 
mir-146 in hematopoietic cells seemed to provide a tumour suppressive 
role. As mir-146 knockout mice had a higher incidence of myeloid 
sarcomas and lymphomas (Zhao and Rao et al., 2011.,Boldin and 
Taganov et al., 2011.,Starczynowski and Kuchenbauer et al., 2011). 
Whereas other miRNAs are proving more straight forwards; mir-31 
expression was noted to be down regulated in breast cancer cells, and 
over expressing mir-31 regressed the metastases of the tumour, 
switching the cancer from an aggressive, invasive tumour to a more 
benign phenotype. Suggesting a possible avenue for novel cancer 
therapeutics to use mir-31 in a supportive role for chemotherapies 
(Valastyan and Reinhardt et al., 2009.,Valastyan and Chang et al., 
2011). 
6.2.4 Encouraging Bone Formation 
Dysregulation of miRNAs by diseases such as osteoporosis can lead to 
bone reabsorption creating weak, brittle bones. MiRNAs have been 
shown to maintain a fine controlled balance of ossification and 
reabsorption, and have therefore become a potential therapeutic 
opportunity. Reports to date have confirmed several miRNAs that inhibit 
osteogenic differentiation, such as mir-31, mir-206, mir-133, mir-125b 
and mir-135 (Guo and Zhao et al., 2011a.,Mizuno and Yagi et al., 
2008.,van Wijnen and van de Peppel et al., 2013), whereas miRNAs 
such as miR-2861 and miR-3960 have been shown to promote 
calcification. (Scott and Goga et al., 2007.,Li and Xie et al., 2009.,Lee 
and Kim et al., 2005.,Mizuno and Yagi et al., 2008.,Inose and Ochi et 
al., 2009.,Kapinas and Kessler et al., 2009).  
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Our study in chapter 4 supported the increasingly established link 
between mir-31 expression and a decrease in osterix; we noted that 
blocking mir-31 in MG63 cells allowed for an increase in osterix. Whilst 
this result in itself is interesting, it is the potential use of the technology 
in MSCs that may prove to have potential. If we can artificially influence 
MSC differentiation towards the bone cell lineage, this will greatly 
benefit regenerative medicine and conditions such as osteoporosis and 
osteo imperfecta. In chapter 5 we carried on to demonstrate that 
blocking mir-31 did indeed encourage osteogenesis, with an early (day 
5) increase in osterix providing a significant increase in bone forming 
osteocalcin further downstream at 3 weeks culture. These types of 
results are extremely encouraging, however it is the verification of 
these results in vivo that is now needed to progress the technology 
further towards the marketplace. 
At last search, over 300 studies were found on clincialtrials.gov linked 
to miRNAs. As was highlighted in the oncology section, all but one of 
the miRNAs currently undergoing clinical trials are being used as 
biomarkers for diagnostics. The exception to this is a miRNA mimic 
(MRX34, Clincial trial number NCT01829971).  MRX34 is a liposomal-
based injection designed to treat patients with advanced liver cancer. 
This is in complete contrast to siRNA, which is only used as a 
therapeutic. This disparity between the two small RNAs is probably in 
part due to the recent discovery of the depth and breadth miRNAs 
control and modulate cells. 
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6.3 Future Work 
The experimental chapters in this thesis are all very encouraging with 
respect to the use of AuNPs in the delivery of small RNAs to cells in 
culture. The use of AuNPs as delivery agents for such therapeutics offer 
an immense potential to help remedy cellular dysregulation and 
“undruggable” diseases. However the use of siRNAs does prove 
problematic, as they present a very narrow field of blocking one target 
without considering the potential off-target effects. In contrast miRNA 
are known to block many mRNAs across a gene family, using miRNAs or 
their inhibitors could provide a safer therapeutic with less off-target 
effects. 
All experimental work during this Ph.D. was performed in vitro. To 
advance this area of research further and develop AuNPs delivering 
siRNA and miRNA (including antagomirs) into a clinical setting, in vivo 
work will be required. This is needed to ensure that the early and 
promising studies in vitro follow through to the in vivo situation. Prior to 
this, however, certain considerations such as the duration of treatment, 
the treatment dose, the subsequent cytotoxicity and longer-term effects 
must all be considered. There is currently a wealth of information in the 
literature, and it is increasing exponentially. The collation of 
toxicological and efficacy data together with the development of 
therapeutic strategies would be of great benefit to this field of research. 
Whilst hurdles still remain, the delivery of small regulatory RNAs offers 
an exciting avenue for nanomedicine and the regenerative medicine 
field as a whole. 
…………………………………………………………………………………………    
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